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According to the World Health Organization, cardiovascular diseases (CVDs) were the 
number one cause of death globally in 2005 and will remain so at least until 2015. CVDs 
include coronary heart disease (CHD), cerebrovascular disease, peripheral artery disease, 
rheumatic heart disease, congenital heart disease, and thrombosis and embolisms. The 
most important contributor to the growing burden of CVD is atherosclerosis. The World 
Health Organization estimated that in 2005, about 30% of all global deaths could be 
attributed to CVD. There are a number of factors that are well known to increase the 
risk for CVD. These risk factors can be divided into non-modifiable and modifiable risk 
factors. Non-modifiable risk factors include gene polymorphisms, gender, and age, 
whereas modifiable risk factors include smoking, increased blood pressure, dietary 
factors, obesity, lack of exercise, thrombogenic factors, dyslipidemia and inflammation.1 
Over 80% of the premature deaths caused by CVDs could be prevented by adjusting life 
style: keeping a healthy diet, practicing regular physical activity, and avoiding tobacco 
smoke.
 Unfortunately, changing lifestyle proves to be very difficult. Furthermore, this 
may not be sufficient for each individual to prevent CVD, as non-modifiable risk factors 
also play a role in the development of CVD. Also, people that suffered from CVD often need 
secondary prevention to decrease the chance for recurrence of disease. Pharmaceutical 
intervention is therefore important to reduce the risk for CVD. The most widely used 
class of drugs to lower CHD risk are statins, which act through lowering low density 
lipoprotein-cholesterol (LDL-C). However, statins reduce the number of cardiovascular 
events with only about 30%.2 This indicates that other factors, besides LDL-C, also 
contribute to CHD. In this thesis we mainly focus on two other factors involved in CHD 
development, namely cholesteryl ester transfer protein (CETP) and inflammation. CETP 
transfers cholesteryl esters from HDL to (V)LDL in exchange for triglycerides, thereby 
lowering HDL-C and increasing (V)LDL-C. HDL-C is inversely correlated with CHD 
prevalence, and is thus thought to have a protective role in CHD development. During 
the past years, a lot of research was aimed at developing strategies to increase HDL-C. 
One of the experimental strategies to achieve this goal is inhibition of CETP. The other 
factor studied in this thesis, inflammation, is increasingly recognized as a factor that 
increases CHD risk, and therefore strategies to reduce inflammation are also under 
development. In this introduction, some background information about lipoprotein 
metabolism, metabolic inflammation, atherosclerosis development and some selected 
targets modulating lipoprotein metabolism and/or inflammation is given.
 
1.2 Lipids and lipoprotein metabolism
 
Triglycerides (TG) and cholesterol, the main dietary lipid constituents, are lipophilic 
molecules that are insoluble in a hydrophilic environment such as blood. Therefore, 
cholesterol and TG are packed into water-soluble particles called lipoproteins. 
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Lipoproteins have a lipid-rich inner core containing TG and cholesteryl esters (CE) and 
an outer core containing hydrophilic phospholipids (PL), unesterified cholesterol and 
proteins to solubilize these lipoproteins. Lipoproteins are subdivided into different 
classes according to density, namely (from lowest to highest density) chylomicrons, very 
low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density 
lipoproteins (LDL) and high density lipoproteins (HDL). Lipoprotein metabolism will be 












































































Figure 1. Schematic overview of lipoprotein metabolism. See text for explanation. 
1.2.1 Chylomicrons
In the intestine, dietary lipids are absorbed and packed into chylomicrons that are 
transported through the lymphatic system to the blood.3 Chylomicrons mainly consist 
of TG, and also contain fat-soluble vitamins. Apolipoproteins on chylomicrons include 
apoAI, apoAIV, apoB48, apoCI, apoCII, apoCIII and apoE.3,4 In the circulation, TG of the 
chylomicrons are lipolyzed by lipoprotein lipase (LPL) into glycerol and fatty acids 
(FAs), which are taken up by skeletal muscle and heart to serve as an energy source, 
or by adipocytes for storage. The resulting chylomicron remnants that are relatively 
enriched in cholesterol and apoE are then taken up by the liver through the LDL receptor 
(LDLr),5,6 LDLr-related protein (LRP),5,6 heparan-sulphate proteoglycans (HSPGs)7 or 




1.2.2 VLDL, IDL and LDL
The liver produces apoB100 (and in some species, including mice, apoB48), a very 
long protein (about 512 kDa) that transports lipids out of the liver in the form of VLDL 
particles. During its translation apoB associates with the microsomal triglyceride 
transfer protein (MTP) in the endoplasmic reticulum (ER), where MTP transfers lipids 
onto apoB, thus forming a pre-VLDL particle. Subsequent fusion with a lipid droplet 
creates a mature VLDL particle that is secreted into the blood.5,9 The lipids loaded onto 
apoB can originate from the diet or can be synthesized de novo by the liver itself. The 
most important genes involved in the de novo synthesis of TG are fatty acid synthase 
(FAS) and stearyl-CoA desaturase-1 (SCD1), while the rate-limiting enzyme for the 
production of cholesterol is 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR).
 In the bloodstream VLDL is enriched with apoCI, apoCII, apoCIII and apoE.5,10,11 
In the fasted state, when there is no chylomicron production by the intestine, VLDL is 
the main donor of TG for extrahepatic tissues. To this end, TG are hydrolyzed by LPL 
that is particularly expressed by skeletal muscle as compared to adipose tissue under 
fasting conditions.12 As a result of lipolysis, VLDL becomes depleted of TG and is thereby 
converted into an IDL particle and eventually an LDL particle that is relatively enriched 
in cholesteryl esters as compared to TG, and contains apoB as its most characteristic 
apolipoprotein.5 LDL is mainly taken up from the plasma through interaction of apoB 
with the LDLr. Up to 50% of LDL is taken up by the liver, while the remainder is taken 
up by extrahepatic tissues that use the cholesterol from LDL to maintain membrane 
integrity or to produce steroid hormones.5,13 High levels of apoB-containing lipoproteins 
(VLDL, IDL, LDL) can lead to deposition of these lipoproteins in the vessel wall, where 
they are modified and taken up by macrophages, initiating the process of atherosclerosis 
development.
1.2.3 HDL
The smallest of lipoproteins is HDL, which is produced by the liver and by the 
intestine.14 These tissues synthesize apoAI, which is secreted into the plasma. ApoAI 
is subsequently lipidated with PL to form nascent, disc-shaped HDL through the 
involvement of the hepatic or intestinal ATP-binding cassette transporter A1 (ABCA1), 
a protein that is essential for HDL biosynthesis.15-18 This HDL particle can take up 
cholesterol from various tissues via ABCA1. The acquired cholesterol is then esterified 
by lecitin:cholesterol acyl transferase (LCAT), and the resulting CE are stored in the core 
of the HDL particle. Through the action of LCAT the HDL particle expands, accumulates 
even more cholesterol and becomes a mature, spherical HDL particle19 that, besides 
apoAI, can acquire other apolipoproteins including apoAII, apoAIV, apoAV, apoCI, 
apoCII, apoCIII and apoE. Additional loading with cholesterol may occur via the ATP-
binding cassette transporter G1 (ABCG1) and/or SR-BI.20,21 HDL can exchange lipids 
with other plasma lipoproteins through interaction with the phospholipid transfer 
protein (PLTP), which facilitates the transport of PL from chylomicrons and VLDL to HDL 
during remodeling of those TG-rich lipoproteins by LPL. Furthermore, the cholesteryl 
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ester transfer protein (CETP) can exchange CE from HDL with TG from apoB-containing 
lipoproteins, resulting in TG-enriched HDL particles. HDL is then remodeled by the 
lipolytic enzymes hepatic lipase (HL) and endothelial lipase (EL) that lipolyze HDL-
TG and HDL-PL, processes that enhance HDL catabolism.22-26 HDL-derived cholesteryl 
esters can be directly taken up by the liver via SR-BI,27 where they can be stored in the 
form of CE, incorporated into newly assembled lipoproteins or excreted into bile in the 
form of bile acids or neutral sterols.
1.3 Inflammation
 
Classically, inflammation is defined as a response to injury and is characterized by 
redness, swelling, pain and fever. This classical response is a strong and acute response 
with a short duration to fight infection, after which the inflammatory reaction fades. In 
contrast to this acute inflammatory response, it has been found in the past decades that 
many subjects have only slightly elevated levels of inflammatory markers in plasma, 
which remain elevated over a longer period of time. This kind of inflammation is 
sometimes referred to as low-grade or chronic inflammation.28
 
1.3.1 Metabolic inflammation
Obesity, one of the risk factors for atherosclerosis development, is often associated with 
low-grade inflammation in the absence of infection or diseases such as rheumatoid 
arthritis (RA) or systemic lupus erythematosus (SLE).29,30 It has recently been 
hypothesized that this type of inflammation is triggered by a surplus of nutrients, 
and therefore this type of inflammation is referred to as metabolically triggered 
inflammation.28 Metabolic inflammation can be induced by several types of nutrients: 
dietary supplementation with FA has been shown to mildly increase inflammatory 
markers in plasma31 and it has been shown that hyperglycemia induces low-grade 
hepatic inflammation.32 Some recent studies indicate that cholesterol also induces 
low-grade hepatic inflammation in humans and in mice,33,34 and that this is dependent 
on the amount of cholesterol in the diet.35 Although it becomes increasingly clear that 
cholesterol metabolism and inflammation are strongly intertwined processes, it is 
not known how an excess of dietary cholesterol leads to the induction of metabolic 
inflammation.
 
1.3.2 The role of chronic inflammation in atherosclerosis development
Chronic inflammation, either originating from a chronic infection, from inflammatory 
diseases such as RA or SLE or from metabolic dysregulation, is increasingly recognized 
as a risk factor for the development of CVD.36-38 Numerous population studies have 
found a relation between serum levels of inflammatory markers, such as C-reactive 
protein (CRP), fibrinogen, serum amyloid A (SAA) and soluble adhesion molecules and 
the prevalence of CVD.36 It is not yet clear whether or not these markers have a causal 
role in the development of CVD, although some studies suggest that these markers 
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have a direct effect on certain processes involved in atherosclerosis development. 
For example, SAA was shown to affect proteoglycan synthesis in a way that leads 
to increased LDL binding.39 Furthermore, in vitro experiments showed that SAA 
stimulates the production of the chemokine monocyte chemoattractant protein (MCP)-
1, thus increasing monocyte recruitment to the site of atherosclerotic lesions.40 CRP 
may negatively affect blood pressure by causing endothelial dysfunction.41,42 The role of 
adhesion molecules and immune cells in the development of atherosclerosis is better 
understood, and is described in the next section.
1.4 Atherosclerosis
 
Atherosclerosis is a multifactorial disease affecting the arteries, in which lipids, 
connective tissue elements, SMC and immune cells accumulate inside the vessel wall 
and cause a narrowing of the blood vessel.43 The pathogenesis of atherosclerosis is 
complex, and over the recent year a lot of insight has been gained in the processes 
involved in its development.
1.4.1 Mechanisms of atherosclerosis development
The vessel wall consists of three layers: the innermost layer is called the intima and 
consists of a mono-layer of endothelial cells (EC). A thin matrix, the internal elastic 
lamina consisting of elastic fibers, separates the intima from the second layer, the media. 
The media consists of smooth muscle cells (SMC) that have a transverse arrangement 
with regard to the intima. The external elastic lamina separates the media from the 
third and outermost layer, the adventitia. The adventitia consists of SMC, fibroblasts 
and connective tissue, the latter serving to stabilize the vessels and anchor it to its 
surroundings.
Atherosclerosis development starts when LDL enters the vessel wall and gets 
modified, for example by oxidation. This induces an inflammatory response in the 
vessel wall, leading to activation of endothelial cells (EC). Activation of EC involves the 
NF-κB pathway and leads to expression of adhesion molecules such as vascular cell 
adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1 and E-selectin, 
to which leukocytes (e.g. monocytes and T-cells) from the circulation can adhere,44 
followed by trans-migration into the vessel wall. There, monocytes differentiate into 
macrophages that proliferate upon stimulation by macrophage-colony stimulating 
factor (M-CSF), and that take up the modified LDL via scavenger receptor (SR)-A and 
cluster designation (CD)36. Inside the macrophage, cholesterol is esterified by acyl 
CoA:cholesterol acyltransferase (ACAT)-1 and is stored in lipid droplets, thus turning 
the macrophage into a lipid-laden foam cell. These foam cells excrete chemokines, 
such as MCP-1, and cytokines that amplify the inflammatory response in the plaque by 
attracting and activating more immune cells.44 Lesions consisting only of macrophage 
foam cells and other immune cells such as T-cells and neutrophils are called fatty streaks 
or mild lesions that have no clinical symptoms.1,43-46 
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However, macrophage foam cells can exert various effects inside a lesion that 
lead to development of a more complex, severe lesion that may cause cardiovascular 
complications. First, macrophage foam cells produce inflammatory stimuli that activate 
SMC. This leads to proliferation and migration of the SMC to the intimal side of the 
lesion. When activated, SMC produce extracellular matrix (ECM) proteins such as 
collagen, and form a fibrous cap that protects the content of the lesion from exposure 
to the blood. Second, macrophage foam cells produce matrix metalloproteinases 
that break down the ECM. Third, upon accumulation of large amounts of cholesterol, 
macrophage foam cells will undergo apoptosis and/or necrosis, forming a necrotic core 
that consists of extracellular lipid and cellular debris, and contains factors that can 
activate the coagulation cascade. The stability of a lesion depends on its composition. 
Stable plaques usually have a thick fibrous cap and a relatively low macrophage and 
lipid content, whereas unstable plaques have a thin fibrous cap, less stabilizing ECM 
and a relatively high content of lipid and macrophages. Thus, depending on the balance 
between ECM production and degradation, a plaque can be less or more vulnerable to 
rupture. Exposure of pro-thrombotic material to the blood triggers the formation of a 
thrombus that can occlude the blood vessel, thus causing an infarction.1,43-46 Figure 2 
illustrates the different steps involved in atherosclerosis development.
1.4.2 The role of lipoproteins in atherosclerosis development
The apoB-containing lipoproteins, chylomicrons, VLDL, their remnants, and LDL, are 
considered to be atherogenic because they can enter the vessel wall, thereby triggering 
the onset of atherosclerosis development as described in the previous section. HDL, 
on the other hand, is considered to be atheroprotective by a number of different 
mechanisms. Firstly, the most important anti-atherosclerotic function of HDL is thought 
to be in reverse cholesterol transport (RCT). It is thought that the CE stored in foam 
cells, after hydrolysis by cholesteryl ester hydrolase (CEH), can be transported out 
of the macrophage foam cells, both passively via aqueous diffusion and actively via 
ABCA1, ABCG1 and possibly also SR-BI, where lipid-poor apolipoproteins (e.g. apoAI) 
or HDL can act as cholesterol acceptors.20,47,48 Through this mechanism HDL may 
deliver cholesterol derived from atherosclerotic lesions to the liver, thus reducing the 
atherosclerotic burden. Secondly, HDL may have anti-inflammatory capacities. HDL has 
been shown to be able to inhibit the expression of adhesion molecules on endothelial 
cells and (thereby) the transmigration of monocytes across an endothelial cell layer.49 
Thirdly, HDL could act as an anti-oxidant and thereby prevent the oxidation of LDL. 
This anti-oxidative capacity could be exerted through apolipoproteins such as apoAI, 
or through enzymes that are present on HDL, including platelet-activating factor acetyl 
hydrolase (PAF-AH), paraoxonase-1 (PON1) or glytathione phospholipid peroxidase.49,50 
Lastly, HDL has been shown to be able to stimulate the release of nitric oxide (NO), 
thereby promoting vasorelaxation and improving endothelial function.50 Because of 
these potentially beneficial properties of HDL-C, new drugs are being developed that 
aim at increasing HDL-C levels as a new strategy to reduce CVD. It should be noted, 
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Figure 2. Schematic overview of the different steps in atherosclerosis development. See 
text for explanation. 
however, that the atheroprotective role of HDL still has to be confirmed in both animal 
and human studies.
 
1.4.3 Mouse models for studying lipid metabolism and atherosclerosis
Epidemiologic studies have largely increased our knowledge about biomarkers and risk 
factors for the development of CVD. However, these studies do not provide mechanistic 
insight in the specific role of certain factors and processes in the development of 
atherosclerosis. Therefore, animal models allowing a detailed analysis of the various 
stages in atherosclerosis are a useful tool to gain insight in processes involved the 
development of atherosclerosis. Since wild type mice show large differences in lipid 
metabolism and inflammation (two major risk factors for atherosclerosis development) 
as compared to humans, genetically modified mouse strains have been developed, 
in which these processes are more similar as compared to humans. There are three 
mouse models that are extensively used for studying atherosclerosis: the apoE-/- model, 
the LDLr-/- model and the apoE*3-Leiden (E3L) model. These three models develop 
atherosclerotic lesions starting in the aortic root and progressing along the arterial 
tree in a time dependent fashion. Furthermore, these lesions are similar in pathology 
to human atherosclerotic lesions, varying from fatty streaks and mild lesions to severe 
and more complex lesions. 
 ApoE-/- mice lack expression of apoE, the apolipoprotein that has an important 
role in the clearance of lipids via LDLr, LRP and HSPGs. As a consequence, these mice 
have increased cholesterol levels compared to wild type mice, ranging from 9 mM on 





















a chow diet to about 80 mM on a western type diet containing fat and cholesterol. 
Taken together with the fact that macrophage-produced apoE has been shown to be 
an important factor in the cholesterol efflux from macrophages,51 these mice develop 
atherosclerosis already on a chow diet, and this process is accelerated on a western 
type diet.52-55
 LDLr-/- mice lack expression of the LDLr. In humans, mutations in the gene 
coding for the LDLr can cause familial hypercholesterolemia, a disease that leads to 
CVD at a very young age. As in LDLr-/- mice only particle clearance via the LDLr route 
is abrogated, leaving clearance of apoE-containing lipoproteins via e.g. LRP and HSPG 
unaffected, these mice have only mildly elevated plasma cholesterol levels on a chow 
diet (about 6 mM). When fed a western type diet, cholesterol levels strongly increase 
(upto about 50 mM) leading to rapid atherosclerosis development.56,57
 E3L mice carry a construct containing the human apoE*3-Leiden gene, a 
dominant negative mutant form of the human apoE3 gene that is characterized by a 
tandem duplication of codons 120-126 and that causes hyperlipidemia in humans, 
together with the gene encoding for human apoCI. Expression of the E3L transgene 
leads to impaired hepatic clearance of apoE-containing lipoproteins, albeit less 
dramatically than in apoE-/- mice. Expression of the human apoCI furthermore leads 
to an increase in plasma TG levels by inhibition of LPL58 and by disturbance of the 
interaction of lipoproteins with the LDLr and LRP.59,60 On a chow diet, E3L mice have 
cholesterol levels of about 2-3 mM and show moderately elevated VLDL and LDL 
levels. On a Western type diet, VLDL and LDL levels increase strongly, leading to the 
development of atherosclerosis. By varying the dietary cholesterol content, plasma 
cholesterol levels can be modulated up to approximately 25 mM. E3L mice therefore 
represent a somewhat milder model for atherosclerosis development than apoE-/- and 
LDLr-/- mice.61-64 In addition to that, E3L mice are more sensitive to lipid-modulating 
therapies, such as statins and fibrates, than the apoE-/- and LDLr-/- mouse models.65 
Recently, E3L mice have been crossbred with mice expressing human CETP under 
control of its own promoter, generating E3L.CETP mice.66 These mice have higher VLDL 
and LDL levels and lower HDL levels as compared to E3L mice and are more responsive 
to HDL-modulating drugs than the other mouse models discussed above. Because of 
their advantageous response to lipid-modifying drugs E3L and E3L.CETP mice were 
used in the studies described in this thesis.
1.5 Selected targets modulating lipid metabolism and/or inflammation
 
In order to develop new treatment strategies to reduce CVD prevalence, the search for 
new drug targets is ongoing. In the following sections five selected factors, which can 
modulate lipid metabolism and/or inflammation through different mechanisms, are 
described. Because of their role in lipid metabolism and/or inflammation, these factors 





NF-κB is the collective name for a family of transcription factors that consists of 5 
members, namely p65, p50, p52, c-Rel and RelB. These members can form different 
combinations of homodimers or heterodimers that bind to an NF-κB consensus 
sequence in target genes to regulate gene transcription. The complex most often 
referred to as NF-κB is the p65/p50 heterodimer. Under unstimulated conditions, the 
NF-κB complex is present in the cytoplasm of the cell where it is bound to its inhibitory 
protein: inhibitor of κB (IκB). Upon an inflammatory stimulus, the IκB kinase (IKK) 
complex phosphorylates IκB, which is then released from the NF-κB complex and is 
subsequently degraded. NF-κB is then free to translocate to the nucleus to activate 
gene transcription. NF-κB regulates the expression of a diverse set of genes, including 
cytokines, chemokines, acute phase proteins, adhesion molecules and genes involved in 
apoptosis.67 Studies addressing the role of NF-κB in atherosclerosis development have 
shown that reduced NF-κB signaling can either reduce or aggravate the development of 
atherosclerosis, apparently depending on the cell type or the stage of lesion development 
studied.68-70 Salicylate, an anti-inflammatory drug, has been shown to inhibit the IKK 
complex, thus preventing the phosphorylation of IκB and the subsequent activation 
of NF-κB.71 Unpublished observations by Zadelaar et al. have shown that salicylate 
lowers inflammatory parameters and plasma lipid levels in E3L mice, concomitant with 
strongly reduced atherosclerosis development. However, in a clinical setting people 
already have some extent of atherosclerosis development at the onset of treatment. 
Several studies have shown that plasma lipid lowering can induce regression of pre-
existing atherosclerotic lesions in mice.72-74 It is however not known if suppression of 
inflammation can have an additional beneficial effect on top of plasma lipid lowering in 
the process of atherosclerosis regression.
1.5.2 LXR
Nuclear receptors form a large family of transcription factors that regulate various 
cellular processes, such as reproduction, development, inflammation and metabolism.75 
A number of nuclear receptors are involved in the regulation of lipid metabolism. Among 
these receptors are the liver-X-receptors (LXRs) α and β. LXRα is expressed mainly in liver, 
but also in macrophages, adipose tissue, kidney, intestine, lung and adrenals, whereas 
LXRβ is ubiquitously expressed. The endogenous ligands for LXRα and β are oxysterols, 
derivatives of cholesterol, and LXRs thus function as cholesterol sensors. As yet, no 
specific ligands for either of the LXR isoforms have been identified. Upon activation, 
LXR heterodimerizes with the retinoid X receptor (RXR) and binds to LXR responsive 
elements to regulate target gene expression.75-77 Genes that are regulated by LXR 
include ABCA1 and ABCG1 that are involved in cholesterol efflux from macrophages;78 
ABCG5 and ABCG8 that mediate the transport of intestinally absorbed cholesterol back 
into the intestinal lumen, thus leading to a decrease in net cholesterol absorption;79,80 
CYP7a1 that converts cholesterol in the liver into bile acids for elimination,81 and FAS 
and SCD-1 that are involved in FA biosynthesis. Furthermore, LXR has been suggested 
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to have anti-inflammatory capacities by inhibiting the NF-κB pathway.77 Despite the fact 
that activation of LXR leads to increased plasma cholesterol and TG levels by enhancing 
VLDL production,82 LXR agonists are able to inhibit the progression of atherosclerosis 
and even to induce regression of pre-existing atherosclerotic lesions.83-86 However, the 
mechanisms underlying these beneficial effects have not been fully revealed as yet.
1.5.3 RXR
The nuclear receptor RXR appears in three isoforms (RXRα, β and γ), of which no 
functional characterization has been made. All three RXR isoforms can form homodimers 
and they are also partners for heterodimerization with other members of the nuclear 
receptor family, such as LXR, farnesoid X receptor (FXR), pregnane X receptor (PXR), 
retinoic acid receptor (RAR) and peroxisome proliferator-activated receptors (PPARs). 
Activation of RXR can therefore affect a diverse set of processes.75,87 RXR agonists 
are used in the clinic as a therapeutic approach to treat cancers and dermatologic 
diseases. However, adverse effects of RXR agonists have been reported regarding lipid 
metabolism, as exemplified by the chemotherapeutic agent bexarotene, which induces 
hypertriglyceridemia and hypercholesterolemia in humans.88 A few studies have 
addressed the effects of bexarotene on lipid metabolism,89-91 but these studies gave 
conflicting results. Therefore, no definite conclusions can be drawn regarding the effect 
of bexarotene on lipid metabolism and the underlying processes that are affected by 
bexarotene.
1.5.4 HMG CoA reductase
HMGCR is the rate-limiting enzyme in the cholesterol biosynthesis pathway, and 
statins, inhibitors of HMGCR, are widely used to lower plasma VLDL-C and LDL-C levels 
in patients at risk for CVD. Statins are structural analogs of HMG CoA, the substrate 
for HMGCR, and therefore block the binding of HMG CoA to HMGCR and thereby 
the formation of mevalonate, a precursor of newly synthesized cholesterol.92,93 As a 
consequence, less VLDL is secreted by the liver, resulting in the formation of less LDL.94 
Furthermore, blocking cholesterol synthesis leads to a lowering of the cholesterol 
content of the liver and a subsequent induction of LDLr expression.95-97 These two 
combined mechanisms result in a lowering of plasma (V)LDL levels of up to -40% and a 
reduction of CHD of up to -30%.2,98 Other mechanisms that are potentially involved in the 
cardioprotective effect of statins are their HDL-C increasing effect (up to approximately 
10%), stimulation of blood vessel growth, protection against oxidative modification of 
LDL and anti-inflammatory effects (i.e. reduction of CRP levels).93,99,100
1.5.5 CETP
CETP is a 74 kDa glycoprotein that is expressed in liver, adipose tissue and macrophages. 
Expression of CETP is regulated by various factors, among which SREBP and LXR.101-105 
CETP protein is secreted into the plasma, where it is mainly bound to HDL and facilitates 
the transfer of neutral lipids (CE and TG) between lipoproteins. This leads to the net 
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transfer of CE from HDL to apoB-containing lipoproteins in exchange for TG and thereby 
to reduced HDL-C levels and increased (V)LDL-C levels.106 Mutations that cause CETP 
deficiency (e.g. Intron 14+1 G>A) or reduce CETP mass and/or activity (e.g. D442G and 
TaqIB) lead to increased HDL-C levels. On the other hand, the effect of CETP reduction 
on TG and LDL-C levels is less manifest: some studies show no effect, while others show 
a mild decrease in TG and/or LDL-C levels.107-112
The fact that CETP decreases HDL-C levels raised the idea that CETP is an 
atherogenic protein, and that inhibition of CETP might reduce CVD risk. This led to 
the development of CETP inhibitors. Two compounds, dalcetrapib (JTT-705) and 
torcetrapib, have been extensively studied in both animal models and humans. In 
rabbits, both dalcetrapib and torcetrapib strongly increased HDL-C and reduced 
atherosclerosis development.113,114 In humans, both compounds also increased HDL-C 
in short-term studies.115-118 Torcetrapib was the first CETP inhibitor tested in large 
clinical trials to evaluate its effect on atherosclerosis progression as determined by 
intima media thickness (IMT) and intravascular ultrasound (IVUS) measurements. In 
those studies, all patients were treated with atorvastatin, and either with or without 
torcetrapib. Combination treatment led to an increase in HDL-C of about 60%. However, 
the combination of torcetrapib and atorvastatin did not reduce atherosclerosis 
progression as compared to patients that were treated with atorvastatin alone,119-121 
and even increased mortality, which was attributed largely to cardiovascular death.122 
Unfortunately, the effect of CETP inhibition alone on atherosclerosis development has 
not been evaluated in humans. Furthermore, it is not clear from the clinical trials if the 
detrimental effects observed in the torcetrapib and atorvastatin-treated subjects are a 
general effect of CETP inhibition, or a compound specific effect of torcetrapib.
Because the studies on the effect of CETP or CETP inhibition on atherosclerosis 
development showed contradicting results, the precise role of CETP in atherosclerosis 
development is still not clear. Studies in established experimental mouse models 
for atherosclerosis that have been crossbred with CETP transgenic mice showed 
that CETP expression increases atherosclerosis development.66,123 However, human 
studies present less unequivocal results. Some studies indicate that CETP is 
atherogenic,108,109,111,124-128 whereas other studies indicate that CETP has no effect on 
atherosclerosis development129-131 or is even atheroprotective.132-136 As CETP can affect 
both (V)LDL-C and HDL-C levels, the relative contribution of either of these changes to 
atherosclerosis development can not be determined easily and is therefore not known 
yet. Furthermore, most studies focus on the role of CETP in plasma, and a possible local 
effect of CETP in atherosclerotic lesions has not been studied.
1.6 Outline of this thesis
 
Although statins efficiently lower LDL-C levels in plasma, they do not reduce the 
prevalence of CVD sufficiently. Therefore, other strategies to treat patients at risk for 
CVD are needed. The research described in this thesis focuses on two important factors 
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in CVD development that may be candidate targets to reduce CVD risk, i.e. inflammation 
and CETP.
 In the first part of this thesis, studies addressing the role of inflammation in 
atherosclerosis are described. The aim of Chapter 2 was to study how high cholesterol 
(HC), but not low cholesterol (LC) diet feeding can lead to metabolic inflammation. To 
this end, E3L mice were fed a control diet, an LC diet or an HC diet and the effect of these 
diets on cholesterol homeostasis and on inflammatory parameters was studied. 
 In Chapter 3 we studied the effect of salicylate, a drug that has both anti-
inflammatory and cholesterol-lowering capacities, on pre-existing atherosclerotic 
lesions in E3L mice. To determine if suppressing NF-κB activity with salicylate has an 
additional effect beyond cholesterol lowering alone, we compared salicylate treated 
mice to a group of mice that were matched for plasma cholesterol levels by reducing the 
dietary cholesterol content.
 A drug that modulates inflammation without lowering plasma cholesterol 
levels is the LXR agonist T0901317. Treating E3L mice with T0901317 therefore 
allowed us to analyze the effect of modulating inflammation independent of cholesterol 
lowering on local inflammatory processes in the vessel wall. The effect of T0901317 
on both atherosclerosis development and on pre-existing atherosclerotic lesions was 
studied in Chapter 4.
 The second part of this thesis describes studies involving the role of CETP. 
Clinical trials with the CETP inhibitor torcetrapib showed that the combination of 
torcetrapib and atorvastatin led to an increase in HDL-C of about 60% compared to 
atorvastatin only. Nonetheless, subjects treated with a combination of torcetrapib and 
atorvastatin had a higher incidence of cardiovascular events and an increased death 
rate. However, the effect of torcetrapib treatment alone on atherosclerosis development 
has not been studied in humans. Therefore, in Chapter 5 the effect of torcetrapib with 
or without atorvastatin treatment on atherosclerosis development was studied in E3L.
CETP mice. In this study we also sought to gain insight in the mechanisms underlying 
the adverse effects of torcetrapib on atherosclerosis development.
 CETP affects both (V)LDL-C and HDL-C levels, but the relative contribution 
of these changes in (V)LDL-C and HDL-C levels to atherosclerosis development is 
not known. To address this question, in Chapter 6 the relative contribution of the 
increase in VLDL-C in E3L.CETP mice compared to E3L was determined by comparing 
atherosclerosis development between E3L mice and E3L.CETP mice that were matched 
for VLDL-C levels. Furthermore, this study investigated if there is a possible local effect 
of CETP in atherosclerotic lesions.
 The aim of the study described in Chapter 7 was to specifically determine the 
adverse effects of the chemotherapeutic agent bexarotene on plasma lipids in humans 
and to unravel the underlying mechanism of these effects in mice. To study the potential 
involvement of CETP, the effect of bexarotene was studied in both E3L and E3L.CETP 
mice.
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Objectives: This study aimed at elucidating the molecular mechanisms by which high 
cholesterol feeding induces hepatic inflammation.
Methods and Results: APOE*3-Leiden mice were fed increasing dietary concentrations 
of cholesterol (0% - CON, 0.25% - LC or 1.0% - HC), whereby the liver switches from 
an adaptive (CON and LC diet) to an inflammatory state (HC diet). Cholesterol feeding 
dose-dependently increases plasma cholesterol levels and hepatic cholesteryl ester 
content, and dose-dependently reduces hepatic cholesterol synthesis. In contrast, 
the intrahepatic free cholesterol (FC) concentration and plasma levels of the hepatic 
inflammation marker serum amyloid A (SAA) increased only with HC feeding and were 
found to be significantly correlated (R=0.675), suggesting that increased hepatic FC is 
the molecular stressor that induces hepatic inflammation. Microarray analysis of livers 
showed that HC, but not LC, compromises the endoplasmic reticulum (ER), as indicated 
by altered expression of ER stress-related genes. In line with this, the activity of ER 
stress-inducible transcription factors and positive regulators of SAA expression, NF-κB 
and STAT3, were found to be enhanced upon HC, but not LC feeding.
Conclusion: We propose that HC feeding induces hepatic inflammation and SAA gene 
expression in the liver through an FC-induced ER stress response and a concomitant 
increase of hepatic NF-κB and STAT3 activity.




It is well established that atherosclerosis can be induced in virtually any animal species 
if the circulating cholesterol can be raised to a sufficiently high level 1. It is equally 
evident that from the very beginning of lesion formation, atherogenesis requires an 
inflammatory component, which is thought to drive the progression of the disease 2. Some 
of the variation in lesion progression rate may relate to variation in the inflammatory 
state, and evidence is accumulating that if an inflammatory component is superimposed 
on hypercholesterolemia, it can promote the atherosclerotic process 3,4. 
 Diet-induced inflammation is increasingly recognized as an important risk factor 
for the development of cardiovascular and other metabolic diseases 5,6. We previously 
demonstrated that upon feeding ApoE*3-Leiden (E3L) mice (a humanized model for 
atherosclerosis 7) a diet containing increasing amounts of cholesterol, the liver switches 
from a mainly resilient, adaptive state to a predominantly inflammatory state, which is 
associated with a concomitant increase in plasma levels of systemic inflammation proteins 
such as serum amyloid A (SAA), cytokines and chemokines 8. This systemic inflammatory 
response precedes the onset of early lesion formation and significantly contributes to the 
atherosclerotic process 8. Understanding the mechanisms of this inflammatory response 
is a critical goal in atherosclerosis research. However, the exact way in which dietary 
cholesterol switches the liver to an inflammatory state remained elusive so far.  
 Notably, the hepatic inflammatory gene response by dietary cholesterol 
occurs in mice with markedly different genetic backgrounds and lipoprotein profiles, 
including C57BL6/J mice 9, low density lipoprotein receptor-deficient (LDLR-/-) mice 10, 
ApoE2 knock in mice 10, and E3L mice 8. These findings indicate that the inflammatory 
effect of dietary cholesterol is a common phenomenon and possibly related to influx 
of chylomicron remnants (i.e. the carriers of dietary cholesterol) into the liver rather 
than to plasma cholesterol levels per se 8,11. The question that arises then is: what 
changes occur in cholesterol homeostasis in the liver as a consequence of feeding 
a high cholesterol diet and how do these changes lead to hepatic inflammation? 
 There is recent evidence that perturbation of homeostatic pathways at 
metabolically active sites by a surplus of nutrients, such as lipids and carbohydrates, 
compromises the endoplasmic reticulum (ER) and induces ER stress 12,13. Subsequently, 
ER stress triggers an inflammatory response (metabolic inflammation), which 
results in a chronic, low-grade inflammatory state that is different from the “classic” 
acute phase response 14-16. We reasoned that the induction of hepatic inflammation 
by high cholesterol diet feeding might be a consequence of dysregulation of hepatic 
cholesterol homeostasis and the ensuing ER stress response. To address the 
outstanding questions, E3L mice were fed increasing amounts of dietary cholesterol 
and effects on hepatic cholesterol homeostasis were analyzed and related to the 
development of liver-specific inflammation (e.g. SAA expression). Using transcriptome 
analysis we investigated whether HC diet feeding compromises the ER and activates 
downstream transcription factors that positively regulate SAA, i.e. nuclear factor-κB 





Mice were housed under standard conditions with a 12 h light-dark cycle and had free 
access to food and water unless indicated otherwise. Female E3L mice (n=11-13 per 
group) were treated with a cholesterol-free diet (diet T; Hope Farms, Woerden, The 
Netherlands) (control group, Con), the same diet supplemented with 0.25% w/w 
cholesterol (low cholesterol group; LC), or 1.0% w/w cholesterol (high cholesterol 
group; HC) for 10 weeks. For the drug intervention study, mice were fed the HC diet 
supplemented with rosuvastatin (HC+ROSU; 0.005% w/w; Astra Zeneca), fenofibrate 
(HC+FF; 0.03% w/w; Sigma), or T-0901317 (HC+T; 0.01% w/w; Sigma Aldrich) for 
10 weeks. After 10 weeks of diet feeding, mice were sacrificed, livers were collected 
and snap-frozen in liquid nitrogen and stored at -80°C until further use. All animal 
experiments were approved by the institutional ethical committee on animal care and 
experimentation.
Analysis of plasma cholesterol, SAA and ALAT
Total plasma cholesterol levels were measured after 4 hours of fasting, using kit No. 
1489437 (Roche Diagnostics, Almere, The Netherlands). The plasma levels of SAA 
(Biosource) were determined by ELISA as reported 17. Plasma ALAT levels were 
determined spectrophotometrically using a Reflotron system (Roche Diagnostics) 17.
Analysis of bile acid composition and concentrations in feces 
Feces were collected during a period of 48 hours. Fecal samples were lyophilized and 
weighed. Dried feces (5 mg) were treated with 1 mL alkaline methanol (methanol : 1 M 
NaOH 3:1 v/v) for 2 h at 80°C in screw capped tubes. Then 9 mL of distilled water was 
added and the tubes were mixed and centrifuged. The supernatant was applied to a 
prepared Sep-Pak C18 solid phase extraction cartridge for determination of individual 
bile acid concentrations. After a clean up by wash procedures, bile acids were eluted 
with 75% methanol 18. Nor-hyodeoxycholate was added as an internal standard. The 
eluate was evaporated to dryness and the bile acids were derivatized as described 18. The 
bile acid derivatives were separated on CP-Sil 5B GC column (Chrompack International, 
Middelburg, The Netherlands) in a Varian 3800 gas chromatograph equipped with flame 
ionization detector (FID). The injector and the FID were kept at 300°C. Helium was used 
as carrier gas at a flow rate of 1.4 mL/min. The column temperature was programmed 
from 230 to 280°C at a rate of 40°/min. Bile acid derivatives were introduced by split-
injection (split ratio 20:1). Quantitation was based on the area ratio of the individual 
bile acid to the internal standard.
Analysis of neutral sterol composition and concentrations in feces
Dried feces (5 mg) were treated with 1 mL alkaline methanol as described for bile acid 
measurement to liberate neutral sterols from feces material. Prior to this treatment 
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5a-cholestane was added as internal standard. After treatment the tubes were cooled 
to room temperature and the neutral sterols extracted two times with 2 mL petroleum 
ether. The combined petroleum ether layers were evaporated to dryness and the neutral 
sterols were silylated as described 18. Analysis of the sterol derivatives was performed 
by GC applying the same column as described for the bile acid derivatives. Quantitation 
was based on the area ratio of the individual neutral sterol to the internal standard.
Analysis of liver lipids and bile acids
To determine the cholesterol content of the liver, liver samples were homogenized and 
samples were taken for measurement of protein content. 2 mg of cholesterol acetate 
was added to each sample as an internal standard. Lipids were extracted according 
to Bligh and Dyer 19. The neutral lipids were separated by high performance thin 
layer chromatography on silica-gel-60 pre-coated plates as described previously 20. 
Quantification of the lipid amounts was performed by scanning the plates with a Hewlett 
Packard Scanjet 4c and by integration of the density areas with the computer program 
Tina version 2.09. To analyze liver histology, livers were fixed in phosphate-buffered 
4% formaldehyde, dehydrated and embedded in paraffin. Cross-sections were stained 
with hematoxylin-phloxin-saffron (HPS) for histological analysis. Quantification of the 
hepatic bile acid content was performed as described 21. 
Gene expression data analysis
For microarray analysis we used a previously published transcriptomics open-
source dataset that investigated the effect of 10 weeks of 0%, 0.25% and 1% (w/w) 
cholesterol diet feeding in E3L mice employing comparable experimental conditions 8. 
Datasets are freely accessible online at www.ebi.ac.uk/arrayexpress. Normalized signal 
intensities below 10 were replaced by 10. Probe sets with an absent call in all arrays 
were removed before further analysis of the data. Statistical analysis was performed 
in BRB ArrayTools (Dr. Richard Simon and Amy Peng Lam, http://linus.nci.nih.gov/
BRB-ArrayTools.html). Con, LC and HC groups were tested for differentially expressed 
genes using class comparisons with multiple testing corrections by estimation of false 
discovery rate (FDR). Differentially expressed genes were identified at a threshold for 
significance of a<0.01 and a FDR<5%. Within the set of differentially expressed genes, 
a Student’s t-test was carried out to analyze differential expression of individual genes 
between the cholesterol-fed groups and the Con group. For the LC and HC groups, 
differences of P<0.01 vs. Con were considered significant. Enrichment analysis of 
differentially expressed genes was performed using GenMAPP, biological processes 
with a Z-score >2 and PermuteP < 0.05 were considered as significantly changed.  
Microarray data are available from the ArrayExpress database (http://www.ebi.ac.uk/
microarray-as/ae/), accession number E-TABM-253. 
Analysis of NF-κB and STAT 3 activity
To determine the amounts of active NF-κB and STAT3 activity in livers, liver homogenates 
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were prepared using the Nuclear Extract Kit (no. 40010, Active Motif, Rixensart, 
Belgium) and samples were taken to determine the protein content. Equal amounts 
of protein were used in the NF-κB and STAT3 TransAM transcription factor assay 
kits no. 40097 and 45196 (Active Motif, Rixensart, Belgium), respectively. The assays 
were performed according to the manufacturer’s instructions. The amount of active 
transcription factor present in each sample was determined by measuring the binding 
of the active transcription factor to a consensus sequence in the presence of either a 
competitive or a mutated (non-competitive) oligonucleotide to be able to correct for 
aspecific binding.
Statistical analysis
In general, significance of difference was calculated by 1-way analysis of variance (ANOVA) 
test followed by a least significant difference post hoc analysis. For analysis of fecal sterols 
and bile acids and for gene expression analysis, differences were assessed using the 
Student’s t test. The level of statistical significance was set at P<0.05 unless stated otherwise. 
SPSS 14.0 for Windows (SPSS, Chicago, USA) was used for statistical analysis.   
Results		 	
	
Dietary cholesterol intake and total fecal cholesterol excretion	
Female E3L mice were fed a control diet without cholesterol (CON), or the same 
diet supplemented with either a low dose (0.25% w/w) of cholesterol (LC) or a 
high dose (1.0% w/w) of cholesterol (HC). After 10 weeks, we explored overall 
cholesterol homeostasis in E3L mice by examining the relationship between 
cholesterol input (calculated from the food intake and the percentage of cholesterol 
in the diet) and cholesterol output, i.e. fecal excretion of neutral sterols, which 
consisted for over 90% of cholesterol, and fecal excretion of bile acids.  
* P<0.05 compared to CON
** P<0.01 compared to CON
*** P<0.001 compared to CON






0.0 ± 0.0 18.5 ± 0.7 *** 66.1 ± 2.2 ***
Fecal	neutral	sterol	
excretion	(mmol/day)
2.2 ± 0.1   6.5 ± 0.0 *** 54.5 ± 4.1 **
Fecal	bile	acid	excretion	
(mmol/day)
1.9 ± 0.3 2.9 ± 0.6 4.3 ± 0.6 *
Intake	-	Excretion	
(mmol/day)
-4.1 ± 0.4 ‡ 9.1 ± 1.2 ‡ 7.3 ± 5.6 ‡
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 The CON group (with no cholesterol in the diet) excreted 4.1±0.4 mmol/day 
cholesterol and cholesterol derivatives in feces, indicating net cholesterol synthesis. In 
the LC group, calculation of the difference between cholesterol intake and fecal excretion 
showed that there was net uptake of 9.1 mmol cholesterol per day (P<0.01). In the HC group, 
there was net uptake of 7.3 mmol cholesterol per day (P<0.05). Notably, the net amount 
of cholesterol uptake is not significantly different between the LC and HC groups.  
 Qualitative analysis of the cholesterol products in feces showed that 
the amount of neutral sterols increases significantly in a dose-dependent way 
from 2.2±0.1 mmol/day in the CON group to 6.5±0.0 mmol/day in the LC group 
(P<0.001) and 54.5±4.1 mmol/day in the HC group (P<0.01). Similarly, the amount 
of bile acids in feces increases in a dose-dependent way from 1.9±0.3 mmol/
day in the CON group to 2.9±0.6 mmol/day in the LC group and 4.3±0.6 mmol/
day in the HC group (P<0.05) (Table 1). This indicates that with increasing dietary 
cholesterol intake, adaptations in hepatic cholesterol homeostasis take place that 
lead to an increase in the excretion of cholesterol and liver-derived bile acids.  
 
Effect of dietary cholesterol on plasma cholesterol and inflammation in E3L mice  
To evaluate the effect of increasing amounts of dietary cholesterol on plasma cholesterol 
and inflammation markers, steady state levels of plasma cholesterol were determined. 


































































levels. Mice were fed a diet containing 0% 
(CON), 0.25% (LC) or 1.0% (HC) cholesterol 
for 10 weeks. Then, plasma cholesterol (A), 
SAA (B) and ALAT (C) levels were measured. 















LC (P<0.001), and was further elevated to 18.7±3.6 mM in HC (P<0.001) (Figure 1A). 
Corresponding plasma levels of the liver-derived inflammation marker SAA were 
2.3±1.5 mg/ml (CON), 2.4±2.2 mg/ml (LC), and 11.2±6.9 mg/ml (HC) (Figure 1B), 
respectively, indicating that with increasing dietary cholesterol, plasma cholesterol 
levels increase, while plasma SAA levels increase with 1.0% cholesterol (P<0.001), but 
not 0.25% cholesterol. Levels of the liver activation marker ALAT were 19±3 U/L in the 
CON group and increased dose dependently upon cholesterol feeding to 46 ±21 U/L in 
the LC (P<0.05) and 77±24 U/L in the HC group (P<0.001).
 
Hepatic cholesterol homeostasis
To get further insight into how the liver handles increasing amounts of cholesterol, the 
contents of hepatic cholesteryl esters (CE), free cholesterol (FC) and bile acids were 
measured. Under CON conditions, the liver contained 15.9±4.7 mg CE/mg protein 
(Figure 2A). This dose-dependently increased to 35.9±8.6 mg/mg protein (P<0.01) and 
58.4±9.6 mg/mg protein (P<0.001) with the LC and HC diets, respectively. The amount 
of FC was 14.1±2.5 mg/mg protein in the CON group and remained unchanged (14.4±0.7 
mg/mg protein) in the LC group, whereas it increased significantly to 19.8±2.8 mg/
mg protein (P<0.01) in the HC group (Figure 2B). Fat accumulation in the liver was 
also markedly increased in livers of HC, but not of LC diet fed mice compared to the 
CON group, as is shown in representative pictures of each group in Figure 2C. Oil-red-O 
staining confirmed the accumulation of lipids in livers of HC diet fed mice (Figure 
2D). Hepatic bile acid levels were not significantly different between the CON group 
(20.4±6.3 ng/mg liver) and the LC group (27.2±7.1 ng/mg liver), but were markedly 
lower in the HC group (11.1±3.0 ng/mg liver, P<0.05) (Figure 2E). 
Next, the expression of genes involved in regulating cholesterol homeostasis 
was analyzed (Table 2) by microarray analysis. Upon cholesterol feeding, cholesterol 
biosynthesis, as reflected by 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) 
mRNA expression, decreased in a dose-dependent manner (P<0.01). Furthermore, the 
expression of the LDL receptor (LDLr), which mediates cholesterol uptake from the 




Bsep 1.0 1.0 1.5 *
Hmgcr 1.0 -2.8 * -10.6 *
Ldlr 1.0 -1.4 * -2.1 *
Saa1 1.0 1.5 3.5 *
Saa2 1.0 1.4 3.2 *
Saa3 1.0 1.4 3.2 *
Saa4 1.0 1.5 4.1 *
*  significantly different from CON, P<0.01
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increase in plasma cholesterol levels (Figure 1A). The expression of genes involved in 
cholesterol excretion (ABCG5, ABCG8) was not significantly changed upon cholesterol 
feeding (data not shown), while the expression of the bile salt export pump (BSEP) was 
significantly increased in the HC group compared to the CON and LC groups (P<0.01), 
explaining the decrease in hepatic bile acid levels in the HC group.
Hepatic FC content correlates with plasma SAA levels
The above data show that cholesterol feeding induces several adaptations in cholesterol 
homeostasis that are dose-dependent, such as the reduction of endogenous cholesterol 
synthesis and cholesterol uptake from the plasma, which are two processes regulated 
via SREBP-1c, and the increase in the levels of plasma cholesterol, hepatic CE and 



















































































Figure	 2. Hepatic	 cholesteryl	 ester	 and	
free	cholesterol	levels.	Mice were fed a diet 
containing 0% (CON), 0.25% (LC) or 1.0% 
(HC) cholesterol for 10 weeks. Then the 
mice were sacrificed and hepatic cholesteryl 
ester (A), free cholesterol (B) and bile acid 
(D) contents were determined. Livers were 
cross-sectioned and representative HPS 
stained pictures of each group are shown (C). 




diet feeding. In all, of the measured parameters only the hepatic FC content changed 
concomitantly with plasma SAA levels, suggesting that the hepatic FC content is the 
molecular trigger involved in inducing hepatic inflammation. Indeed, linear regression 
analysis showed a significant correlation between hepatic FC and plasma SAA (R=0.675; 
P<0.01).
	
Intervention with drugs modulating cholesterol metabolism 
underlines the relation between hepatic FC and plasma SAA 
To further explore the relationship between hepatic FC and inflammation, we have 
evaluated how drugs that modulate cholesterol metabolism affect hepatic FC levels 
and inflammation. To that end, mice were fed the HC diet supplemented with either 
the HMGCR inhibitor rosuvastatin (ROSU), the PPARα agonist fenofibrate (FF) or the 
LXR agonist T-0901317 (T) for 10 weeks. Intervention with ROSU or FF normalized 
hepatic FC levels, and concommitantly SAA levels were reduced to a level that was 
comparable to that in CON fed mice. On the other hand, hepatic FC levels remained high 
in mice treated with HC+T (Figure 3A), and plasma SAA levels also remained elevated 
(Figure 3B). These data show that lowering of hepatic FC levels by drug intervention 
is paralleled by a reduction in plasma SAA levels, thus supporting our finding of that 
hepatic FC levels are linked to the development of hepatic inflammation.
HC diet but not LC diet feeding induces ER stress and increases the activity of the 
inflammatory mediators NF-κB and STAT3
FC has been shown to induce ER stress and subsequently an inflammatory response in 
macrophages in vitro 15. We hypothesized that ER stress may also underlie the metabolic 








































































Figure	3.	Hepatic	FC	 levels	and	plasma	SAA	after	drug	 intervention.	Mice were fed a diet 
containing 0% (CON), 0.25% (LC) or 1.0% (HC) cholesterol or the HC diet supplemented with 
ROSU, FF, or T) for 10 weeks. Then the mice were sacrificed and hepatic free cholesterol (FC) and 












Cholesterol Homeostasis and Metabolic Inflammation
43
process analysis on microarray data of livers from CON, LC, and HC mice revealed that 
the expression of ER stress responsive genes was significantly changed upon HC (Z>2; 
P<0.01), but not LC feeding, identifying HC feeding as an inducer of ER stress (Table 3).
One of the reported consequences of ER stress is the induction of an 
inflammatory response. To further evaluate whether or not the dietary cholesterol-
induced ER stress observed in the present study also is paralleled by an inflammatory 
response, and to gain insight into the nature of this inflammation we examined the 
activity of NF-κB, STAT3 and CCAAT-enhancer-binding protein (C/EBP)a/b, which are 
important transcription factors involved in the regulation of SAA gene expression 8. 
Notably, NF-κB (Figure 4A) and STAT3 (Figure 4B) activity did not change upon LC diet 




Hspa4 1.0 1.1 1.2 *
Hspa8 1.0 -1.1 -1.5 *
Hspb1 1.0 1.0 2.2 *
Vcp 1.0 1.1 1.3 *
Herpud1 1.0 -1.1 -1.6 *
Hspa14 1.0 1.1 1.3 *
Edem1 1.0 1.1 1.5 *
 
Hsp is heat shock protein; Vcp is valosin containing protein; Herpud1 is homocysteine-inducible, 
endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1; Edem1 is ER degradation 
enhancer, mannosidase alpha-like 1










































Figure	4.	Hepatic	NF-κB	and	STAT3	activity.	Mice were fed a diet containing 0% (CON), 0.25% 
(LC) or 1.0% (HC) cholesterol for 10 weeks. Then the mice were sacrificed and hepatic NF-κB (A) 
and STAT3 (B) activity were determined. Values are means ± SD. *P<0.05. 
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not differ in C/EBPa or C/EBPb activity (data not shown). Analysis of hepatic SAA gene 
expression showed increased mRNA levels of all four SAA isoforms, i.e. SAA1, SAA2, 
SAA3 and SAA4 in the HC but not the LC group, thus reflecting the observed increase in 
STAT3 and NF-κB activity and explaining the increased plasma levels of SAA upon HC, 
but not LC diet feeding (Table 2).
Discussion	 	
Nutrient excess-induced inflammation is increasingly recognized as an important risk 
factor for the development of cardiovascular and other metabolic diseases 5,6, but the 
mechanistic basis for the connection between metabolic overload and inflammation is 
poorly understood. In a previous study we demonstrated that upon feeding E3L mice a 
diet containing increasing amounts of cholesterol, the liver switches from a mainly 
resilient state to an inflammatory state, characterized by increased expression of genes 
coding for inflammatory factors such as  cytokines and chemokines, which significantly 
contributed to atherogenesis 8. The present study was directed at understanding the 
mechanisms underlying the link between high cholesterol feeding and the inflammatory 
responses in liver by feeding E3L mice a CON, LC, or HC diet. We demonstrated that the 
HC, but not the LC or CON diet induces a hepatic inflammatory response in E3L mice, as 
exemplified by increased gene expression of the NF-κB/STAT3-regulated inflammation 
marker SAA, and accompanied by an increase in cellular FC levels in HC only. Elevated 
FC is a known inducer of ER stress and inflammation 15. In line with this we showed that 
an increase in hepatic FC levels was paralleled by changes in the expression of ER stress-
related genes. Furthermore, we found increased activity of downstream targets of ER 
stress, the transcription factors NF-κB and STAT3, which positively regulate SAA gene 
expression. Taken together, our data suggest that a disturbed cholesterol homeostasis 
caused by feeding a HC diet results in elevated intrahepatic FC concentrations, which 
evoke an ER stress-type response and a concomitant increase in hepatic NF-κB and 
STAT3 activity, thereby inducing enhanced SAA gene expression.  
  Our data indicate that increased hepatic FC levels due to high dietary cholesterol 
intake, but not plasma cholesterol levels, correlate with the occurrence of hepatic 
inflammation. The lack of a relationship between plasma cholesterol and hepatic 
inflammation in our study is in line with reports stating that chylomicron remnants, 
which transport the dietary cholesterol to the liver, rather than plasma cholesterol 
levels are related to dietary cholesterol-induced inflammation 8,11. This conclusion is 
deviant from a recent report suggesting that increased plasma lipoprotein levels trigger 
hepatic inflammation 10. This latter conclusion was based on the observation that a high 
fat/high cholesterol (HFC) diet led to an increase in Mac1 positive cells in livers of LDLR-
/- and ApoE2 knock-in mice, but not of C57BL6/J wild type (wt) mice. However, the 
authors also reported increased expression of CD68, tumor necrosis factor-α, and 
monocyte chemoattractant protein-1 in all three mouse-models, indicating that hepatic 
inflammation was also present in wt mice fed an HFC diet, despite low plasma lipoprotein 
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levels. Unfortunately hepatic FC levels were not reported in this study.  
  This study addresses the important question why disturbance of hepatic 
cholesterol homeostasis leads to an inflammatory response. In vitro studies showed 
previously that FC loading of macrophages leads to ER stress, and subsequently to NF-
κB mediated cytokine expression 15. In line with this notion, we now show that FC-
induced ER stress may also be relevant for HC diet-induced hepatic inflammation in 
vivo. An increase in hepatic FC was paralleled by changes in the expression of ER stress-
related genes. Furthermore, we found increased activity of downstream targets of ER 
stress, the transcription factors NF-κB and STAT3 that regulate SAA gene expression 
and increased mRNA expression of all SAA isoforms. Also, a positive and statistically 
significant correlation was found between hepatic FC levels and plasma SAA levels. 
Strikingly, this relationship between hepatic FC levels and plasma SAA was maintained 
in the presence of drugs that interfere in cholesterol metabolism in different ways 
(ROSU, FF and T). ROSU and FF lowered hepatic FC levels to control levels and 
correspondingly reduced plasma SAA concentrations, while with T increased hepatic FC 
and plasma SAA levels were maintained. Reduction of hepatic FC therefore seems an 
interesting therapeutic target to reduce cholesterol-induced metabolic inflammation. 
  In addition to cholesterol, other nutrients have also been shown to induce 
metabolic inflammation via increased NF-κB activity, and there is increasing evidence 
that the ER is the central site for the sensing of metabolic stress and the translation of 
that stress into chronic inflammatory signals and responses 14. For example, high fat diet 
feeding induces a 2-fold increase in NF-κB activity in livers of wild type mice 22. 
Furthermore, infusion of free fatty acids in rats increases hepatic NF-κB activity about 
1.7 fold 23. Beside lipids, hyperglycemia has also been shown to mildly induce NF-κB 
activity in vitro in hepatocytes 24. The mild increase in NF-κB activity we observe during 
metabolic inflammation is thus comparable to other types of metabolic inflammation 
that have been described. In the studies mentioned, STAT3 activity was either not 
determined or not changed. However, it is known that STAT3 activity is part of the 
insulin signaling cascade and that impaired STAT3 signaling leads to an insulin resistant 
state 25. The increase in STAT3 activity that we observed as a consequence of HC diet 
feeding may thus well be typical for cholesterol-induced metabolic inflammation.  
  Although many of the same mediators and signaling pathways are involved, 
metabolic inflammation (sometimes referred to as “low-grade” or “chronic” 
inflammation) and classic or acute phase inflammation clearly differ in cause, intensity, 
duration, and long-term consequences. Classically, inflammation is defined as a response 
to injury and is characterized by redness, swelling, pain and fever 14. This response is 
usually short and is a crucial and beneficial component of tissue repair. Metabolic 
inflammation is principally triggered by nutrients and metabolic surplus and its 
induction is mild compared to an acute phase response 14. During the acute phase 
response, NF-κB and STAT3 activity have been shown to be increased manifold 26,27, 
whereas we only find mild increases in NF-κB and STAT3 activity upon cholesterol-
induced metabolic inflammation. Although the induction of inflammation that we 
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observe upon HC diet feeding is very mild compared to an acute phase response, it is not 
less important: low grade, systemic inflammation has increasingly been recognized as a 
risk factor for the development of cardiovascular disease, insulin resistance and diabetes 
over the past decades 28-31. 
  The current lifestyle of people in our Western society is increasingly associated 
with metabolic overload. Although there are acute compensatory mechanisms to 
maintain metabolic homeostasis healthy, these mechanisms are not sufficient in the 
long term: 4 weeks of high dietary cholesterol intake in the form of eggs induces an 
increase in plasma CRP levels in humans 32.  As our western life style favors long term 
exposure to nutrient excess, slightly shifting the metabolic balance towards enhanced 
clearance of nutrients may have a significant beneficial impact on health. However, 
before such manipulation becomes feasible, much more needs to be understood about 
the pathways that lead to accumulation of an excess of hepatic FC and about the reason 
that the liver is not capable of handling the additional amount of cholesterol to which it 
is exposed upon HC diet feeding compared to LC diet feeding. Future studies are needed 
to elucidate how the liver changes from an adaptive state (under conditions of LC diet 
feeding) to a non-adaptive state (under conditions of HC diet feeding) that leads to 
accumulation of FC in the liver. This may then lead to new treatment strategies that 
improve the capacity of the liver to handle increasing amounts of cholesterol, thus 
preventing the accumulation of FC and the resulting inflammatory response. 
  In conclusion, our data show that a high dietary intake of cholesterol induces a 
chronic, low-grade inflammatory state in liver, as reflected by increased plasma SAA 
levels. We propose that as a result of disturbed cholesterol homeostasis, intrahepatic FC 
levels increase, which is accompanied by induction of ER stress (as suggested by altered 
expression of ER stress-related genes) and increased activity of the SAA expression-
inducing transcription factors NF-κB and STAT3.
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Aims: This study aimed at determining if suppressing inflammation using the NF-κB 
inhibitor salicylate contributes to atherosclerosis regression on top of cholesterol-
lowering.
Methods and Results: ApoE*3-Leiden mice were fed a high cholesterol diet to induce 
the formation of mild atherosclerotic lesions. Subsequently, one group of mice was 
sacrificed to determine lesion area and lesion severity at the start of different regression 
treatments (reference group). A second group of mice was then fed the same high 
cholesterol diet supplemented with salicylate (HC+SAL) to suppress NF-κB activity. As 
salicylate not only quenches inflammation but also reduces plasma cholesterol levels 
(- ~50%), a third group of mice was fed a low cholesterol (LC) diet to establish similar 
plasma cholesterol levels as obtained by salicylate treatment. The effects of these 
treatments on lesion area and severity were assessed at 8 and 16 weeks. Compared 
to the reference group, HC+SAL suppressed hepatic NF-κB activity, tended to suppress 
hepatic STAT3 activity and reduced plasma levels of the hepatic inflammation marker 
SAA. Compared to HC+SAL, LC diet feeding suppressed hepatic NF-κB activity to a lesser 
extent, similarly suppressed STAT3 activity, and more strongly reduced plasma SAA 
levels; HC+SAL and LC feeding similarly suppressed aortic NF-κB activity. At 16 weeks 
after starting the regression treatments, neither HC+SAL nor LC treatment showed an 
effect on lesion area (compared to the reference group), but HC+SAL had reduced the 
macrophage area of lesions and increased the plaque stability index (ratio of collagen 
to macrophage area) more strongly than LC diet feeding.
Conclusions: The combined effect of suppressing NF-κB activity and reducing plasma 
cholesterol with SAL promotes lesion regression by reducing macrophage area and 
induces lesion stability more efficiently than cholesterol lowering alone.
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Introduction
Hypercholesterolemia is widely recognized as an important risk factor for atherosclerosis 
development.1 In addition, it is well-established that inflammation plays a role in all 
stages of atherosclerosis development, from initiation of lesion formation to progression 
into a more complex lesion and eventually to plaque rupture.2,3 Targeting either of these 
factors can reduce the formation of new atherosclerotic lesions, which is of obvious 
importance. However, in a clinical setting, subjects at risk for cardiovascular events 
often already have established atherosclerotic lesions. For these subjects, treatment 
strategies aimed at regression of pre-existing lesions are important to reduce the 
prevalence of cardiovascular events. It is therefore crucial to gain insight in the processes 
involved in lesion regression. As a first approach to tackle this research question we 
chose to evaluate the effect of lowering plasma cholesterol and inflammation on plaque 
regression, because of their key role in atherosclerotic lesion development.
 Over the past years, a number of animal studies have addressed the effect of 
cholesterol lowering on pre-existing lesions. These studies have shown that reducing 
plasma cholesterol induces a strong decrease in the number of lesional macrophage 
foam cells4-6 after a few days.7 Later in time, a reduction of plaque size was reported.4,5,7 
In humans, non-invasive imaging confirmed that plasma cholesterol-lowering leads to 
atherosclerosis regression.8 Thus, various studies have shown that cholesterol lowering 
can induce atherosclerosis regression. However, the role of inflammation in regression 
of pre-existing plaques has been poorly studied.
Salicylate (SAL) is an anti-inflammatory drug that inhibits the activity of nuclear 
factor-κB (NF-κB), a key mediator of the inflammatory response. SAL acts by suppressing 
the activity of the inhibitor of κB (IκB) kinase (IKK) complex,9 thereby preventing the 
phosphorylation of IκB, and the subsequent release and nuclear translocation of NF-κB. 
We found that SAL also lowered plasma cholesterol levels in APOE*3-Leiden (E3L) mice 
(Zadelaar et al., unpublished results).
In the present study we aimed at determining whether or not suppressing NF-
κB activity with SAL can induce regression of pre-existing atherosclerotic lesions on top 
of its cholesterol-lowering effect. To study this, we used E3L mice, a mouse model that 
responds in a human-like manner to anti-atherosclerotic drugs and that has been shown 
to be a useful model for atherosclerosis regression.4,6,10 After inducing atherosclerosis 
formation by feeding E3L mice a high cholesterol (HC) diet for 19 weeks, we treated 
these mice with the same diet, supplemented with SAL for 8 or 16 weeks to study 
the effect of SAL on pre-existing plaques. As SAL treatment resulted in a lowering of 
plasma cholesterol, we used a control group that was fed a diet with a lower cholesterol 
content (LC diet) to match for the plasma cholesterol levels in the SAL treated mice. 
This experimental set-up enabled us to study the effect of suppressing NF-κB activity on 






Female E3L mice of 12-14 weeks old (n=14-15 per group) were housed under standard 
conditions with a 12 h light-dark cycle and had free access to food and water unless 
indicated otherwise. All mice were fed a HC diet containing 15% (w/w) cacao butter 
(diet T, Hope Farms, Woerden, the Netherlands) supplemented with 1.0% (w/w) 
cholesterol (Sigma) for 19 weeks. After this period, mice were randomized into four 
groups according to their plasma cholesterol levels. One group of mice (n=15) was 
sacrificed by CO2 inhalation and hearts and livers were isolated for further analysis. 
One group of mice (n=30) received an HC diet supplemented with 0.4% (w/w) salicylic 
acid (cat. no. 24,758-8, Aldrich, Steinheim, Germany) for 8 (n=15) or 16 (n=15) weeks. 
The other group of mice (n=30) received an LC diet containing 15% (w/w) cacao butter 
supplemented with 0.12% (w/w) cholesterol for an additional 8 (n=15) or 16 (n=15) 
weeks. After these periods the mice were sacrificed by CO2 inhalation and hearts and 
livers were isolated for further analysis. During the study, blood was drawn every 4 
weeks after 4 h of fasting. All animal experiments were approved by the institutional 
ethical committee on animal care and experimentation.
Analysis of plasma cholesterol, cholesterol distribution over lipoproteins and inflammatory 
markers
Plasma total cholesterol was measured by an enzymatic procedure using kit no. 
1489437, Roche Diagnostics, Mannheim, Germany. For lipoprotein profiles, plasma was 
pooled per group and fractionated using an ÄKTA fast protein liquid chromatography 
(FPLC) system (Pharmacia, Roosendaal, The Netherlands) as described.11 Fractions 
of 50 µL were collected and assayed for cholesterol as described above. Plasma levels 
of serum amyloid A (SAA) (Tridelta, Ireland) were determined by ELISA, according to 
manufacturer’s instructions.
Analysis of NF-κB and STAT 3 activities in liver and aorta
To determine the amounts of active NF-κB and STAT3 activity in livers and/or aortas, 
homogenates of each tissue were prepared using the Nuclear Extract Kit (no. 40010, 
Active Motif, Rixensart, Belgium) and samples were taken to determine the protein 
content. Equal amounts of protein were used in the NF-κB TransAM and STAT3 TransAM 
transcription factor assay kits no. 40097 and 45196 (Active Motif, Rixensart, Belgium), 
respectively. The assays were performed according to the manufacturer’s instructions. 
The amount of active transcription factor present in each sample was determined by 
measuring the binding of the active transcription factor to a consensus sequence in the 
presence of either a competitive or a mutated (non-competitive) oligonucleotide to be 
able to correct for non-specific binding.
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Atherosclerosis quantification
After isolation, hearts were fixed in phosphate-buffered 4% formaldehyde, dehydrated, 
embedded in paraffin, and cross-sectioned throughout the aortic root area. For each 
mouse, 4 sections with 50 µm intervals were used for atherosclerosis measurements. 
Sections were stained with hematoxylin-phloxin-saffron (HPS) for histological analysis. 
Lesion area was determined using Cell D imaging software (Olympus Soft Imaging 
Solutions). AIA 31240 antiserum (1:3000, Accurate Chemical and Scientific) was used 
to quantify the macrophage area and Sirius Red was used to quantify the collagen 
area. The plaque stability index was determined by dividing the collagen area by the 
macrophage area for each mouse.
Statistical analysis
Significance of difference was calculated by one-way analysis of variance (ANOVA) 
test followed by a least significant difference post hoc analysis. SPSS 16.0 for Windows 
(SPSS, Chicago, USA) was used for statistical analysis.
Results
Salicylate treatment and LC diet feeding reduce HC diet-induced plasma VLDL-cholesterol 
to a similar extent
To study the effect of suppressing inflammation on top of cholesterol lowering on 
pre-existing atherosclerotic lesions, 75 E3L mice were fed a high cholesterol (HC) 
diet containing 1.0% (w/w) cholesterol for 19 weeks to induce the formation of mild 
atherosclerotic lesions. HC diet feeding increased plasma cholesterol levels from 
approximately 2 mM to 15.4±2.7 mM (Figure 1A). After 19 weeks, the mice were 
randomized into 3 different groups according to plasma cholesterol levels. One group 
of mice was sacrificed at this time point as a reference group (HC/REF, n=15) for 
atherosclerotic lesion development. A second group of mice was then fed the HC diet 
supplemented with 0.4% (w/w) SAL to suppress NF-κB activity for an additional 8 
(n=15) or 16 weeks (n=15). As HC+SAL treatment reduced plasma cholesterol levels (to 
7.9±1.5 mM), a third group of mice was fed a low cholesterol (LC) diet for an additional 
8 (n=15) or 16 weeks (n=15) to match for the plasma cholesterol levels in the HC+SAL 
treated mice, resulting in an average plasma cholesterol of 7.6±1.7 mM that was not 
significantly different from plasma cholesterol in the HC+SAL treated group at any of 
the time points measured. Lipoprotein profiling showed that the observed decrease in 
plasma cholesterol was mainly confined to the VLDL fraction and to a lesser extent to 
the LDL/HDL-1 fraction and that the cholesterol distribution profile was similar in the 
HC+SAL and LC groups (Figure 1B). After prolonged 8 or 16 weeks of HC+SAL or LC diet 





















































Figure 1: SAL treatment and 
LC diet feeding reduce HC diet-
induced plasma VLDL-cholesterol 
to a similar extent. E3L mice were 
fed a HC diet for 19 weeks. After 19 
weeks, mice were randomized into 
three different groups. One group of 
mice was sacrificed as a reference 
group. A second group of mice was 
then fed the HC diet supplemented 
with SAL for an additional 8 or 16 
weeks. A third group of mice was 
fed an LC diet for an additional 8 or 
16 weeks to match for the plasma 
cholesterol levels in the HC+SAL 
treated group. At the indicated time 
points, blood was drawn and plasma 
was assayed for total cholesterol (A). 
Values are means±SD. (***P<0.001 
compared to the HC group at t=19 
weeks) Pooled plasma samples were 
fractionated using FPLC and the 
individual fractions were assayed for 
TC at different time points during the 
course of the study. Representative 
pictures of one time point are shown 
(B) (HC group: t=19 weeks; HC+SAL 
group: t=27 weeks; LC group: t=27 
weeks).
Salicylate suppresses hepatic NF-κB activity, but not overall hepatic inflammation, beyond 
LC diet feeding
To evaluate the effect of SAL treatment on hepatic inflammation, plasma levels of the 
hepatic inflammatory marker SAA were measured. HC diet feeding increased plasma 
SAA from 5.4±0.4 μg/mL at baseline (t=0) to 10.3±3.9 μg/mL after 19 weeks (Figure 
2A). Subsequent treatment with HC+SAL reduced SAA to 8.0±3.9 μg/mL after 8 weeks 
(P<0.05) and to 7.6±3.3 μg/mL after 16 weeks (P<0.01 compared to 19 weeks of HC diet 
feeding). LC diet feeding reduced SAA levels to 6.2±2.0 μg/mL after 8 weeks (P<0.001) 
and to 5.5±2.0 μg/mL after 16 weeks (P<0.001 compared to 19 weeks of HC diet 
feeding). The reduction of SAA by cholesterol lowering alone was beyond that achieved 
with HC+SAL treatment, and became significantly different after 16 weeks (P<0.05).
 To verify that SAL treatment reduced hepatic NF-κB activity, livers were 
homogenized and assayed for NF-κB activity. NF-κB activity in HC diet fed mice was set 
at 100 AU (Figure 2B). Compared to HC diet fed mice, prolonged treatment of 8 weeks 
with HC+SAL strongly suppressed NF-κB activity (-75%, P<0.001), which was sustained 
after 16 weeks of prolonged treatment (-63%, P<0.001). Compared to the HC group, 
prolonged feeding with the LC diet reduced NF-κB activity to a lesser extent than HC+SAL 
























































































Figure 2: Salicylate suppresses hepatic 
NF-κB activity, but not overall hepatic 
inflammation beyond LC diet feeding. 
E3L mice were fed a HC diet for 19 weeks. 
After 19 weeks, mice were randomized 
into three different groups. One group 
of mice was sacrificed as a reference 
group. A second group of mice was then 
fed the HC diet supplemented with SAL 
for an additional 8 or 16 weeks. A third 
group of mice was fed an LC diet for an 
additional 8 or 16 weeks to match for the 
plasma cholesterol levels in the HC+SAL 
treated group. Blood was drawn at the 
time points indicated and plasma SAA 
levels were determined (A). (*P<0.05, 
**P<0.01, ***P<0.001 compared to t=0 weeks; #P<0.05, ##P<0.01, ###P<0.001 compared to 
the HC diet group at t=19 weeks; $P<0.05 compared to the LC diet fed group at the same time 
point) After prolonged 8 or 16 weeks of HC+SAL or LC diet feeding, the mice were sacrificed and 
livers were isolated and homogenized. The presence of active NF-κB (B) and STAT3 (C) in liver 
homogenates was determined. Values are means±SD. (*P<0.05, **P<0.01, ***P<0.001)
treatment (P<0.01), both after an additional 8 weeks (-33%, P<0.01) and 16 weeks 
(-27%, P<0.05) of experimental treatment. To verify that the enhanced suppression of 
NF-κB activity observed for HC+SAL treatment compared to LC treatment was not a 
general anti-inflammatory effect, we also determined the activity of signal transducer 
and activator of transcription 3 (STAT3), which is another transcription factor that can 
regulate the expression of inflammatory genes. Compared to the HC group, cholesterol 
lowering reduced STAT3 activity (-42%, P<0.05 at 8 weeks and -39%, P<0.05 at 16 
weeks of prolonged treatment) (Figure 2C). A comparable reduction was found for 
HC+SAL (-36%, P<0.05 at 8 weeks and -16%, n.s. at 16 weeks), indicating that SAL 






































































































































Figure 3: Salicylate reduces lesion macrophage area and increases lesion stability beyond 
cholesterol lowering alone. E3L mice were fed a HC diet for 19 weeks. After 19 weeks, mice were 
randomized into three different groups. One group of mice was sacrificed as a reference group. A 
second group of mice was then fed the HC diet supplemented with SAL for an additional 8 or 16 
weeks. A third group of mice was fed an LC diet for an additional 8 or 16 weeks to match for the 
plasma cholesterol levels in the HC+SAL treated group. After prolonged 8 or 16 weeks of HC+SAL 
or LC diet feeding, the mice were sacrificed and hearts and thoracic aortas were isolated. Aortas 
were homogenized and the presence of active NF-κB in aorta homogenates was determined 
(A). Hearts were embedded in paraffin and cross-sectioned throughout the aortic root area. 
Four sections per mouse with 50 µm intervals were analyzed. Total lesion area was determined. 
Horizontal bars indicate mean lesion area. Each point corresponds to one mouse (B). In addition, 
the macrophage content of the lesions was quantified (C) and the plaque stability index (ratio of 
collagen-to-macrophage area of the lesions) was determined (D). Values are means±SD. (*P<0.05, 
**P<0.01, ***P<0.001)
lowering. These data suggest that the effect of SAL treatment on NF-κB activity is not a 
general phenomenon.
B
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Salicylate induces lesion regression by reducing macrophage area and increases lesion 
stability beyond cholesterol lowering alone
To evaluate if SAL suppresses NF-κB activity in the vessel wall as it did in the liver, NF-
κB activity was determined in homogenates of the thoracic aorta. Compared to HC diet 
fed mice, SAL treatment significantly reduced aortic NF-κB activity (-51%, P<0.01 after 
8 weeks and -53%, P<0.01 after 16 weeks) (Figure 3A). Cholesterol lowering alone also 
reduced NF-κB activity, with -32% at 8 weeks (P<0.05) and with -34% after 16 weeks 
of prolonged treatment (P<0.05), which reduction was not significantly different from 
that obtained with SAL treatment. We then set out to analyze atherosclerotic 
lesions in the aortic root. After 19 weeks of HC diet feeding, mild atherosclerotic lesions 
had developed in the HC group (52±31 x103 μm2). Total lesion area did not progress 
with either treatment in time: total lesion area in mice fed the LC diet was 77±66 x103 
μm2 at 8 weeks, and 60±50 x103 μm2 at 16 weeks of prolonged treatment, and HC+SAL 
treatment resulted in a total lesion area of 65±49 x103 μm2 at 8 weeks, and 42±41 x103 
μm2 at 16 weeks of prolonged treatment (Figure 3B). 
 Next, the effect of NF-κB suppression on the regression of macrophage area, 
an early process in lesion regression that improves the severity of atherosclerotic 
lesions, was determined. Both LC diet feeding and HC+SAL treatment markedly induced 
regression of the macrophage content of lesions (Figure 3C) compared to the HC group. 
At 8 weeks of prolonged treatment, the macrophage area in lesions of LC diet fed mice 
had decreased by -69% to 2.4±1.4 x103 μm2 compared to 7.6±5.1 x103 μm2 in the HC 
group at time point 19 weeks of the study (P<0.001), and remained at this level also at 
week 16 (3.0±4.9 x103 μm2). HC+SAL treatment induced this regression more efficiently, 
by -87% (1.0±0.8 x103 μm2) after 8 additional weeks (P<0.001) and by -92% (0.6±0.7 
x103 μm2) after 16 additional weeks of treatment (P<0.001). The difference between 
HC+SAL and LC became significant at t=16 weeks (P<0.05).
 The relative collagen content of the lesions increased in both the LC and HC+SAL 
groups compared to the HC group. We therefore determined the ratio of collagen-to-
macrophage area as a measure of plaque stability. Plaque stability increased in both 
LC diet fed mice (P<0.01) and the HC+SAL treated group (P<0.001) compared to the 
HC diet fed reference group in a time-dependent fashion (Figure 3D), and was higher 




It is well recognized that hypercholesterolemia and inflammation are important factors 
in the development of atherosclerotic lesions. While it has been shown that plasma 
cholesterol-lowering can induce regression of pre-existing lesions, it is not yet clear if 
suppressing inflammation can lead to further regression of pre-existing atherosclerotic 
lesions on top of cholesterol-lowering. In this study, we showed that treatment of 
mice with pre-existing atherosclerotic lesions with HC+SAL strongly lowered plasma 
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cholesterol levels and suppressed hepatic and aortic NF-κB activity. A group of mice that 
was fed an LC diet to match for plasma cholesterol levels in the HC+SAL group showed 
a less pronounced decrease in hepatic NF-κB activity, and a similar reduction of aortic 
NF-κB activity. HC+SAL treatment and LC diet feeding markedly induced regression of 
the macrophage content of lesions and increased plaque stability as compared to the 
reference group. This induction of regression and increase in plaque stability were more 
pronounced in the HC+SAL treated mice than in the LC group. Our data indicate that 
suppressing NF-κB activity with SAL induces regression of pre-existing atherosclerotic 
lesions and increases plaque stability beyond those obtained by cholesterol-lowering 
alone.
 We studied the effect of the NF-κB inhibitory capacity of SAL on top of its 
cholesterol-lowering effect on atherosclerosis regression in a time dependent manner. 
While we did not find a change in total lesion area during the chosen experimental 
treatment period of 16 weeks, lesion composition markedly changed: the macrophage 
content of lesions decreased, and the lesion stability index increased in time. Our data 
show a reduction of 69% in the macrophage content of LC diet fed mice and of 90% in 
HC+SAL treated mice after 8 weeks of intervention, while there is no significant further 
decrease in the number of macrophages in both the LC and HC+SAL treated groups from 
8 to 16 weeks of intervention. Our data are in line with a study reporting a very strong 
decrease in the number of macrophages from existing lesions already after a few days,7 
indicating that the decrease in macrophage number is a very early process in lesion 
regression. On the other hand, our data show that the plaque stability index as determined 
by the collagen-to-macrophage ratio increased during the first 8 weeks of intervention 
in both HC+SAL treated and LC diet fed mice, and further increased during the next 8 
week period in both groups. This is in line with studies that reported a reduction in 
the macrophage content of lesions and an increase in the collagen-producing cell types 
fibroblasts 4 or smooth muscle cells (SMCs) 5,12 after periods of regression ranging from 6 
weeks until 6 months, although these studies did not evaluate lesion regression in time. 
While the decrease in macrophage number occurs in an early stage of lesion regression, 
the increase in plaque stability index occurs both in the 0-8 and 8-16 week periods of 
intervention. These data thus indicate that lesion regression is a long-term process that 
is characterized by various stages. In addition, we show that the effects on macrophage 
content and on plaque stability index are more pronounced in HC+SAL treated mice as 
compared to the LC group, indicating that suppressing NF-κB activity has a beneficial 
effect beyond cholesterol lowering alone in modulating both macrophage content and 
lesion stability during regression of pre-existing atherosclerotic lesions.
 We investigated the effect of suppressing NF-κB activity on atherosclerosis 
regression. While, to our knowledge, there are no other reported studies evaluating the 
role of NF-κB in atherosclerosis regression, several studies addressed the role of NF-
κB in atherosclerosis development. However, this did not lead to unequivocal results. 
Studies investigating the effect of a macrophage-specific reduction in NF-κB activity 
on atherosclerosis development in hyperlipidemic LDLr deficient mice showed that 
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this leads to increased numbers of inflammatory cells in atherosclerotic lesions.13,14 
This was thought to be the consequence of reduced lipid uptake by macrophages, 
leading to an inflammatory response of the non-phagocytosed lipids and consequently 
to enhanced recruitment of leukocytes to the site of the lesion.14 In contrast, our 
study did not show an increase in inflammatory cells upon inhibiting NF-κB activity. 
However, our regression study was carried out under conditions of low plasma 
cholesterol. Since there is little lipid deposition in the vessel wall under low cholesterol 
conditions, this may explain why there is no increase in lesional macrophages in our 
study upon suppressing NF-κB activity. On the other hand, our data are in line with a 
study evaluating a genetic model with whole body increased NF-κB activity showing 
increased atherosclerosis development and increased numbers of inflammatory cells in 
the lesions.15 Furthermore, a study evaluating the effect of acetyl salicylic acid (aspirin) 
on the development of atherosclerosis in LDLr deficient mice showed that aspirin 
reduced NF-κB activity in aortic tissue, which was associated with reduced lesion size, a 
reduced number of macrophages and increased smooth muscle cells and collagen, also 
reflecting increased plaque stability.16 However, since aspirin also reduces inflammation 
by reducing prostaglandin synthesis, the specific contribution of NF-κB inhibition in 
this study was not clear. The latter two studies show a beneficial effect of suppressing 
NF-κB activity even under high plasma cholesterol conditions. In those studies, whole 
body NF-κB activity was suppressed compared to a macrophage-specific reduction in 
the studies showing that suppressing NF-κB activity leads to more inflammatory cells 
in atherosclerotic lesions. Together, these data suggest that reducing NF-κB activity 
can have a beneficial effect on atherosclerosis development and atherosclerosis 
regression, depending on plasma cholesterol levels and/or the cell type in which NF-κB 
is suppressed.
 Our data indicate that cholesterol lowering and suppressing NF-κB activity 
with SAL leads to a reduction in the macrophage content of lesions beyond the effect 
obtained by cholesterol lowering alone. This reduction could be due to a decreased 
influx of monocytes or faster turnover or increased emigration of macrophages. We 
found that the number of monocytes adhering to the endothelium was not different for 
LC or HC+SAL treated mice (data not shown), suggesting that the monocyte influx is not 
different in HC+SAL treated mice compared to LC diet fed mice. Regarding emigration 
of macrophages, suppression of NF-κB activity has been reported to coincide with 
decreased expression of C-C chemokine receptor 7 (CCR7),17 a factor that is required for 
emigration of dendritic cell-like macrophages out of existing lesions.7 As a consequence, 
suppressing NF-κB activity may lead to decreased rather than increased emigration of 
monocytes from lesions. It is thus not likely that increased emigration of monocytes 
lead to the decreased macrophage content in HC+SAL treated mice compared to LC 
diet fed mice. The reduction in macrophages could be related to increased macrophage 
turnover. We found that SAL treatment reduced NF-κB activity. NF-κB has been shown 
to regulate the expression of genes involved in apoptosis, and to stimulate cell survival.18 
In line with this, suppressing NF-κB activity may abolish cell survival signaling, leading 
Chapter 3
60
to induction of apoptosis. This was also reported in a study evaluating atherosclerosis 
development in mice lacking IKK2 specifically in macrophages. Deletion of IKK2 
results in diminished NF-κB activation, and atherosclerotic lesions in mice lacking 
IKK2 expression in macrophages showed increased cell death.13 Together, these data 
suggest that increased apoptosis as a consequence of suppressing NF-κB activity may 
be underlying the reduction in macrophage content of lesions we observed in HC+SAL 
treated mice compared to LC diet fed mice.
 We found that HC+SAL treatment markedly down regulated hepatic NF-κB 
activity, and that this down regulation was more manifest in HC+SAL treated mice than 
in LC diet fed mice. Nevertheless, plasma levels of the hepatic inflammation marker 
serum amyloid A (SAA) were reduced to a lesser extent in the HC+SAL treated group 
than in the LC fed group compared to the HC group. In a recent study we showed that 
feeding of an HC, but not an LC diet induces a hepatic inflammatory reaction leading to 
increased plasma SAA levels. Three major pathways were identified that are involved 
in mediating HC-diet induced inflammation, namely pathways involving NF-κB, STAT3 
and CCAAT-enhancer binding protein (C/EBP)α/β.19 In the present study, we show 
that HC+SAL treatment specifically inhibits the NF-κB pathway in liver. Although NF-
κB activity is suppressed in HC+SAL treated mice, the STAT3 pathway continues to be 
activated as a consequence of HC diet feeding. In contrast, switching mice from the HC 
to the LC diet reduces the activation of all cholesterol-induced inflammatory pathways. 
This could explain our observation that plasma SAA levels are lower in the LC group as 
compared to the HC+SAL group.
 The clinical importance of gaining insight in processes that are involved in 
remodeling of pre-existing atherosclerosis to induce regression of atherosclerotic 
lesion has been increasingly recognized over the past years. Our data indicate that 
HC+SAL treatment has additive beneficial effects beyond cholesterol lowering alone in 
the regression of pre-existing lesions by further reducing the macrophage content of 
lesions and by further increasing lesion stability. These additive effects may at least 
partly be mediated by SAL’s capacity to suppress NF-κB activity. Future studies are 
needed to determine if reducing cholesterol levels and NF-κB activity with SAL is also 
more beneficial than cholesterol lowering alone in the regression of pre-existing lesions 
in humans. In all, our data show that cholesterol-lowering and suppression of NF-κB 
activity by SAL promote lesion regression and increase plaque stability more efficiently 
than cholesterol lowering alone. Our data also illustrate that targeting multiple factors 
has additional value for the treatment of pre-existing atherosclerosis.
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Background: The aim of this study was to define the anti-atherosclerotic role of liver-
X-receptors (LXRs) under both lesion progressive and lesion regressive conditions, to 
establish a temporal line of events, and to gain insights into the mechanisms underlying 
the anti-atherogenic potency of LXRs.  
Methods and results: We used ApoE*3-Leiden mice to comprehensively and time-
dependently dissect how T0901317, an LXR-agonist, inhibits initiation and progression 
of atherosclerotic lesions, and regresses existing lipid- and macrophage-rich lesions. 
T0901317 strongly suppresses lesion evolution and promotes lesion regression 
regarding lesion number, area, and severity. Quantitative plasma and vessel wall 
analyses corroborated by immunohistochemical evaluation of the aortic lesions revealed 
that under progressive (high-cholesterol diet) as well as regressive (cholesterol-
free diet) conditions T0901317 (i) significantly increases plasma triglyceride and 
total cholesterol levels; (ii) does not affect the systemic inflammation marker, SAA; 
(iii) suppresses endothelial monocyte adhesion; and (iv) induces the expression of 
the cholesterol efflux-related genes ApoE, ABCA1 and ABCG1. Furthermore, under 
progressive conditions, T0901317 suppresses the vascular inflammatory status (NF-
κB) and the vascular expression of adhesion molecules (E-selectin, ICAM-1, and CD44), 
lowers lesional macrophage accumulation, and blocks lesion evolution at the transition 
from lesional stage II to III. Under regressive conditions, T0901317 induces lesional 
macrophage disappearance and increases the expression of the chemokine receptor 
CCR7, a factor functionally required for regression.
Conclusions: The LXR-agonist T0901317 retards vascular lesion development and 
promotes lesion regression at several levels. The findings support that vascular LXR is a 
potential anti-atherosclerotic target.
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Introduction
Coronary atherosclerosis represents the leading cause of morbidity and mortality of men 
and women throughout the Western world. Hypercholesterolemia is a well-established 
risk factor for the incidence of atherosclerosis and its pathologic complications1. However, 
despite the success of cholesterol-lowering statins in reducing cardiovascular causes of 
death, two thirds of the statin-treated patients still experience cardiovascular events. 
Consequently, focus has switched to risk factors other than hypercholesterolemia.
 Atherosclerosis is now recognized as a multifactorial, multistep disease with 
numerous etiologies which have to act in concert to initiate and promote the atherosclerotic 
process. In addition to traditional risk factors such as hypertriglyceridemia, low high-
density lipoprotein (HDL), and hypertension, inflammation is accepted as a major 
driving force of atherosclerotic lesion development. Inflammation has a key role in lesion 
initiation and evolution, and encompasses both cellular and molecular components2.
 Liver-X-receptor (LXR) belongs to the nuclear hormone receptor superfamily 
of ligand-activated transcription factors. Two LXR isoforms have been described so far, 
LXRa and LXRb. LXRb has a ubiquitous tissue distribution, whereas LXRa predominates 
in liver, adipose tissue, intestinal tissue, and macrophages; both isoforms respond 
to the same natural and synthetic ligands3. LXRs control genes involved in intestinal 
cholesterol absorption, hepatic bile acid synthesis, cholesterol efflux, vascular foam 
cell formation, and inflammation4. These properties make LXRs a potential target for 
therapeutic intervention in the atherosclerotic process. Studies performed over the last 
several years have established that LXRs are anti-atherosclerotic factors owing to their 
ability to regulate cholesterol and lipid homeostasis and to inhibit inflammation within 
the arterial wall5-8. However, these studies mainly focused on lesion growth but not 
lesion regression, did not establish a temporal line of events, and only partly addressed 
the mechanisms underlying the anti-atherogenic potency of LXRs.
 Here we describe the impact of an LXR-agonist, T0901317, on the progression 
and regression of atherosclerosis in transgenic ApoE*3-Leiden (E3L) mice, a well-
established mouse model for atherosclerosis.9,10 E3L mice are highly responsive to 
cholesterol-containing diets, resulting in strongly elevated plasma cholesterol and 
triglyceride levels, with a prominent increase in VLDL- and LDL-sized lipoprotein 
particles. E3L mice do not develop atherosclerosis on a regular chow diet, but 
atherosclerosis in E3L mice can be initiated by feeding of a cholesterol-containing, 
Western type diet10, whereas regression of pre-existing lesions can be induced using 
cholesterol-depleted diets11. E3L mice respond to hypolipidemic drugs with cholesterol-
lowering and appear useful in predicting effects of pharmaceutical modifiers in humans10. 
Our study confirms the results previously published by other groups in different mouse 
models (ApoE-/- or Ldlr-/- mice) regarding some of the effects of LXR-agonists on lesion 
development, but adds some important novel information with regard to the action of 
the LXR-agonist on the vasculature, in particular to vascular inflammation, adhesion 
molecule expression and under regressive conditions, potential mechanisms involved 
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in macrophage disappearance. Also, the analysis of the experiments at different time 
points allowed establishing a temporal line of events.
Methods
Animals 
Female ApoE*3-Leiden transgenic (E3L) mice (TNO-Pharma, Gaubius Laboratory, 
Leiden, The Netherlands) were characterized for expression of human ApoE by 
enzyme-linked immunosorbent assay (ELISA). The animals were housed in wire-
topped Macrolon cages with a layer of sawdust as bedding, and diets and water were 
given ad libitum.
T0901317-Atherosclerosis studies
Progression studies: To establish a time course of events, three separate progression 
studies were performed, with mice (age 10-12 weeks at start of experiment) sacrificed 
after t=2 weeks, t=10 weeks, or t=15 weeks of experimental treatment, respectively. 
Study 1: (main study; sacrifice at 10 weeks). During a run-in period of 3 weeks, 24 female 
E3L mice received an atherogenic, 1% (w/w) cholesterol-containing Western-type diet 
(Hope Farms, Woerden, The Netherlands), further referred to as high-cholesterol (HC) 
diet. Then, mice were subdivided into 2 experimental groups (n=12) and matched for 
plasma cholesterol and triglycerides. In one group, HC was continued for another 10 
weeks (HC group). The other, T0901317-treated group (HC+T0901317 group) received 
HC supplemented with 0.01% w/w T0901317 (Sigma Aldrich). Based on food intake in 
the HC+T0901317 group, the daily dose of T0901317 was 11 mg/kg bodyweight.
Study 2: as study 1, but sacrifice at 15 weeks; n=15 per group. 
Study 3: (short study; sacrifice at 2 weeks). E3L mice were treated with HC-diet 
supplemented with or without 0.01%(w/w) T0901317 (n=8 per group; no run-in) and 
were sacrificed after 2 weeks of treatment.
Regression study: Twenty-six female E3L mice received HC for 18 weeks to develop 
atherosclerotic lesions. Then, 10 mice were sacrificed for atherosclerotic lesion analysis. 
The 16 remaining mice were subdivided into two groups of 8 mice each and switched 
for 8 weeks to a regressive, cholesterol-depleted diet (RD), supplemented  with  0.01% 
(w/w)  T0901317 (RD+T0901317 group) or not (RD group).
Analysis of plasma lipids, lipoproteins and plasma inflammation markers
Total plasma cholesterol and triglyceride levels were measured after 4 hours of fasting, 
using kits No. 11489437 and 11488872 (Roche Diagnostics, Almere, The Netherlands), 
respectively. For lipoprotein profiles, pooled plasma was fractionated using an ÄKTA 
FPLC system (Pharmacia, Roosendaal, The Netherlands).12 The plasma levels of 
E-selectin (R&D Systems) and SAA (Biosource) were determined by ELISA as reported.13
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Atherosclerotic lesion analysis 
At the end of a treatment period, mice were euthanized to collect hearts and aortas. 
Hearts were fixed and embedded in paraffin to prepare serial cross sections (5 µm-
thick) throughout the entire aortic root area for (immuno)histological analysis.12,14 
Cross-sections were stained with hematoxylin-phloxine-saffron and atherosclerosis 
was analyzed blindly in 4 cross-sections of each specimen (at intervals of 40 µm). QWin-
software (Leica)12,14 was used for morphometric computer-assisted analysis of lesion 
number, lesion area and lesion severity according to the classification of the American 
Heart Association15 as reported.12,14 Monocyte adhesion and macrophage area were 
determined essentially as described previously.14,16,17 For immunostaining of ICAM, 
LXRα/β, p50-NF-κB, p65-NF-κB, CD44 and CCR7 antibodies GTX76543 (Genetex), sc-
1000, sc-114, sc-109, sc-18849 and sc-9701 (Santa Cruz Biotechnology) were used, 
respectively.18
Nucleic acid extraction and Real-time PCR 
Total RNA was extracted from individual aortas (n=5 per group) using RNAzol (Campro 
Scientific, Veenendaal, The Netherlands) and glass beads according to the manufacturer’s 
instructions. The integrity of each RNA sample obtained was examined by Agilent Lab-
on-a-chip technology using the RNA 6000 Nano LabChip kit and a bioanalyzer 2100 
(Agilent Technologies, Amstelveen, The Netherlands). Then, cDNA was prepared using 
kit #A3500 (Promega, Leiden, The Netherlands) for real-time polymerase chain reaction 
(RT-PCR) analysis. Mastermix (Eurogentec, Seraing, Belgium), the ABI-7700 system 
(Perkin-Elmer Biosystems, Nieuwekerk a/d IJssel, the Netherlands), and established 
primer/probe sets were used according to the manufacturer’s instructions. Cyclophilin 
A (PE Biosystems) was used as a reference.
Statistical methods
Significance of difference was calculated by analysis of variance (ANOVA) test followed 
by a least significant difference post hoc analysis using SPSS 11.5 for Windows (SPSS, 
Chicago, USA). The level of statistical significance was set at P<0.05.
 
Results
T0901317 enhances plasma lipid levels in E3L mice 
Food intake of mice fed HC+T0901317 for ten weeks was slightly lower than that in 
animals on HC (2.2±0.2 grams per day (g/day) vs. 2.5±0.2 g/day; P<0.05; Table 1). 
At the end of the treatment period, there was no significant difference in bodyweight 
between the two groups (HC+T0901317, 19.6±0.5 g; HC, 20.8±0.4 g; Table 1). Plasma 
cholesterol levels in HC+T0901317 (23.4±4.1 mM) were significantly increased 
compared with HC (18.7±3.6 mM, P<0.05; Table 1). This rise in plasma total cholesterol 
levels in HC+T0901317 can be mainly ascribed to a particular subfraction (fractions 
10-17; Figure 1A), co-eluting with particles in the IDL/LDL range. T0901317 strongly 
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(6.8 times) increased fasting plasma triglyceride levels (HC+T0901317, 12.3±4.4 mM; 
HC, 1.8±0.4 mM; P<0.05; Table 1), which rise is entirely confined to particles in the 
VLDL-range (Figure 1B). Quantitative RT-PCR analysis of liver samples indicates that 
the strong increase in triglyceride levels in the T0901317-treated group may at least 
partly be explained by the 2.2-fold (P<0.01) elevated expression of the lipogenic gene, 
sterol regulatory binding protein (SREBP)-1c.
Table 1.  Metabolic parameters of control and T0901317-treated, cholesterol-fed E3L mice. 
HC HC+ T0901317
Average food intake (g/day) 2.5 ± 0.2 2.2 ± 0.2*
Average body weight (g) 20.8 ± 0.4 19.6 ± 0.5
Average total cholesterol level (mM) 18.7 ± 3.6 23.4 ± 4.1*
Average triglyceride level (mM) 1.8 ± 0.4 12.3 ± 4.4*
Metabolic parameters of control and T0901317-treated, cholesterol-fed E3L mice. Data are 
expressed as means ± SD; n=12 for each group;  *P<0.05 vs. HC
T0901317 reduces atherosclerotic lesion number, size and severity
After 10 weeks of experimental treatment, early atherosclerotic lesion formation was 
analyzed in cross-sections of the aortic valve area. The average lesion number per 
mouse was 18.3±2.3 in HC and reduced by 64% to 6.5±1.3 in HC+T0901317 (P< 0.01; 
Figure 2A). Measurement of the total cross-sectional lesion area showed a similar 
picture (Figure 2B): HC displayed a cross-sectional lesion area of 37027±7450 µm2 and 
HC+T0901317 reduced the lesion area by 85% to 5484±2019 µm2 (P<0.05). 
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Figure 1: Lipoprotein profiles of control and T0901317-treated, cholesterol-fed E3L mice. 
(A), Cholesterol content in fractionated plasma samples. (B), Triglyceride content in fractionated 
plasma samples. Solid squares indicate HC, open squares indicate HC+T0901317.





















































































































Figure 2: Effect of T0901317 on atherosclerosis development in aortic valve area. Shown 
are effects of T0901317 on total lesion number after 10 weeks (A) and 15 weeks (C) of treatment 
and effects of T0901317 on total cross-sectional lesion area after 10 weeks and 15 weeks (D) of 
treatment. The effect of T0901317 on lesion severity is presented as percentage of cross-sections 
analyzed (E). Data represent mean values ± SEM (n≥10 mice per group) #P<0.05 vs. HC-10 weeks, 
*P<0.05 vs. HC-15 weeks.
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of the disease process or are the result of diminished lesion initiation and progression, 
lesion number and size were also analyzed (in a separate experiment) after a 15-weeks-
treatment. The difference in lesion number of the two groups resembled that of the 
10-week experiment (Figure 2C), while the lesion area was substantially increased in 
HC (3.2 fold), but only marginally (1.5 fold) in HC+T0901317 after 15 weeks (Figure 
2D), indicating that T0901317 is interfering with both lesion initiation and lesion 
development rather than retarding the onset of the disease process.
Table 2. Plasma inflammation markers of control and T0901317-treated, cholesterol-fed 
E3L mice. 
 t=0 HC HC+ T0901317
Serum Amyloid A (µg/ml) 10.1 ± 4.6 21.7 ± 15.3# 24.5 ± 12.1#
E-Selectin (ng/ml) 84.4 ± 9.7 97.2 ± 13.7# 84.4 ± 12.2*
Plasma inflammation markers of control and T0901317-treated, cholesterol-fed E3L mice. Shown 
are average plasma levels of Serum Amyloid A and E-Selectin at the start (t=0) and the end (t=10 
weeks) treatment period (means ± SD n=12 for each group; #P<0.05 vs. t=0 and *P<0.05 vs. HC).
 
This conclusion was further strengthened by evaluating lesion severity. Cross-sections 
of the aortic root were morphologically analyzed and lesions were graded according 
to the classification of the American Heart Association.15 Grading after 10 weeks 
demonstrated that lesions from both HC and HC+T0901317 mainly contained mild 
type I/II lesions (~80% of all classified lesions) and hardly type IV/V lesions (Figure 
2E). After 15 weeks, a clear shift in lesion severity was observed in HC but not in 
HC+T0901317. In HC, 24%±6% of all cross-sections contained type I/II lesions and 
76%±5% contained type III/IV/V lesions (Figure 2E). In contrast, in HC+T0901317 
treated mice 77%±10% of all cross-sections contained type I/II lesions and 23%±4% 
contained type III/IV/V lesions, thereby remarkably resembling the findings obtained 
after the 10-weeks-treatment. Importantly, T0901317 blocked lesion progression at the 
transition from lesion severity stage II to III, which is characterized by the absence of 
smooth muscle cell (SMC) proliferation and migration to the cap, a hallmark of type III 
lesions. Thus, T0901317 strongly suppresses atherogenesis, both at the initiation and 
the progression phase of disease. The question therefore arises by what mechanism 
T0901317 interferes with the atherosclerotic process.
The vessel wall as target for T0901317 
To evaluate whether the anti-atherosclerotic effects of T0901317 are paralleled by anti-
inflammatory effects, we analyzed systemic inflammatory markers originating from 
liver (SAA) or vasculature (E-selectin). HC markedly and significantly elevated plasma 
levels of both SAA (2.1-fold) and E-selectin (1.2-fold) (Table 2). T0901317 significantly 
suppressed HC-induced E-selectin but not SAA plasma levels, pointing to a direct anti-
inflammatory effect of T0901317 on the vascular endothelium. To seek further evidence 
for a direct effect of T0901317 on the vessel wall we evaluated vascular expression of 
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Figure 3: Vascular LXRα/β expression is induced in cholesterol-fed E3L mice. Representative 
photomicrographs of immunohistochemical staining of LXRα/β-immunoreactivity (IR) in cross-
sections of the aortic root: in basal chow-fed E3L mice (A); after 2 weeks of HC (B) or HC+T0901317 
(C); after 10 weeks of HC (D) or HC+T0901317 (E); after 15 weeks of HC (F).  Bar= 50 µm.
t= 2 weeks
Basal
HC                      HC+T0901317                        HC
A B
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LXRα/β inmmunohistochemically using an antibody recognizing both LXR isoforms 
(see Methods section). In chow-fed E3L mice no LXRα/β expression was detectable 
in the vasculature (Figure 3A), but 2 weeks after starting the HC diet, expression of 
LXRα/β was demonstrable in both the HC and HC+ T0901317 group (Figure 3B-C) and 
remained so for the rest of the experimental treatment period (Figure 3D-E). In both 
experimental groups expression of LXRα/β was mainly confined to the endothelium and 
to a lesser extent to SMC; no notable difference in staining intensity was seen between 
the two groups (Figure 3B-E). Upon lesion progression, accumulating monocyte-
derived macrophages in the lesions also stained positive for LXRα/β (Figure 3F). QRT-
PCR analysis revealed that both LXRα and LXRβ were about two-fold up-regulated by 
dietary cholesterol. 
 Together, these data demonstrate, for the first time, that dietary cholesterol 
induces LXR protein expression in the vasculature (endothelium, SMC, monocyte-
derived macrophages), thus enabling T0901317 to specifically suppress HC-induced 
expression of endothelial E-selectin and thereby to lower plasma levels of E-selectin. 
         t=                                                t=15 weeks
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Figure 4: Effect of T0901317 on vascular ICAM-1 and NF-κB expression. Representative 
photomicrographs of immunohistochemical staining of ICAM-1-IR (A) after 10 weeks of treatment 
with HC or HC+T0901317. Analyzed percentage of ICAM-1-IR positive EC in control vs treatment 
group (B). Representative photomicrographs of immunohistochemical staining of p50-NF-κB-IR 
(C), and p65-NF-κB-IR (D) after 10 weeks of treatment with HC or HC+T0901317. (*P<0.05 vs. 
HC). Bar= 100 µm. Analyzed percentage of nuclear p50-NF-κB-IR positive EC (E), and nuclear 
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Anti-atherogenic action of T0901317 in the vasculature 
The anti-inflammatory effect of T0901317 in the vasculature is not restricted to 
E-selectin. Immunohistochemical staining of ICAM-1 underlines that T0901317 
suppresses endothelial adhesion molecule expression more generally. Whereas in HC 
55%±17% of the aortic endothelial cells (EC) expressed ICAM-1, in HC+T0901317 
only 22%±7% (P<0.05) of the cells did so (Figures 4A and 4B). Furthermore, the total 
number of EC per cross-section with positive p65-NF-κB- or p50-NF-κB-staining (in 
cytosol and/or nucleus) was strongly reduced in HC+T0901317 (Figure 4C-D). Also, 
the number of EC showing nucleus-associated (i.e. active) p65-NF-κB or p50-NF-κB 
immunoreactivity was strongly and significantly (P<0.05) reduced in HC+T0901317 
compared with HC (Figure 4E-F). These results are further evidence that T0901317 
not only lessens the number of NF-κB-positive EC, but also the number of active NF-κB-
containing EC, thus providing a rationale for the reduced expression of cellular adhesion 
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Figure 5. Effect of T0901317 on aspects of atherogenesis in the aortic valve area. Shown 
are effects of T0901317 on number of monocytes adhering to endothelium after 2 weeks (A) 
and 10 weeks of HC (B), on absolute macrophage containing lesion area after 10 weeks (C), and 
on macrophage density (i.e. macrophage area expressed as percentage of cross-sectional lesion 
area) after 10 weeks of HC. Data are presented as mean ± SD, #P<0.05 vs. chow-fed E3L mice 
(basal) and *P<0.05 vs. HC.
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T0901317-reduced expression of adhesion molecules is paralleled by diminished 
recruitment of blood monocytes. As early as 2 weeks after starting HC-treatment, the 
number of adherent monocytes was significantly increased in HC (7.7±1.7 compared 
with 4.5±0.7 in chow fed E3L mice (Figure 5A)), but not so in HC+T0901317 (4.0±0.9). 
After 10 weeks, monocyte adhesion was further increased in HC (16.7±4.0; Figure 5B); 
monocyte adherence was also elevated in HC+T0901317 (8.3 ± 2.1 vs. 4.0±0.9 at t=2 
weeks; P<0.05), but remained significantly lower than in HC. Since monocyte-adhesion 
is a prerequisite, but not sufficient, for formation of early lesions, we subsequently 
determined lesional macrophage content and macrophage density. Figure 5C shows 
that the absolute macrophage-containing lesion area at 10 weeks was substantially 
(by 85%; P<0.05) reduced in HC+T0901317 compared with HC (1227±507 µm2 vs. 
8238±3168 µm2). On the other hand, the macrophage density (the macrophage area 
expressed as percentage of the cross-sectional lesion area) is very similar in the two 
groups (Figure 5D). 
 Markedly, in HC+T0901317 lesions are less severe, with lesion progression 
seemingly blocked at the transition from lesion severity stage II to III (Fig. 2E), a 
phenotype that is also seen in CD44-deficient mice.19 CD44 is a cellular adhesion 
molecule that promotes adhesion and recruitment of monocytes/macrophages and 
regulates the migration and proliferation of SMC.19,20 CD44 expression after 10 weeks 
of HC-treatment is mainly confined to monocytes and macrophage/foam cells in the 
intima, and expression is further increased and extended to SMC during subsequent 
atherogenesis progression after 15 weeks (Figure 6A-B). T0901317 strongly and 
significantly reduced CD44 expression in the vasculature (Figures 6A-C), both at the 
mRNA (RT-PCR analysis) and protein (immuno-histochemical analysis) level. In contrast 
to CD44, T0901317 strongly increased the expression of genes reportedly involved in 
reverse cholesterol efflux (ApoE, ABCA1 and ABCG1; Table 3). Collectively, the data 
show that in HC+T0901317 lesion number, area, and severity are strongly suppressed 
with a parallel decrease in monocyte adhesion and SMC migration and proliferation. 
These effects can at least partly be explained by diminished expression of the adhesion 
molecules E-selectin, ICAM-1, and CD44, and by an up-regulation of factors promoting 
cholesterol efflux, ApoE, ABCA1 and ABCG1.
Table 3. Vascular gene expression of control and T0901317-treated, cholesterol-fed E3L 
mice.
 HC HC+ T0901317
apoe 100% ± 11% 211% ± 22.3% *
abca1 100% ± 15% 821% ± 211% *
abcg1 100% ± 13% 491% ± 109% *
 
Vascular gene expression of control and T0901317-treated, cholesterol-fed E3L mice. Shown are 
the average aortic gene expression levels of apoe, abca1, and  abcg1 at the end of the 10-weeks 
treatment period as percentage values relative to corresponding values at the start (t=0) of the 
treatment (means ± SD; n=12 for each group;  *P<0.05 vs. HC).
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Effect of T0901317 on pre-existing lesions
Considering the anti-inflammatory and anti-atherosclerotic activities of T0901317, 
the question arises whether T0901317 can also promote lesion regression. To address 
this question E3L mice were fed HC-diet for 18 weeks to induce moderately severe 
(type III-IV) lesions. One group of animals was then sacrificed (reference group) and 
HC                                                HC+T0901317
HC                                               HC+T0901317
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Figure 6. Effect of T0901317 on vascular CD44 expression. Representative photomicrographs 
of immunohistochemical staining of CD44-IR in cross-sections of the aortic root after treatment 
with HC or HC+T0901317 for 10 weeks (A) and 15 weeks (B). Bar= 100 µm. Shown is also aortic 
cd44 mRNA expression after 10 weeks of HC or HC+T0901317 (C). *P<0.05 vs. HC.
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two others received a cholesterol-free regression diet (RD) for 8 weeks, supplemented 
(RD+T0901317) or not (RD) with T0901317. The switch from HC to RD resulted in 
a fall in total plasma cholesterol from 21.2±5.6 mM to 6.4±2.3 mM  (P<0.05, Figure 
7A) in the RD group, but no significant change in plasma cholesterol levels was seen 
in RD+T0901317 (20.7±2.4 mM). Lipoprotein distribution profile analysis (Figure 
7B) shows that the decrease in plasma cholesterol in RD is mainly in the VLDL range 
and to a lesser extent in the IDL/LDL range, but not in the HDL fractions, whereas the 
profile in RD+T0901317 very much resembles that seen in HC+T0901317, with an 
increase of cholesterol in fractions 10-17, corresponding to particles in the IDL/LDL 
range. Whereas lesion area in RD (85924±31016 µm2) was not significantly decreased 
as compared to the reference group (97203±16432 µm2), it was markedly reduced (by 
76%) in RD+T0901317 (20699±7995 µm2; P<0.05; Figure 7C). 
 In both RD and RD+T0901317, a strong decrease in the plaque content of foam 
cells was observed: from 18040±3205 µm2 in the reference group to 2876±315 µm2 
in RD (P<0.05) and 363±351 µm2 in RD+T0901317 (P<0.05; Figure 7D). Similarly, a 
significant drop (P<0.05; Figure 7E) in monocyte adherence was seen in the two groups: 
from 23±5 monocytes per section (reference) to 16±4 (RD) and 10±2 (RD+T0901317) 
monocytes per section.
 A number of molecular mechanisms underlying regression in mice have been 
proposed, including macrophage apoptosis,21 CCR7-mediated migration of foam cells to 
lymph nodes22,23 and reverse cholesterol transport.24 RT-PCR gene expression analysis 
(Table 4; values normalized for the number of macrophages and reference mice set at 
100%) revealed strongly increased expression of the apoptotic genes BCL-2, Caspase-3, 
BAX, and FAS in aortas from RD mice, and even further enhanced in RD+T0901317 mice. 
The presence of condensed nuclei in the lesions (Figure 7F) illustrates the occurrence of 
ongoing apoptosis in RD+T0901317 mice.
 Recently, Trogan et al.23 reported that the chemokine receptor CCR7 is expressed 
in foam cells and functionally required for regression. QRT-PCR analysis shows that 
CCR7 gene expression is significantly increased in RD (225%±47%; P<0.05) and even 
more so in 
RD+T0901317 (861%±132%; P<0.01), indicating that CCR7 could also be a key factor 
in atherosclerosis regression in the present study. This is underlined by demonstrating 
enhanced CCR7-stained leukocytes accumulated in the adventitial space (Figure 7G).
 Finally, we sought evidence supportive for increased reverse cholesterol efflux 
by measuring gene expression of cholesterol efflux pathway-related factors. QRT-PCR 
analysis of ApoE (87%±10%), ABCA1 (24%±3%; P<0.05) and ABCG1 (62%±6%; 
P<0.05) showed decreased gene expression in RD as compared with the reference 
group, while T0901317 strongly induced these genes under regression conditions 
(ApoE: 306%±20%; ABCA1: 149%±24% and ABCG1: 314%±29%; P<0.05, Table 4), 
even if  the macrophage content in RD+T0901317 was stronger decreased than that in 
RD.
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Figure 7: Effect of T0901317 on aspects of atherosclerotic lesion regression.  Shown are (A) 
plasma cholesterol concentrations during regression period (arrow indicates start of RD feeding), 
with solid squares indicating RD treatment group and open squares indicating RD+T0901317 
group. Data are represented as mean ± SD, *P<0.05 vs. RD; (B) Lipoprotein distribution profiles 
of the two experimental groups (n=8 for each group) after 8 weeks of RD (open squares) or 
RD+T0901317 (solid squares). For comparison, the lipoprotein profile of pooled plasma of the 
reference group (n=10; t= 18 weeks) is also shown (triangles); (C) total cross-sectional lesion 
area of reference, RD, and RD+T0901317 groups, with data representing mean values ± SEM 
(n=8 per group); (D) absolute macrophage containing lesion area, with data representing mean 
values ± SEM (n=8 mice per group); (E) number of monocytes adhering to endothelium, with data 
representing mean values ± SEM (n=8 mice per group); (F) Representative photomicrographs 
illustrating condensed nuclei (arrowheads), (G) Representative photomicrographs of 
immunohistochemical staining of adventitial CCR7-IR.
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Table 4: Vascular gene expression of control and T0901317-treated E3L mice on a 
cholesterol-free, regressive diet (RD).
 t=18 weeks                             Regression t=26 weeks
 Reference RD RD+T0901317
fas 100% ± 4% 291% ± 11%* 2726% ± 148%*,#
bax 100% ± 6% 876% ± 87%* 3072% ± 374%*,#
bcl-2 100% ± 6% 897% ± 83%* 6162% ± 376%*,#
caspase-3 100% ± 5% 434% ± 34%* 2173% ± 386%*,#
ccr7 100% ± 16% 225% ± 47%* 861% ± 132%*,#
apoe 100% ± 11% 87% ± 10% 306% ± 20%*,#
abca1 100% ± 8% 24% ± 3%* 149% ± 24%*,#
abcg1 100% ± 7% 62% ± 6%* 314% ± 29%*,#
 
Vascular gene expression of control and T0901317-treated E3L mice on a cholesterol-free, 
regressive diet (RD). Shown are average aortic gene expression levels of cholesterol-efflux-related 
(apoe, abca1, and abcg1) and apoptosis/regression-related genes (fas, bax, bcl-2, caspase-3, and 
ccr7) at the end of the regression period (t= 26 weeks) relative to reference group which was set 
at 100%. Values are normalized for aortic monocyte/macrophage content (means ± SD; *P<0.05 
vs. Reference and #P<0.05 vs. RD).
 
Discussion 
We evaluated the effects of an LXR agonist, T0901317 on specific aspects of atherosclerotic 
lesion progression and regression in E3L mice, a model for atherosclerosis with 
predictive value for the human situation. In E3L, vascular LXRα and LXRβ expression 
was induced in aortic EC, SMC and macrophages under atherogenic dietary conditions. 
T0901317 strongly suppresses atherosclerotic lesion evolution and promotes lesion 
regression with respect to lesion number, area, and severity, despite elevated plasma 
total cholesterol and triglyceride levels. T0901317 exerts its actions at several levels. 
Under lesion-progressive conditions T0901317 suppresses dietary cholesterol-induced 
vascular expression of the inflammatory transcription factor, NF-κB, adhesion molecules 
(E-selectin, ICAM-1, and CD44), monocyte adhesion, and lesional macrophage content. 
T0901317 also induces the expression of the cholesterol efflux-related genes ApoE, 
ABCA1 and ABCG1, and blocks lesion evolution at the transition from stage II to III. 
 The ability of T0901317 to promote regression of preexisting atherosclerotic 
lesions under regressive conditions is linked mechanistically to i) increased cholesterol 
efflux from macrophages in the aortic lesions (through induction of expression of ApoE, 
ABCA1 and ABCG1); ii) reduction of macrophage content of the lesions by apoptosis; 
and iii) increased expression of the chemokine receptor CCR7, a factor functionally 
required for regression.
 The T0901317-induced increase in plasma cholesterol and triglycerides in E3L 
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has also been described previously25 and is similar to findings in ApoE-/- mice26. The 
T0901317-induced rise in cholesterol in E3L is confined to particles co-eluting with the 
IDL/LDL fraction and very much resembles findings described for fenofibrate-treated 
E3L mice14. The induced fraction contains mainly the apolipoprotein ApoE, to a minor 
extent ApoB, and no ApoA1. In contrast, the T0901317-induced increase in cholesterol 
in ApoE-/- was in HDL and accompanied by a marked increase in ApoA1, but not ApoB 
levels26. Interestingly, the apolipoprotein composition and size of the T0901317-induced 
particle in E3L is comparable to that induced by T0901317 in C57/Bl6 mice which was 
designated “enlarged HDL”27. The particle also shows the characteristics of HDL1, which 
has been suggested to be involved in ApoA1-independent cholesterol efflux, possibly 
sustained by ApoE28,29. 
 Different effects of LXR agonists on cholesterol have been described in 
Ldlr-/- mice. In one report, T0901317 did not affect plasma total cholesterol levels in 
Ldlr-/- mice fed an atherogenic diet8, and in other studies a decrease in plasma cholesterol 
levels was observed with LXR agonists5,6. 
 A common finding in studies using T0901317 or other LXR ligands is the rise 
in triglyceride levels, which can be ascribed to the induction of the transcription factor 
SREBP-1 and its target genes FAS and SCD, two key enzymes involved in lipogenesis3,4. 
Noteworthy, T0901317 also is a high-affinity ligand for the xenobiotic receptor, pregnane–
X-receptor (PXR). Because PXR and the LXRs are co-expressed in liver and PXR plays 
an important role in lipid metabolism, some of the hepatic effects of T0901317 may 
have resulted from simultaneous stimulation of LXR and PXR activation30. Importantly, 
vascular effects of T0901317 reported here most likely reflect LXR activation only since 
CD36, a PXR target 31 was not induced by T0901317 in E3L mice (data not shown).
 Our finding that T0901317 strongly suppresses atherosclerotic lesion evolution 
in E3L mice is in line with previous gain-of-function and loss-of-function studies7 and 
results obtained in ApoE-/- and Ldlr-/- mice with T0901317 and the LXR agonist GW39655,8. 
Relevantly, the present study reveals several levels of anti-atherosclerotic action of 
T0901317. Firstly, a strong reduction of aortic inflammation as reflected by diminished 
vascular endothelial NF-κB activity, adhesion molecule expression (E-selectin, ICAM-1, 
and CD44), monocyte adhesion, and lesional macrophage content, all in the absence 
of systemic inflammation (cf. SAA). Secondly, T0901317 strongly increases gene 
expression of factors important for cholesterol efflux from vascular macrophages (ApoE, 
ABCA1, and ABCG1). ABCA1 mediates cholesterol efflux from macrophages to lipid-free 
ApoA132 whereas ABCG1 is a mediator of macrophage cholesterol efflux to mature HDL 
in vitro33. Up-regulation of ABCA1 and ABCG1 in the vasculature has previously been 
suggested to contribute to the anti-atherogenic capacity of T09013175,8. Another LXR 
agonist, GW3965 was shown to increase aortic expression of ABCA1 and ABCG1 in 
ApoE-/- mice5. 
 Thirdly, T0901317 blocked lesion progression from lesion severity stage II 
to III, characterized by the absence of SMC in the cap15. Proliferation and migration of 
SMC from the media towards the intima, a hallmark of type III lesions, is a key event in 
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lesion progression and regulated by CD4434,35. The detected down-regulation of CD44 
by T0901317 in our study may thus provide an explanation for the observed blockage 
of lesion progression. 
 Atherosclerosis regression is an important clinical goal, but mouse studies 
on regression are relatively few. We observed that under dietary cholesterol-free 
(“regressive”) conditions, there was a rapid loss of plaque foam cells from existing 
plaques, and this process was further enhanced by T0901317. In line with a previous 
study in E3L mice macrophage disappearance preceded reduction in plaque size under 
regressive conditions11. Remarkably, the effect of T0901317 on plaque regression 
occurred while plasma cholesterol level and lipoprotein profile were very similar 
to those found with T0901317 under progressive (HC) conditions. Also, monocyte 
adherence in the presence of T0901317 was not different between regressive and 
progressive conditions. 
 Three processes were identified that could be relevant for explaining the 
T0901317-stimulated disappearance of macrophages. First, the disappearance of 
macrophages could be the result of apoptosis. Indeed, we found evidence for increased 
number of apoptotic bodies with a parallel up-regulation of pro-apoptotic genes 
(Caspase-3, BAX, and FAS) in the aorta. Secondly, T0901317 enhances gene expression 
of reverse cholesterol transport markers, ApoE, ABCA1 and ABCG1. This is of relevance 
because it is thought that the elevated plasma membrane cholesterol content in foam 
cells inhibits cell migration36. Since plaque progression may result in part from long-
term retention of foam cells in the plaque, promoting emigration of foam cells from 
atherosclerotic lesions through lowering cellular cholesterol content might lead to 
plaque regression. Thirdly, findings from a study by Trogan et al.23 raised the possibility 
that, during regression, foam cells acquire dendritic cell (DC) characteristics that permit 
them to migrate to draining lymph nodes. This migration depends on the chemokine 
receptor CCR7, which might become up-regulated in foam cells in plaques undergoing 
regression. When CCR7 function was abrogated in vivo by treatment with antibodies 
to CCR7 ligands CCL19 and CCL21, lesion size and foam cell content were substantially 
preserved. In line with this, we found that CCR7 expression in the vasculature is located 
at the adventitial space and is increased 2-fold when regression is induced  by RD and 
8-fold by RD+T0901317, despite the decreases in macrophage content. Concomitantly, 
increases in hepatic CCL19 and CCL21 expression were observed (data not shown). 
 In summary, our findings show a comprehensive analysis of the beneficial effects 
of T0901317 on lesion evolution and regression in E3L mice and provide plausible 
mechanisms for its mode of action, including stimulation of cholesterol efflux-related 
genes and suppression of the inflammatory state. The data also revealed CCR7 induction 
in foam cells, a chemokine receptor reportedly functionally required for regression. LXR 
agonists could thus contribute in abrogating (pre-existing) atherosclerosis. 
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Background: Although CETP inhibition is regarded as a promising strategy to reduce 
atherosclerosis by increasing HDL-cholesterol, the CETP inhibitor torcetrapib given on 
top of atorvastatin had no effect on atherosclerosis and even increased cardiovascular 
death in the recent ILLUMINATE trial. Therefore, we evaluated the anti-atherogenic 
potential and adverse effects of torcetrapib in humanized APOE*3-Leiden.CETP (E3L.
CETP) mice.
Methods and Results: E3L.CETP mice were fed a cholesterol-rich without drugs or 
with torcetrapib (12 mg/kg/day), atorvastatin (2.8 mg/kg/day) or both for 14 weeks. 
Torcetrapib decreased CETP activity both in the absence and presence of atorvastatin 
(-74% and -73% respectively, P<0.001). Torcetrapib decreased plasma cholesterol 
(-20%, P<0.01), albeit to a lesser extent than atorvastatin (-42%, P<0.001) or the 
combination of torcetrapib and atorvastatin (-40%, P<0.001). Torcetrapib increased 
HDL-cholesterol in the absence (+30%) and in the presence (+34%) of atorvastatin. 
Torcetrapib and atorvastatin alone both reduced atherosclerotic lesion size (-43% and 
-46%, P<0.05), but combination therapy did not reduce atherosclerosis as compared 
to atorvastatin alone. Remarkably, as compared to atorvastatin, torcetrapib induced 
enhanced monocyte recruitment and expression of monocyte chemoattractant 
protein-1 and resulted in lesions of a more inflammatory phenotype, as reflected by an 
increased macrophage content and reduced collagen content.  
         
Conclusions: CETP inhibition by torcetrapib per se reduces atherosclerotic lesion size but 
does not enhance the anti-atherogenic potential of atorvastatin. However, as compared 
to atorvastatin, torcetrapib introduces lesions of a less stable phenotype.
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Introduction
The cholesteryl ester transfer protein (CETP) is an important regulator of the HDL-C 
level. CETP is secreted predominantly by the liver and mainly associates with HDL in 
plasma, where it transports cholesteryl esters (CE) from HDL to (V)LDL in exchange 
for triglycerides,1,2 and thus lowers HDL-C. HDL is atheroprotective as it mediates 
reverse cholesterol transport (i.e. transport of cholesterol from the vessel wall to the 
liver) and it has anti-inflammatory, anti-thrombotic and anti-oxidative properties.3,4 
Therefore, CETP inhibition is regarded as a promising strategy to increase HDL-C levels 
and to reduce atherosclerosis.1 However, the effect of CETP activity on atherosclerosis 
in humans has not been unequivocally determined. Mutations in the CETP gene that 
reduce CETP mass and activity (e.g. D442G and Int14 G(+1)>A) lead to elevated HDL-C 
levels,5,6 but the effects of these mutations on atherosclerosis are still in dispute.7-10
Torcetrapib, which forms an inactive complex between CETP and HDL1 has been the 
first CETP inhibitor tested in large human trials, in which it was shown to increase 
HDL-C levels by approx. 60%.11-13 The resulting HDL particles were able to mediate 
cellular cholesterol efflux more efficiently.14 However, the large scale ILLUMINATE 
trial was stopped prematurely because of an excess of deaths in patients receiving 
torcetrapib with atorvastatin as compared to those receiving atorvastatin alone, mainly 
related to cardiovascular events.15 In addition, the RADIANCE and ILLUSTRATE trials 
revealed no therapeutic benefit of combining torcetrapib with atorvastatin with respect 
to atherosclerosis progression as assessed by coronary intima-media thickness (IMT) 
and intravascular ultrasonography (IVUS) measurements.11-13
The effect of torcetrapib alone on atherosclerosis, however, has not yet been evaluated 
in humans, and the mechanism underlying the increased death rate associated with 
torcetrapib treatment has not been elucidated as yet. Therefore, we now examined the 
effect of torcetrapib with or without atorvastatin on atherosclerosis development in 
humanized APOE*3-Leiden.CETP (E3L.CETP) transgenic mice.16 E3L mice show a human-
like response to lipid-lowering therapies.17 Cross-breeding with CETP transgenic mice, 
which express human CETP under control of its natural flanking regions, resulted in 




Human CETP transgenic mice which express CETP under control of its natural flanking 
regions (strain 5203)20 were obtained from Jackson laboratories (Bar Harbor, MC) and 
crossbred with E3L mice21 to obtain E3L.CETP mice.16 All mice used in this study were 
heterozygous E3L.CETP transgenic females on a C57Bl/6 background. Mice were housed 
under standard conditions with a 12 h light-dark cycle and had free access to food and 
water unless indicated otherwise. Mice were fed regular chow (Ssniff, Soest, Germany) 
or a diet with 15% (w/w) cacao butter (diet T, Hope Farms, Woerden, the Netherlands) 
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supplemented with 0.1% or 0.25% (w/w) cholesterol (Sigma) with or without 
torcetrapib (2R,4S)-4-[[[3,5bis(trifluoromethyl) phenyl]methyl]-(methoxycarbonyl)
amino]-2-ethyl-3,4-dihydro-6-trifluoromethyl)-3-phenyl-1(2H)-quinolinecarboxylic 
acid, ethyl ester (C26H25N2O4F9), (kindly provided by Roche, Basel, Switzerland) and/or 
atorvastatin ([R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-
3-phenyl-4[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (C33H24FN2O5) 
(Lipitor). Unless indicated otherwise, blood was drawn after 4 h fasting in EDTA-
containing cups by tail bleeding and plasma was isolated. All animal experiments were 
approved by the institutional ethical committee on animal care and experimentation.
Single Torcetrapib Treatment
To verify that torcetrapib inhibits CETP activity in E3L.CETP mice in vivo, mice on a 
chow diet were given a single intragastric gavage of torcetrapib (0, 1, 3 and 10 mg/
kg) in approx. 200 µL of ethanol: solutol: saline 10:10:80 (v:v:v). Blood was drawn 
before gavage and at 1, 2, 4, 6, 8 and 24 h after gavage. During the first 8 h after the 
gavage mice were fasted. Plasma was assayed for total CETP activity as described below. 
Alternatively, mice were fed a diet containing 15% cacao butter with 0.1% or 0.25% 
cholesterol, and the effect of 10 mg/kg torcetrapib was determined on plasma CETP 
activity at 2 h after gavage.
Total Plasma CETP Activity, Endogenous CETP Activity and CETP Mass
Total plasma CETP activity was measured as the transfer of [3H]cholesteryl oleate (CO) 
from LDL to HDL.16 Briefly, 5 µL (diluted) mouse plasma was incubated with human 
[3H]CO-labeled LDL and HDL in sodium phosphate buffer containing 5,5’-dithio-bis(2-
nitrobenzoic acid) to inhibit lecithin-cholesterol acyltransferase (LCAT) activity. After 
overnight incubation, LDL was precipitated. The supernatant containing [3H]CO-HDL 
was counted for 3H activity. CETP activity was calculated as nmol CE transfer/ mL 
plasma/ h. Endogenous CETP activity was determined by a fluorescent method using 
donor liposomes enriched with nitrobenzoxadiazole (NBD)-labeled cholesteryl esters 
(RB-CETP, Roar Biomedical, NY, USA), as described.22 CETP mass was determined using 
the DAIICHI CETP ELISA kit according to manufacturer’s instructions (Daiichi, Tokyo, 
Japan).
Long-term Torcetrapib Treatment
To determine the effect of torcetrapib without and with atorvastatin on atherosclerosis 
development and plasma cholesterol, E3L.CETP mice were fed a diet containing 0.25% 
cholesterol to increase plasma cholesterol levels to ~16 mM. After 4 weeks, mice were 
randomized into four groups according to their plasma cholesterol levels. Mice were fed 
a control diet, a diet with atorvastatin (0.0023% ~ 2.8 mg/kg/day), torcetrapib (0.01% 
~ 12 mg/kg/day) or both. Blood was drawn one week before randomization and at 
week 6, 9 and 14 of drug treatment, and was assayed for lipids, CETP mass and activity. 
After 14 weeks, mice were euthanized and atherosclerosis development was assessed 
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as described below. 
Plasma Lipids and Lipoprotein Profiles
Plasma was assayed for cholesterol and phospholipids (PL) using commercially available 
enzymatic kits according to the manufacturer’s protocols (236691, Roche Molecular 
Biochemicals, Indianapolis IN, USA, and phospholipids B Wako Chemicals, Neuss, 
Germany, respectively). To determine the lipid distribution over plasma lipoproteins, 
lipoproteins were separated using fast protein liquid chromatography (FPLC). Plasma 
was pooled per group and 50 µL of each pool was injected onto a Superose 6 HR 10/30 
column (Äkta System, Amersham Pharmacia Biotech, Piscataway, NJ, USA) and eluted at 
a constant flow rate of 50 µL/min in PBS, 1 mM EDTA, pH 7.4. Fractions of 50 µL were 
collected and assayed for cholesterol and PL as described above. 
Atherosclerosis Quantification
After 14 weeks of drug intervention, mice were sacrificed by CO2 inhalation. Blood 
was drawn via cardiac puncture and hearts were isolated. Hearts were fixed in 
phosphate-buffered 4% formaldehyde, dehydrated, embedded in paraffin and were 
cross-sectioned (5 µm) throughout the aortic root area. Per mouse 4 sections with 50 
µm intervals were used for atherosclerosis measurements. Sections were stained with 
hematoxylin-phloxin-saffron (HPS) for histological analysis. Lesions were categorized 
for severity according to the American Heart system adapted for mice.23,24 Various 
types of lesions were discerned: type 0 (no lesions), type 1-3 (early fatty streak-like 
lesions containing foam cells) and type 4-5 (advanced lesions containing foam cells 
in the media, presence of fibrosis, cholesterol clefts, mineralization and/or necrosis). 
Lesion area was determined using Leica Qwin image analysis software (EIS, Asbury 
NJ). AIA 31240 antiserum (1:3000, Accurate Chemical and Scientific, Westbury, NY) 
was used to quantify the macrophage area and the number of monocytes adhering to 
the endothelium. Sirius Red was used to quantify the collagen area, and the antibody 
M0851 (1:800, DAKO) against smooth muscle cell actin to quantify the smooth muscle 
cell area. Monocyte chemoattractant protein-1 (MCP-1) was detected using goat anti-
mouse MCP-1 (M18, 1:300; Santa Cruz Biotechnology, Santa Cruz, Calif).
Statistical Analysis
Data are presented as means ± SD unless indicated otherwise. Statistical differences 
were assessed using the Mann Whitney U test. For lesion typing, differences were 
assessed by the Chi Square test. SPSS 14.0 was used for statistical analysis. Values of 
P<0.05 was regarded as statistically significant. 
The authors had full access to and take full responsibility for the integrity of the data. All 




Torcetrapib Inhibits CETP Activity in E3L.CETP mice
To verify that E3L.CETP mice appropriately respond to CETP inhibition, E3L.CETP mice 
on a chow diet received an oral garage of torcetrapib (1, 3 and 10 mg/kg) or vehicle. 
As expected, torcetrapib time- and dose-dependently reduced plasma CETP activity, 
reaching a minimum at 2 h after gavage (-59±8%, -83±4%, and -96±4%; P<0.01). At 
3 and 10 mg/kg, significant reductions were still observed after 8 h (-45±25% and 
-45±17% respectively; P<0.01) (Fig. 1A). Because cholesterol-feeding of E3L.CETP mice 
increases plasma CETP mass and activity,16 we next measured the inhibitory capacity 
of torcetrapib on plasma CETP activity in mice fed a diet without or with 0.1% (w/w) 
or 0.25% (w/w) cholesterol, which increased plasma CETP activities (3.4-fold and 
4.3- fold, respectively). Despite the increase in plasma CETP activity, an oral gavage of 
torcetrapib (10 mg/kg) still profoundly decreased CETP activity in the presence of 0.1% 
(-64±11%; P<0.05) and 0.25% (-59±13%; P<0.05) cholesterol in the diet (Fig. 1B).
 
Torcetrapib Reduces Plasma Cholesterol Levels to a Lesser Extent than Atorvastatin
To determine the effect of torcetrapib on plasma lipid levels in the absence or presence 
of atorvastatin, E3L.CETP mice were fed a diet containing 0.25% (w/ w) cholesterol 
without or with torcetrapib and/or atorvastatin. Addition of torcetrapib, atorvastatin 
or both to the diet did not affect food intake or body weights of E3L.CETP mice (not 
shown). The cholesterol-rich diet resulted in a plasma cholesterol level of 16.1±3.5 
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Figure 1. A single dose of torcetrapib inhibits CETP in vivo. E3L.CETP mice fed a chow diet 
received the indicated amounts of torcetrapib via intragastric gavage. Blood was drawn at 
the indicated time points and plasma was assayed for CETP activity (A). E3L.CETP mice, fed a 
chow diet or a diet containing 0.1% and 0.25% cholesterol, received torcetrapib (10 mg/kg) by 
intragastric gavage and total CETP activity was measured 2 h after gavage (B). Values are means ± 
SD (n=4-6); *P<0.05, **P<0.01, ***P<0.001 as compared to the control group.
Time after gavage (h)
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to a lesser extent as compared to atorvastatin (-42%; P<0.001). The combination of 
torcetrapib and atorvastatin did not decrease plasma cholesterol further as compared 
to atorvastatin alone (-40% vs -42%) (Fig. 2A). Since torcetrapib and atorvastatin 
consistently lowered plasma cholesterol throughout the study, they similarly decreased 
total cholesterol exposure (Fig. 2B). Thus, torcetrapib alone reduced total cholesterol 
exposure to a lower extent as compared to atorvastatin and combination therapy (Fig. 
2B). 
To determine the distribution of lipids over lipoproteins, lipoproteins were fractionated 
by FPLC and cholesterol and PL were measured in the individual fractions (Fig. 3). 
Torcetrapib reduced (V)LDL-C (-26%) (Fig. 3A) to a lesser extent than atorvastatin 
(-42%) (Fig. 3A and 3B), and torcetrapib did not enhance the (V)LDL-C reducing 
effect of atorvastatin (Fig. 3B). In addition, torcetrapib increased plasma HDL-C levels 
by +30% in the absence of atorvastatin (Fig. 3A) and by +34% in the presence of 
atorvastatin, as judged from the cholesterol content of the FPLC fractions 17-22 (Fig. 
3B). This torcetrapib-induced increase in HDL-C was paralleled by an increase in PL in 
the HDL fractions (Fig. 3C and 3D). Despite these increased HDL-C levels, apoAI levels 
were not altered by torcetrapib treatment (not shown).
Torcetrapib Reduces CETP Activity and Increases CETP Mass Whereas Atorvastatin 
Decreases Both CETP Activity and Mass
 Torcetrapib decreased CETP activity efficiently both in the absence (-73%; P<0.001) 
and presence of atorvastatin (-74%; P<0.001) (Fig. 4A). Atorvastatin alone also 
decreased CETP activity, but to a lesser extent (-32%; P<0.001). Despite the decreased 
Figure 2. Torcetrapib reduces plasma cholesterol to a lesser extent than atorvastatin. Mice 
were fed a diet containing 0.25% cholesterol without or with torcetrapib (0.01%), atorvastatin 
(0.0023%) or both. After 9 weeks of drug intervention, blood was drawn and plasma was assayed 
for cholesterol (A). Blood was drawn at additional time points (0, 6, 9, and 14 weeks) and TC was 
measured. Total cholesterol exposure during the study was calculated (B). Values are means ± SD 












































































CETP activity, torcetrapib treatment increased CETP mass (+33%; P<0.001). On the 
contrary, atorvastatin decreased CETP mass (-24%; P<0.001), whereas the combination 
therapy did not significantly affect CETP mass as compared to untreated mice (Fig. 4B). 
These data are in line with previous observations that torcetrapib increases CETP mass 
in humans despite the decrease in CETP activity25 and that atorvastatin decreases CETP 
levels26,27 by decreasing CETP expression.18
Torcetrapib Reduces Atherosclerotic Lesion Severity and Lesion Area but Does Not Enhance 
the Anti-Atherogenic Effect of Atorvastatin
To determine the effect of torcetrapib on atherosclerosis development in the absence or 
in the presence of atorvastatin, the 4 groups of mice were euthanized after 14 weeks and 
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Figure 3. Torcetrapib reduces plasma VLDL and increases HDL levels. Mice were fed a diet 
containing 0.25% cholesterol without or with torcetrapib (0.01%), atorvastatin (0.0023%) or 
both. After 14 weeks of drug intervention, blood was drawn and plasma was pooled per treatment 
group (n=14-15). Pooled plasma was fractionated using FPLC on a Superose 6 column and the 
individual fractions were assayed for total cholesterol (A, B) and phospholipid (C, D).
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pictures of each group are shown in Fig. 5A. As compared to the control group, mice 
treated with torcetrapib, atorvastatin or both had more lesion-free sections and fewer 
severe lesions of type 4 to 5. Thus, torcetrapib, atorvastatin and the combination of both 
reduced lesion severity similarly (Fig. 5B). Accordingly, 
torcetrapib and atorvastatin alone induced a similar reduction in lesion area (-43% 
torcetrapib and atorvastatin alone induced a similar reduction in lesion area (-43% and 
-46% respectively; P<0.05). Combination treatment also reduced atherosclerosis as 
compared to the control group (-60%; P<0.001), but did not significantly enhance the 
atherosclerosis-reducing potency of atorvastatin alone (Fig. 5C).
Torcetrapib Induces Monocyte Recruitment and Results in a More Pro-Inflammatory 
Lesion Phenotype as Compared to Atorvastatin
We next evaluated the effect of torcetrapib, atorvastatin and the combination of both 
on monocyte recruitment and lesion composition with respect to the macrophage area, 
smooth muscle cell area and collagen area. Torcetrapib alone and in combination with 
atorvastatin increased the adherence of monocytes to the vessel wall as compared 
to the control and atorvastatin- treated group (Fig 6A). Although torcetrapib did not 
significantly raise MCP-1 as compared to the control group, torcetrapib significantly 
increased MCP-1 as compared to atorvastatin (+99%; P<0.05) (Fig. 6B). The increase 
in adhering monocytes as induced by torcetrapib was accompanied by an increased 
area of macrophages in the intima (Fig. 6C). Although torcetrapib did not appear to 
affect the smooth muscle cell content (Fig. 6D), torcetrapib alone and in combination 
with atorvastatin tended to decrease the area of collagen (P=0.14 and P=0.13, resp.) 
Figure 4. Torcetrapib reduces plasma CETP activity and increases CETP mass. Mice were fed 
a diet containing 0.25% cholesterol without or with torcetrapib (0.01%), atorvastatin (0.0023%) 
or both. After 9 weeks of drug intervention, blood was drawn and plasma was assayed endogenous 
























































































(Fig. 6E). Thus, whereas atorvastatin reduces lesion size and P=0.13, resp.) (Fig. 6E). 
Thus, whereas atorvastatin reduces lesion size without affecting lesion composition as 
compared to untreated mice, torcetrapib reduces lesion size accompanied by a more pro-
inflammatory torcetrapib reduces lesion size accompanied by a more pro-inflammatory 
lesion phenotype, reflected by an increased macrophage-to-collagen ratio, as compared 
to control-treated mice (+75%) and atorvastatin-treated mice (+67%).
Discussion
Torcetrapib has been shown to markedly raise HDL-C and was, therefore, expected to 
reduce atherosclerosis in humans. Despite this, the recent RADIANCE, ILLUSTRATE 





















































































Figure 5. Torcetrapib reduces ath-
erosclerosis development but does 
not enhance the atherosclerosis re-
ducing effect of atorvastatin. Mice 
were fed a diet containing 0.25% cho-
lesterol without or with torcetrapib 
(0.01%), atorvastatin (0.0023%) or 
both. After 14 weeks of drug interven-
tion, hearts were isolated, fixed, dehy-
drated and embedded in paraffin and 
representative HPS stained pictures of 
each group are shown (A). Four sections 
per mouse with 50 µm intervals were 
typed and categorized according to 
lesion severity (B), and total lesion area 
was calculated (C). Values are means 
± SEM (n=14-15) *P<0.05, **P<0.01, 





























































































































































































Figure 6. Torcetrapib unfavorably 
alters plaque composition as com-
pared to atorvastatin. In the sections 
obtained as described in Figure 5, the 
adhesion of monocytes to the lesions 
was determined (A), as well as the 
MCP-1 content (B) and macrophage 
content (C) of the lesions. In addition, 
the SMC content (D) and collagen con-
tent (E) of the lesions were quantified. 
Values are means ± SEM (n=14-15); 














atherosclerosis11-13 and increased clinical event rate.15 However, it should be realized 
that the effectiveness of torcetrapib has only been assessed in dyslipidemic patients 
who also received atorvastatin. Therefore, in the present study we examined the 
effect of torcetrapib per se on atherosclerosis development. In our study we show that 
torcetrapib alone reduces the progression of atherosclerosis, but does not enhance the 
anti-atherosclerotic potency of atorvastatin and that torcetrapib results in a more pro-
inflammatory lesion phenotype as compared to atorvastatin.
Torcetrapib reduced total cholesterol exposure to a lesser extent (-17%) as compared 
to atorvastatin (-41%), whereas torcetrapib and atorvastatin equally reduced 
atherosclerotic lesion size (both ~-45%). Previous diet-induced atherosclerosis studies 
in mice have consistently demonstrated that atherosclerotic lesion area could generally 
be reliably predicted from cholesterol exposure (H.M.G. Princen PhD and P.C.N. Rensen 
PhD, unpublished data, 2007). Therefore, torcetrapib decreased atherosclerosis 
development more drastically than could be expected based merely on the observed 
reduction in cholesterol exposure. Since torcetrapib treatment results in increased HDL 
levels, it is likely that HDL is involved in the atheroprotective effect of torcetrapib. In line 
with this hypothesis, we have observed previously that E3L.CETP mice show a 7-fold 
increased atherosclerotic lesion area as compared to E3L only mice, which was much 
more than could be expected based on a modest increase in total plasma cholesterol per 
se. In fact, we showed that plasma from E3L.CETP mice was less effective in mediating 
SR-BI-dependent cholesterol efflux than plasma from E3L mice, as accompanied by a 
large reduction in HDL-1.16 In the present study, we did not detect an effect of torcetrapib 
on either SR-BI or ABCA1-mediated cholesterol efflux (not shown), possibly related to 
the relatively mild effect of torcetrapib on the HDL level as compared to total CETP 
deficiency. We therefore speculate that effects of torcetrapib on other properties of 
HDL, including its anti-inflammatory, anti-oxidative and/or anti-thrombotic properties 
may have resulted in the more prominent reduction in atherosclerotic lesion size than 
could be expected merely on the basis of a reduction in total cholesterol.
The fact that torcetrapib alone reduced atherosclerosis development is in line with a 
previous study showing that torcetrapib treatment alone reduces atherosclerosis in 
rabbits.28 However, we also show that torcetrapib did not significantly enhance the 
anti-atherogenic potential of atorvastatin. We have evaluated the effects of torcetrapib 
and atorvastatin in E3L.CETP mice with a relatively high plasma cholesterol level of 
approx. 16 mM, to avoid the possibility that the combined cholesterol-lowering actions 
of atorvastatin and torcetrapib would result in a plasma cholesterol level below that 
required for atherosclerosis development in E3L.CETP mice (i.e. 6-8 mM). Despite this 
limitation, torcetrapib per se (i.e. without concomitant administration of atorvastatin) 
may thus have an anti-atherosclerotic effect in humans as well. 
From the recent clinical trials, it has become clear that torcetrapib has several adverse 
effects. The ILLUMINATE trial showed that torcetrapib elevated blood pressure, increased 
cardiovascular events and increased death rate, mainly related to cardiovascular 
causes.15 However, the mechanisms underlying these unexpected adverse effects have 
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not completely been elucidated yet. In the present study, we did not detect a significant 
effect of torcetrapib on blood pressure, probably because of small experimental 
groups (data not shown). However, compared with atorvastatin, torcetrapib enhanced 
monocyte adherence to the vessel wall, enhanced vascular MCP-1 expression, and 
increased the macrophage area within the lesions. Torcetrapib thus appears to enhance 
the recruitment of monocytes to the endothelium and transmigration of the monocytes 
into the intima resulting in an enhanced macrophage content of the plaque, compared 
with similarly sized lesions resulting from atorvastatin treatment. The observation 
that torcetrapib tended to reduce the collagen content of the plaque independent of 
the smooth muscle cell content can be explained by induction of collagen breakdown 
by macrophages, (e.g., via secretion of metalloproteinases). Although plaque rupture 
is a rare phenomenon in mice, such inflammatory lesions with a high macrophage to 
collagen ratio are more unstable and may well have caused an increased incidence of 
plaque rupture in humans, thereby explaining increased cardiovascular death. It would 
be interesting to evaluate in future studies whether these effects of torcetrapib are 
compound-specific or related to its effect on lipoprotein metabolism, by comparison 
with other CETP inhibitors that are currently under development (e.g. JTT-705 and 
anacetrapib).
Interestingly, recent data from the ILLUMINATE trial indicate that torcetrapib increased 
plasma aldosterone levels via an as yet unknown mechanism.15 In addition to increasing 
blood pressure,29 aldosterone increases atherosclerosis development in mice.30-32 This 
is related to its pro-inflammatory properties including increased MCP-1 expression, 
increased monocyte infiltration into the coronary artery, increased lipid loading of 
macrophages, and increased expression of matrix metalloproteinases.29,30 Preliminary 
data on aldosterone levels in pooled plasma of the various mouse groups indicated 
that the average aldosterone level is higher in the torcetrapib-treated group (+15%) 
and combination-treated group (+48%) than in the atorvastatin-treated group. This 
suggests that the torcetrapib-induced increase in aldosterone levels may causally 
increase the inflammatory plaque phenotype in mice.
In conclusion, torcetrapib inhibits the progression of atherosclerosis, but does not 
enhance the anti-atherosclerotic potency of atorvastatin. In addition, as compared 
to atorvastatin, torcetrapib causes a more pro-inflammatory and unstable lesion 
phenotype.
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Objective: CETP adversely affects the plasma lipoprotein profile by increasing VLDL-
cholesterol and decreasing HDL-cholesterol. The relative contribution of either of 
these changes to atherosclerosis development is not known. We investigated to what 
extent the increase in VLDL-cholesterol can explain the atherogenic action of human 
CETP expression in APOE*3-Leiden (E3L) mice, a model for human-like lipoprotein 
metabolism.
Methods and Results: E3L and E3L.CETP mice were fed a low cholesterol (LC) diet, 
resulting in a 4-fold increased VLDL-cholesterol level as well as a 9-fold increased 
atherosclerotic lesion area in the aortic root in E3L.CETP mice compared to E3L-
LC mice. E3L mice fed a high cholesterol (HC) diet to match for the increased VLDL-
cholesterol levels in E3L.CETP mice, displayed a similar atherosclerotic lesion area 
as observed in E3L.CETP mice. Hence, the CETP-induced raise in atherosclerosis can 
largely be explained by increased VLDL-cholesterol. Despite similar atherosclerosis 
development, E3L.CETP mice had lower HDL-cholesterol as compared to E3L-HC 
mice (-49%) indicating that the HDL-cholesterol lowering effect of CETP is unlikely to 
contribute to atherosclerosis development in this experimental setting. Remarkably, 
atherosclerotic lesions in CETP-expressing mice were enriched in collagen, suggesting 
a role of CETP or the diet in modifying lesion collagen content.
Conclusions: In this experimental setting, the pro-atherogenic effect of CETP is largely 




Atherosclerosis is a disease affecting the large arteries and is one of the leading 
causes of death in the Western world. An important risk factor for the development 
of atherosclerosis is dyslipidemia, as characterized by high levels of (very) low 
density lipoprotein-cholesterol ((V)LDL-C) and low levels of high density lipoprotein-
cholesterol (HDL-C). The cholesteryl ester transfer protein (CETP) plays a role in the 
regulation of both (V)LDL-C and HDL-C levels, as CETP transfers cholesteryl esters from 
HDL to (V)LDL in exchange for triglycerides (TG) 1. In this way, CETP lowers HDL-C and 
at the same time increases (V)LDL-C, thereby unfavorably modifying two risk factors for 
atherosclerosis development 2.
Indeed, in established hyperlipidemic mouse models for atherosclerosis, CETP 
expression aggravated atherosclerosis development 3,4. However, contradicting effects of 
CETP on atherosclerosis development have been reported in humans. In studies where 
a reduced CETP mass led to increased HDL-C a beneficial effect on CHD was found only 
with concomitantly reduced (V)LDL-C  2,5-7, while in studies where (V)LDL-C was not 
affected an increased CHD prevalence was observed 8-10. These studies suggest that (V)
LDL-C levels are of great importance in determining the effect of CETP on CHD. On the 
other hand, a recent meta-analysis suggests that mutations in CETP that are associated 
with reduced CETP activity and increased HDL-C coincided with a reduced CHD risk 11. 
Together, these studies demonstrate the complex role of CETP in atherosclerosis.
This complexity is further illustrated by the RADIANCE 1 12 and 2 13, 
ILLUSTRATE 14 and ILLUMINATE 15 trials, which evaluated the CETP inhibitor 
torcetrapib in combination with the LDL-C lowering drug atorvastatin. Combination 
therapy led to a strong increase in HDL-C (up to +63%) that was accompanied by a 
mild decrease in LDL-C (up to -20%) compared to atorvastatin only, but no beneficial 
effect on atherosclerosis progression was seen 12-14. The ILLUMINATE trial was even 
stopped prematurely because of an excess of deaths in the torcetrapib/atorvastatin-
treated group, attributed largely to cardiovascular death 15. The mechanism behind 
the increased death rate is still unclear. Unexpected effects could have occurred due to 
adverse effects of CETP inhibition or to off-target drug effects of torcetrapib treatment, 
such as an increased blood pressure, increased plasma aldosterone levels 16 and 
potentially increased plaque instability 17.
Despite the large number of studies that have been performed to get insight 
into the effect of CETP on atherosclerosis, the precise role of CETP in atherosclerosis 
development is thus still unclear. Firstly, as CETP affects (V)LDL-C as well as HDL-C 
levels, it is difficult to distinguish between the relative contributions of either of these 
factors to lesion development. Secondly, it is not known whether CETP produced in 
atherosclerotic lesions by macrophages 18,19 and smooth muscle cells 20 has a local effect 
on atherosclerosis development.
In the current study we aimed at determining whether the CETP-induced 
increase in atherosclerosis as evident from experimental studies 3,4 can be explained 
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by an increase in VLDL-C or if other effects of CETP, such as a decrease in HDL-C or a 
local effect of CETP in atherosclerotic lesions, also affect atherosclerosis development. 
To this end, we used APOE*3-Leiden (E3L) mice and E3L.CETP mice, models for human-
like lipoprotein metabolism in which plasma cholesterol levels can be titrated to desired 
levels by adjusting the dietary cholesterol content. By comparing atherosclerosis 
development between E3L mice and E3L.CETP mice that were matched for VLDL-C, we 




E3L mice were crossbred with mice expressing human CETP under control of the natural 
flanking regions, resulting in E3L.CETP mice 3. Female E3L mice and E3L.CETP mice of 
12-14 weeks old (n=14-15 per group) were housed under standard conditions with a 
12 h light-dark cycle and had free access to food and water unless indicated otherwise. 
Mice were fed a diet containing 15% (w/w) cacao butter (diet T, Hope Farms, Woerden, 
the Netherlands) supplemented with 0.1% or 0.4% (w/w) cholesterol (Sigma) for 15 
weeks. Blood was drawn after 4 h of fasting at t=0, 4, 8, 13 and 15 weeks after the start 
of experimental diet feeding. After 15 weeks of experimental diet feeding, the mice were 
sacrificed by CO2 inhalation and hearts were isolated for atherosclerosis analysis. All 
animal experiments were approved by the institutional ethical committee on animal 
care and experimentation.
Analysis of plasma cholesterol, cholesterol distribution over lipoproteins and inflammation 
markers
Plasma total cholesterol and TG were measured (kit no. 1489437 and kit no. 1488872, 
Roche Diagnostics, Mannheim, Germany respectively). For lipoprotein profiles, plasma 
was fractionated using an ÄKTA fast protein liquid chromatography (FPLC) system 
(Pharmacia, Roosendaal, The Netherlands) as described 21. Fractions of 50 µL were 
collected and assayed for cholesterol (using kit no. 1489437, Roche Diagnostics, 
Mannheim, Germany).
Plasma levels of fibrinogen (in house assay) 22, serum amyloid A (SAA) (Tridelta, 
Ireland, according to manufacturer’s instructions) and E-selectin (R&D systems) 23 were 
determined by ELISA.
Atherosclerosis Quantification
After isolation, hearts were fixed in phosphate-buffered 4% formaldehyde, dehydrated, 
embedded in paraffin, and cross-sectioned throughout the aortic root area. For each 
mouse, 4 sections with 50 µm intervals were used for atherosclerosis measurements. 
Sections were stained with hematoxylin-phloxin-saffron (HPS) for histological analysis. 
Lesions were categorized for severity according to the American Heart system adapted 
CETP and Atherosclerosis
105
for mice 24. Various types of lesions were discerned: no lesions, mild lesions (type 1-3) 
and severe lesions (type 4-5). Lesion area was determined using Cell D imaging software 
(Olympus Soft Imaging Solutions). AIA 31240 antiserum (1:3000, Accurate Chemical 
and Scientific) was used to quantify the macrophage area and the number of monocytes 
adhering to the endothelium and Sirius Red was used to quantify the collagen area.
Statistical Analysis
Significance of difference was calculated by one-way analysis of variance (ANOVA) test 
followed by a least significant difference post hoc analysis. For lesion typing, differences 
were assessed by the Chi Square test. SPSS 14.0 for Windows (SPSS, Chicago, USA) was 
used for statistical analysis.
Results
Plasma total cholesterol and cholesterol distribution
To compare atherosclerotic lesion development between female E3L mice and E3L.
CETP mice, both groups of mice were fed a Western-type diet containing 0.1% (w/w) 
cholesterol (LC-diet). A third group consisting of E3L mice was fed a Western-type 
diet supplemented with 0.4% (w/w) cholesterol (HC-diet) in order to match for the 
elevated plasma VLDL-C levels in the E3L.CETP group. Lipoprotein profiling confirmed 
that VLDL-C levels were comparable for E3L.CETP and E3L-HC mice and were about 
4-fold higher than in the E3L-LC group (Figure 1A). The HDL fractions of E3L-LC and 
LDL/HDL-1 b












































Figure 1. Plasma cholesterol and triglyceride distributions and total cholesterol. Two 
groups of mice were fed a diet containing 0.1% cholesterol (E3L-LC and E3L.CETP), whereas a 
third group of mice was fed a diet containing 0.4% cholesterol (E3L-HC) for 15 weeks. After 15 
weeks, blood was drawn, and the distribution of cholesterol over the individual lipoproteins was 
determined after separation by FPLC (A), and total plasma cholesterol (B) was measured. Values 
are means ± SD (n=14-15). a: fractions 4-9 of the E3L.CETP group and the E3L-HC group are 
significantly different from the E3L-LC group (P<0.001). b: fractions 10-15 of the E3L.CETP group 
and the E3L-HC group are significantly different from each other and from the E3L-LC group 
(P<0.01). c: fractions 16-20 of the E3L-HC group are significantly different from both the E3L-LC 




E3L-HC mice had an increased cholesterol content compared to E3L.CETP mice. These 
concomitant effects resulted in plasma total cholesterol levels that were increased 
in the E3L-HC (+107%, P<0.001) and E3L.CETP groups (+67%, P<0.001) compared 
to the E3L-LC group (Figure 1B). The data in Figure 1, obtained at 15 weeks, are 
representative for the whole experimental period (t=4, 8, 13 and 15). Plasma TG levels 
did not differ between the E3L-LC (1.6±0.5 mM) and E3L-HC (1.6±0.6 mM) groups, but 
were somewhat increased in E3L.CETP mice (2.7±1.2 mM; P<0.001).
Systemic inflammation markers do not differ between the experimental groups
Because inflammation is increasingly recognized as an important risk factor for 
atherosclerosis development, we evaluated whether or not the three experimental groups 
differed in circulating levels of the systemic inflammation markers SAA, fibrinogen, and 
sE-selectin. As shown in Table 1, plasma SAA levels were slightly increased in E3L-
HC mice compared to E3L-LC mice (+37%, P<0.05), but were not different from E3L.
CETP mice. Fibrinogen levels increased in time in all groups (+16-23%, P<0.01) and 
were increased in E3L.CETP mice compared to E3L-LC mice (+13%, P<0.05), but not 
compared to E3L-HC mice. As compared to t=0 values, sE-selectin levels were slightly 
increased in E3L-LC mice (+20%, P<0.01) and in E3L-HC mice (+32%, P<0.001), but not 
in E3L.CETP mice. These data show that systemic inflammation markers are not or only 
slightly increased upon experimental treatment. There is no indication for a consistent 
difference in systemic inflammation between the three groups.
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Two groups of mice were fed a diet containing 0.1% cholesterol (E3L-LC and E3L.CETP), 
whereas a third group of mice was fed a diet containing 0.4% cholesterol (E3L-HC). After 0 and 
13 weeks of experimental diet feeding, blood was drawn and plasma levels of serum amyloid A 
(SAA), fibrinogen and soluble E-selectin (sE-selectin) were determined. Values are means (SD). 
**Significantly different compared to t=0 from same group, P<0.01. #Significantly different 
from E3L-LC at same time point, P<0.05. ##Significantly different from E3L-LC at same time 
point, P<0.01. $$$Significantly different from E3L.CETP at same time point, P<0.001. 
Atherosclerosis development is strongly increased in E3L.CETP and E3L-HC mice compared 
to E3L-LC mice, but is not different between VLDL-C matched groups
After 15 weeks of experimental diet feeding, all mice were sacrificed to analyze 
atherosclerosis development in the aortic root, with particular attention to comparing 
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lesion formation in the VLDL-C matched E3L.CETP and E3L-HC groups. Representative 
pictures of each group are shown in Figure 2A. Lesion area was 7-fold increased in 
E3L-HC mice (P<0.001) and 9-fold increased in E3L.CETP mice (P<0.001) compared 
to E3L-LC mice. There was no significant difference in lesion area between VLDL-C-
matched E3L.CETP mice and E3L-HC mice (Figure 2B). A similar picture was seen for 
lesion severity analysis: E3L-LC mice mostly developed mild or no lesions, whereas the 
VLDL-C-matched E3L.CETP mice and E3L-HC mice showed less lesion-free segments 
and developed considerably more severe lesions (Figure 2C: P<0.001 and P<0.01, 
respectively). Again, no difference in lesion severity was noted between the VLDL-C-
matched E3L.CETP and E3L-HC groups.
Collagen content is strongly increased in E3L.CETP mice compared to E3L-LC and E3L-HC 
mice
One of the initial processes in lesion formation is the adhesion of monocytes to the 
endothelium. To assess whether there is a difference in monocyte adhesion between 
E3L - LC E3L.CETP E3L - HC
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Figure 2. Analysis of atherosclerosis development. Two groups of mice were fed a diet 
containing 0.1% cholesterol (E3L-LC and E3L.CETP), whereas a third group of mice was fed a diet 
containing 0.4% cholesterol (E3L-HC). After 15 weeks of experimental diet feeding, hearts were 
isolated to analyze atherosclerosis development. Representative HPS stained pictures of each 
group are shown (A). Four sections per mouse with 50 µm intervals were analyzed. Total lesion 
area was determined (B) and lesions were typed and categorized according to lesion severity 













































































the three treatment groups, the amount of monocytes adhering to the endothelium 
was determined. As shown in Figure 3A, monocyte adhesion was increased to the same 
extent in the E3L.CETP (+92%, P<0.001) and E3L-HC (+85%, P<0.001) groups compared 
to E3L-LC mice. Similarly, macrophage area was not significantly different between E3L.
CETP mice and E3L-HC mice, and was increased 11-fold and 9-fold compared to E3L-LC 
mice respectively (Figure 3B). Notably, collagen content of the lesions was increased 
in E3L.CETP mice compared to both the E3L-LC group (10-fold, P<0.001) and VLDL-C-
matched E3L-HC mice (1.6-fold, P<0.05) (Figure 3C).
Discussion
In a previous study we showed that CETP expression in E3L mice led to an increase in 
VLDL-C and a decrease in HDL-C, accompanied with a strong increase in atherosclerosis 
development 3. In the current study we provide evidence that this increase in 
atherosclerotic lesion formation can be explained by the rise in VLDL-C levels in E3L.
CETP mice, rather than by reduction of HDL-C levels, or than by changing the systemic 
inflammatory status. Furthermore, the collagen content of atherosclerotic lesions in 
E3L.CETP mice is strongly increased compared to lesions in VLDL-C matched E3L-HC 
mice, indicating that CETP has a previously unknown role in increasing collagen levels 
in atherosclerotic lesions.
Figure 3. Analysis of vascular 
inflammatory markers and lesion 
composition. Two groups of mice were fed 
a diet containing 0.1% cholesterol (E3L-
LC and E3L.CETP), whereas a third group 
of mice was fed a diet containing 0.4% 
cholesterol (E3L-HC) for 15 weeks. The 
adhesion of monocytes to the endothelium 
in the aortic root was determined (A). 
In addition, the macrophage content (B) 
and collagen content (C) of the lesions 












First, our present data show that, under the current experimental conditions, 
the CETP-induced increase in VLDL-C levels largely explains the observed increase in 
atherosclerosis development in E3L mice. In fact, atherosclerotic lesion area appeared 
to be well predicted by changes in VLDL-C (R2 = 0.694; P<0.001), but not by changes 
in LDL/HDL-1-C (R2 = 0.000; P=0.909) or HDL-C (R2 = 0.045; P=0.259) (Figure 4). In 
contrast, our recent study in E3L.CETP mice investigating the effect of torcetrapib and/
or atorvastatin on plasma lipid levels and atherosclerosis showed that atorvastatin 
more potently decreased VLDL-C levels than torcetrapib, while both compounds 
similarly reduced atherosclerotic lesion area 17. These previous data thus suggest 
that besides VLDL-C, other factors may also influence atherosclerosis development, 
including HDL. Our present finding that the CETP-induced rise in VLDL-C is the most 
important determinant for atherosclerotic lesion development is in line with studies 
in rabbits. Administration of the CETP inhibitor JTT-705 to rabbits similarly caused a 
decrease in (V)LDL-C in addition to an increase in HDL-C and decreased atherosclerosis 
Figure 4. Correlation between VLDL-
cholesterol, LDL/HDL-1-cholesterol or 
HDL-cholesterol with atherosclerotic 
lesion area. Two groups of mice were fed a 
diet containing 0.1% cholesterol (E3L-LC and 
E3L.CETP), whereas a third group of mice 
was fed a diet containing 0.4% cholesterol 
(E3L-HC). After 15 weeks, blood was drawn, 
and the distribution of cholesterol over the 
individual lipoproteins was determined after 
separation by FPLC. From each FPLC profile 
the VLDL, LDL/HDL-1 and HDL content of 
the plasma of each mouse was determined 
by calculating the sum of fractions 3-9, 10-
15 and 16-23 respectively. Correlation was 
judged from linear regression analysis.
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development 25. Interestingly, treatment of rabbits with JTT-705 in a subsequent 
study increased HDL-C without affecting (V)LDL-C, and did not affect atherosclerosis 
development 26.
Second, our data show that CETP expression in E3L mice increases the collagen 
composition of atherosclerotic lesions. These data solidify findings of a recent study 
in which we investigated the effect of torcetrapib on atherosclerosis development in 
E3L.CETP mice, and found that partial CETP inhibition tended to decrease the collagen 
content of atherosclerotic lesions 17. From that study it was not clear if the effect on 
collagen content was a compound-specific effect of torcetrapib or a general effect of 
CETP inhibition. Our current data suggest that the torcetrapib-induced reduction in 
collagen content of the lesions was a direct result of CETP inhibition, albeit that the 
mechanism is still unknown. A decrease in the collagen content of atherosclerotic 
lesions by CETP inhibition, thereby destabilizing these lesions, could theoretically 
explain the increased cardiovascular death rate in the torcetrapib/atorvastatin-treated 
group compared to the atorvastatin-treated group in the ILLUMINATE trial 15, but more 
research is needed to confirm this theory.
It should be noted that LDL is the most abundant atherogenic lipoprotein in 
humans, whereas larger cholesterol-enriched VLDL remnants accumulate in E3L and 
E3L.CETP mice, which may thus limit the extrapolative value of our data to the human 
situation. Despite the different nature of the accumulating atherogenic lipoprotein, 
the apparently contradicting observations in human studies investigating the effect 
of mutations in CETP, leading to a decreased CETP mass and increased HDL-C levels, 
on CHD could be explained by different effects on atherogenic lipoprotein levels (i.e. 
LDL). When LDL-C did not change, there was an increase in CHD prevalence 8-10, while 
a decrease in LDL-C levels coincided with a reduction in the incidence of CHD 2,5-7. 
Although some human studies indicate a protective role of CETP-related changes in 
HDL-C and not LDL-C on CHD 11,27, in the RADIANCE 1 and 2 trials, carotid intima-media 
thickness progression correlated with changes in LDL-C and not HDL-C 28, which is in 
line with the data from our study. 
As the aim of this study was to evaluate the role of the CETP-induced increase 
in VLDL-C on atherosclerosis development, this unavoidably led to differences in 
levels, size and composition of HDL between the experimental groups. Although the 
differences in HDL do not seem to have a large impact on atherosclerosis development, 
we should point out that this study was not designed to investigate the specific role 
of CETP-induced changes in HDL on atherosclerosis development. Therefore, future 
studies should demonstrate if CETP-induced differences in HDL affect HDL functionality 
and thereby also influence atherosclerosis development.
In this study we show that, under the current experimental conditions, 
the proatherogenic role of CETP is mainly the consequence of its VLDL-C increasing 
effect, suggesting that CETP inhibition could lead to a reduction in atherosclerosis 
development mainly by lowering (V)LDL-C levels. As a consequence, CETP inhibition 
may not be a good alternative or additive for current LDL-C lowering therapies, e.g. 
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with statins. CETP inhibition may even interfere with the beneficial effect of CETP on 
stabilization of atherosclerotic lesions by increasing collagen 17. Thus, favorable effects 
of CETP inhibition on plasma (V)LDL-C and HDL-C levels, may not outweigh possible 
detrimental effects on plaque stability. Therefore, the strategy of CETP inhibition as 
a novel strategy to reduce atherosclerosis development in the general dyslipidemic 
population should be pursued with care.
 In conclusion, our data indicate that the increase in VLDL-C is the most 
important factor contributing to the proatherogenic effect of CETP in E3L mice. 
Furthermore, our data argue that CETP may positively influence atherosclerotic lesion 
stability by enhancing the collagen content of atherosclerotic lesions.
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A common dose-limiting side effect of treatment with the RXR agonist bexarotene is 
dyslipidemia. We evaluated the effects of bexarotene on plasma lipid metabolism in 
patients with metastatic differentiated thyroid carcinoma (DTC), and investigated the 
underlying mechanism(s) in APOE*3-Leiden mice without (E3L) and with human CETP 
(E3L.CETP). To this end, ten patients with metastatic DTC were treated with bexarotene 
(300 mg/day) for 6 weeks. Bexarotene increased plasma TG (+150%), primarily 
associated with VLDL, and raised plasma total cholesterol (TC) (+50%). However, 
while bexarotene increased VLDL-C and LDL-C (+63%), it decreased HDL-C (-30%) and 
tended to decrease apoAI (-18%) concomitant with an increase in endogenous CETP 
activity (+44%). To evaluate the cause of the bexarotene-induced hypertriglyceridemia 
and the role of CETP in the bexarotene-induced shift in cholesterol distribution, E3L 
and E3L.CETP mice were treated with bexarotene through dietary supplementation 
(0.03% w/w). Bexarotene increased VLDL-associated TG in both E3L (+47%) and 
E3L.CETP (+29%) mice, by increasing VLDL-TG production (+68%). Bexarotene did 
not affect the TC levels or distribution in E3L mice, but increased VLDL-C (+11%) 
and decreased HDL-C (-56%) as well as apoAI (-31%) in E3L.CETP mice, concomitant 
with increased endogenous CETP activity (+41%). This increased CETP activity by 
bexarotene-treatment is likely due to the increase in VLDL-TG, a CETP substrate that 
drives CETP activity. In conclusion, bexarotene causes combined dyslipidemia as 
reflected by increased TG, VLDL-C and LDL-C and decreased HDL-C, which is the result 





Bexarotene (TargretinÒ, Ligand Pharmaceuticals Inc., LGD1069) is used as a 
chemotherapeutic agent for the treatment of cutaneous T-cell lymphoma 1, and is 
evaluated as a strategy to treat patients with metastasis of differentiated thyroid 
carcinoma (DTC) 2, breast cancer 3, non-small-cell lung cancer 4 and psoriasis 5. 
Bexarotene is a selective retinoid X receptor (RXR) agonist, which class of agonists is 
also called rexinoids. When activated, RXR can form homodimers or heterodimers with 
other nuclear hormone receptors, including the liver X receptor (LXR) 6. These RXR 
homo- or heterodimers can bind to specific responsive elements in target genes to alter 
their transcription.
Hypertriglyceridemia, an important risk factor for the development of 
cardiovascular disease 7, is one of the most frequently occurring side-effects in patients 
treated with bexarotene 8. Some studies have been performed to unravel the underlying 
mechanism, but this did not lead to unequivocal results. A study in APOE2 knock-in 
mice showed that bexarotene increased the expression of hepatic genes involved in 
TG synthesis, which may imply that bexarotene increases VLDL production 9. However, 
bexarotene also increases the expression of angiopoietin-like protein 3 (Angptl3) in 
vivo 9 and of apoCIII in vitro 10, factors that are both inhibitors of the TG-hydrolyzing 
activity of lipoprotein lipase (LPL) and could thus affect TG clearance. The relevance 
of either of these findings for the effect of bexarotene on triglyceride metabolism has 
not been evaluated in vivo. Thus, as yet it is not clear whether the bexarotene induced 
hypertriglyceridemia is caused by increased TG production, decreased TG clearance or both. 
              Hypercholesterolemia, besides hypertriglyceridemia, is another reported side 
effect of bexarotene 8. Notably, the distribution of cholesterol over the various lipoproteins, 
very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density 
lipoprotein (HDL), has not yet been studied in humans. Furthermore, mouse studies 
investigating the effect of RXR agonists on cholesterol distribution showed inconsistent 
data. In db/db mice, an RXR agonist was shown to increase HDL-C 11, whereas in APOE2 
knock-in mice, bexarotene had no effect on HDL-C levels 9. However, in contrast to 
humans, mice do not naturally express the cholesteryl ester transfer protein (CETP). 
CETP plays an important role in the metabolism of both TG and cholesterol, as it transfers 
TG from VLDL and LDL to HDL in exchange for cholesteryl esters (CE) 12. In this way, CETP 
increases the cholesterol content of VLDL and LDL, while decreasing HDL-C levels. The 
importance of CETP in HDL-C metabolism has been illustrated by studies showing that the 
HDL-C-raising effect of the drugs atorvastatin 13, fenofibrate 14, niacin 15 and torcetrapib 
16 is CETP-dependent. The contradicting data on the effect of bexarotene on cholesterol 
distribution obtained in previous studies may thus relate to the absence of CETP. 
                The aim of our study was to investigate the effect of bexarotene on lipoprotein 
levels in humans treated with bexarotene in more detail, and to study the underlying 
mechanism as well as the potential involvement of CETP therein in mice. We found 
that bexarotene increases VLDL-TG, increases VLDL-C and LDL-C and decreases 
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HDL-C levels in humans. The mechanisms underlying these changes were studied 
in APOE*3-Leiden mice without (E3L) and with expression of human CETP under 
control of its own promoter and regulatory flanking regions (E3L.CETP), as E3L and 
E3L.CETP mice are well-established models for human-like lipoprotein metabolism 
and have been shown to respond in a human-like manner to lipid-modifying drugs 
13-17. Using these mice we showed that bexarotene increases TG by increasing VLDL-





The effects of bexarotene on lipid metabolism were studied in 10 patients with metastases 
of DTC who received 300 mg/day bexarotene (Targretin capsules, Ligand Pharmaceuticals, 
Crawley, UK) for 6 weeks. Exclusion criteria were pregnancy, contraindications for the 
application of recombinant human TSH (rhTSH), and contraindications for the use of 
bexarotene such as hematological malignancies, leukopenia or coagulopathy, a history 
of pancreatic disease and severe hypertriglyceridemia (fasting TG levels >4.5 mmol/L). 
Two patients had a history of well controlled hypertension, for which they used beta 
receptor blocking agents, angiotensin converting enzyme blocking agents and diuretics. 
Two other patients had well controlled type 2 diabetes mellitus, for which they used 
oral antidiabetic medication (metformin and glimepiride). Their fasting glucose levels 
were 5 and 5.7 mmol/L. One patient with type 2 diabetes mellitus also used simvastatin, 
an HMG-CoA reductase inhibitor. Baseline total cholesterol and triglycerides were 
4.38 mmol/L and 1.87 mmol/L respectively. Another patient had a history of a mild 
myocardial infarction, with normal cardiac function. This patient also used simvastatin 
for secondary prevention. Baseline total cholesterol and triglycerides were 5.08 and 
1.23 mmol/L. One patient had a history of obstructive pulmonary disease for which 
she used brochospasmolytic drugs. The institutional review board approved the study, 
and all patients gave written informed consent. This study was designed based on 
previously published studies 2,18,19. Measurements were performed prior to, and after 
this intervention. Each patient served as his/her own control.
Animals
Male E3L mice and E3L.CETP mice (n=7-8 per group) were housed under standard 
conditions with a 12 h light-dark cycle and had free access to food and water unless 
indicated otherwise. Mice were fed a standard chow diet (Sniff, Soest, Germany) or 
the same diet supplemented with 0.03% (w/w) bexarotene (4-[1-(5,6,7,8-tetrahydro-
3,5,5,8,8-pentamethyl-2-naphthalenyl) ethenyl] benzoic acid, C24H28O2) (Targretin, 
Ligand Pharmaceuticals, Crawley, UK) for 3 weeks. Experiments were performed after 
4 h of fasting, unless stated otherwise. All animal experiments were approved by the 
institutional ethical committee on animal care and experimentation.
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Analysis of plasma lipids and lipoproteins
In the human study, blood samples were collected after an overnight fast. In all mouse 
experiments, blood was collected from the tail vein after 4 hours of fasting. Plasma TG and 
total cholesterol (TC) were measured using kit no. 1488872 and kit no. 1489437 (Roche 
Diagnostics, Mannheim, Germany), respectively. HDL-C levels were measured after 
heparin/manganese chloride-induced precipitation of apoB-containing lipoproteins as 
described 15. Lipoprotein profiles were measured after fractionation of plasma using an 
ÄKTA fast protein liquid (FPLC) system (Amersham Pharmacia Biotech, Piscataway, NJ, 
USA) as described 20. Fractions of 50 µL were collected and assayed for TC and TG as 
described above.
Analysis of apoAI levels in human and mouse plasma
Plasma levels of human apoAI were determined by ELISA. Shortly, goat anti-human 
apoAI antibody (Academy Biomedical Company, Inc., Houston, USA; 11A-G2b) was 
coated overnight onto Costar medium binding plates (Costar, Inc., New York, NY) at 
4°C and subsequently incubated with diluted human plasma (dilution: 1:1,000,000) for 
2 h at 37°C. Next, horse radish peroxidase (HRP)-conjugated goat anti-human apoAI 
(Academy Biomedical Company, Inc., Houston, USA; 11H-G1b) was added and incubated 
for 2 h at 37°C. HRP was detected by incubation with tetramethylbenzidine (Organon 
Teknika, Boxtel, The Netherlands) for 15 min at room temperature. Human apoAI 
(Academy Biomedical Company, Inc., Houston, USA; 11P-101) was used as a standard. 
Plasma mouse apoAI levels were determined by ELISA as described 15.
Analysis of plasma CETP activity and mass and hepatic mRNA expression
Endogenous CETP activity was determined by a fluorescent method using donor 
liposomes enriched with nitrobenzoxadiazole-labeled cholesteryl esters (RB-CETP, 
Roar Biomedical, New York, NY) as described 21. This method determines CETP activity 
by measuring the transfer of cholesteryl esters from donor liposomes to endogenous 
lipoproteins by endogenous CETP. CETP mass was measured with the Daiichi CETP 
ELISA kit according to the manufacturer’s instructions (Daiichi, Tokyo, Japan). For 
analysis of CETP mRNA expression, RNA was isolated from livers as described 22 
using RNA-Bee (Campro Scientific, Veenendaal, The Netherlands). Integrity of RNA 
obtained was confirmed by Agilent Lab-on-a-chip technology using the RNA 6000 Nano 
LabChip kit and a bioanalyzer 2100 (both from Agilent Technologies, Amstelveen, The 
Netherlands). Preparation of cDNA was performed using the Revert Aid First strand 
cDNA synthesis kit (Fermentas Life Sciences, St. Leon-Rot, Germany) and RNA expression 
was determined by RT-PCR on a MyiQ Single-Color real-time PCR detection system (Bio-
Rad Laboratories, Hercules, CA). Primers for CETP 21 and Apob 23 have been described 
previously. Primers for Scd1 (forward: 5’-GCGATACACTCTGGTGCTCA-3’; reverse: 
5’-CCCAGGGAAACCAGGATATT-3’) and Fas (forward: 5’- ATTGCATCAAGCAAGTGC AG-
3’; reverse: 5’- GAGCCGTCAAACAGG AAGAG-3’) were designed using Primer 3 Software 
and primer efficiency was 90-100%.
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Analysis of in vivo clearance of VLDL-like TG-rich particles
VLDL-like TG-rich emulsion particles (80 nm) labeled with glycerol tri[3H]oleate 
(triolein, TO) and [14C]cholesteryl oleate (CO) were prepared and characterized 
as described previously 24. After 3 weeks of experimental diet feeding, mice were 
anesthetized by intraperitoneal injection with 6.25 mg/kg vetranquil (Alfasan, Woerden, 
The Netherlands), 6.25 mg/kg dormicum (Midazolam, Delta Select GmbH, Dreieich, 
Germany) and 0.31 mg/kg fentanyl (Janssen-Cilag B.V., Tilburg, The Netherlands). 
Emulsion particles were injected intravenously (i.v.) at a dose of 1 mg TG per mouse. 
Blood samples were taken via tail bleeding at 2, 5, 10, 20 and 30 minutes after injection 
and 3H and 14C activities in plasma were counted. Plasma volumes (mL) were calculated 
as 0.04706 x bodyweight (g) as determined from 125I-BSA clearance studies as described 
previously 25. After 30 minutes, liver, heart, spleen, hind limb muscle and white adipose 
tissue (WAT) (i.e. gonadal, perirenal and intestinal) were isolated. Organs were dissolved 
overnight at 60°C in Tissue Solubilizer (Amersham Biosciences, UK) and then 3H and 14C 
activity were counted. Values were corrected for plasma radioactivity present in the 
respective tissues 24.
Analysis of hepatic VLDL production
To study hepatic VLDL production, mice were fed the experimental diets for 3 weeks. 
Mice were anesthetized as described above and received an i.v. injection of Tran 35S 
label (150 mCi/mouse, MP Biomedicals, Eindhoven, The Netherlands) to label newly 
produced apoB, followed after 30 minutes by an i.v. injection of Triton WR-1339 to 
inhibit VLDL clearance (0.5 mg/g bodyweight, 10% solution in PBS). Blood samples 
were drawn at t=0, 15, 30, 60 and 90 minutes after injection. Plasma TG levels were 
measured as described above. After 120 minutes, mice were exsanguinated via the retro-
orbital plexus. VLDL was quantitatively isolated from plasma after density gradient 
ultra centrifugation at d<1.006 g/mL. VLDL-apoB was counted for incorporated 35S and 
VLDL-TG was measured as described above.
Statistical Analysis
Data are presented as means ± SD unless indicated otherwise. For patient data, statistical 
differences between pre- and post-treatment samples were assessed with the paired 
t-test. Statistical differences between control-treated and bexarotene-treated mice 
were assessed with the Mann-Whitney U test using SPSS 14.0 (SPSS Inc, Chicago, Ill). 
Values of P<0.05 were regarded as statistically significant.
Results
Bexarotene increases VLDL and LDL and decreases HDL in humans
To evaluate the effect of bexarotene treatment on plasma lipid levels, blood was 
drawn after an overnight fast from 10 patients with metastatic DTC before and after 
6 weeks of treatment with 300 mg bexarotene per day. Baseline TSH levels were 
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0.24±0.68 mU/L. After bexarotene treatment, mean TSH levels were 0.13±0.33 mU/L 
(P=0.648). Bexarotene treatment resulted in a strong increase in plasma TG (+150%, 
P<0.001) (Figure 1A) and TC (+50%, P<0.001) (Figure 1B). In addition, bexarotene 
decreased HDL-C (-30%, P<0.05) (Figure 1C) and tended to decrease its most abundant 
apolipoprotein apoAI (-18%, P=0.09) (Figure 1D).
Lipoprotein profiling showed that the bexarotene-induced increase in TG was 
mainly present in VLDL (+173%, P<0.05) and to a lesser extent in LDL (+76%, P<0.05) 


























































































































































in humans. Blood was drawn from patients before and after 6 weeks of bexarotene treatment, 
and plasma was assayed for TG (A) and TC (B). Furthermore, HDL-C (C) and apoAI (D) levels were 
determined. Values are means ± SD (n=10, *P<0.05, ***P<0.001; paired t-test). Lipoproteins from 




VLDL-C (+145%, P<0.05) and LDL-C (+41%, P<0.05), whereas HDL-C was decreased 
(-20%, P<0.05) (Figure 1F).
To investigate whether CETP could be involved in the shift in cholesterol 
distribution upon bexarotene treatment, plasma CETP activity and mass were measured. 
Bexarotene increased CETP activity (+44%, P<0.05) (Figure 2A) without changing 
CETP mass (Figure 2B). The effects of bexarotene on lipid profiles appeared not to be 
influenced by medications as mentioned in the Methods section.
Bexarotene increases VLDL-TG in both E3L and E3L.CETP mice and decreases HDL-C only 
in E3L.CETP mice
To investigate the mechanism behind the bexarotene-induced changes in plasma lipid 
metabolism, E3L and E3L.CETP mice were fed a regular chow diet with or without 
0.03% (w/w) bexarotene for 3 weeks. Similarly as in humans, bexarotene increased 
plasma TG both in E3L mice (+47%, P<0.05) (Figure 3A) and in E3L.CETP mice (+29%, 
P<0.01) (Figure 3B) compared to control-treated mice. Although bexarotene did not 
affect plasma TC in E3L mice (Figure 3C) and E3L.CETP mice (Figure 3D), bexarotene 
strongly decreased HDL-C in E3L.CETP mice (-56%, P<0.01) (Figure 3F), but not in E3L 
mice (Figure 3E). Similarly, bexarotene decreased apoAI levels in E3L.CETP mice (-31%, 
P<0.05) (Figure 3H) but not in E3L mice (Figure 3G).
 Lipoprotein profiling showed that the rise in TG upon bexarotene treatment 
was confined to VLDL in both E3L mice (Figure 4A) and E3L.CETP mice (Figure 4B). 
Whereas bexarotene did not affect the distribution of cholesterol over lipoproteins in 
E3L mice (Figure 4C), bexarotene shifted cholesterol from HDL to VLDL in E3L.CETP 
mice (Figure 4D). These combined data show that CETP expression does not influence 
the hypertriglyceridemic effect of bexarotene, but is crucial for the bexarotene-induced 


















































mass  in  humans. Blood was drawn from patients before and after 6 weeks of bexarotene 
treatment. In plasma, lipoprotein-dependent CETP activity (A) and CETP mass (B) were 








































































































































































and apoAI levels only in E3L.CETP mice. E3L (A, C, E, G) and E3L.CETP (B, D, F, H) mice were 
fed a diet without or with 0.03% bexarotene. After 3 weeks blood was drawn and plasma was 
assayed for TG (A, B) and cholesterol (C, D). Furthermore, plasma HDL-C (E, F) and apoAI (G, 
H) were determined. Values are means ± SD (n=7-8, *P<0.05; **P<0.01 compared to the control 
group, Mann-Whitney U test).
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Bexarotene does not affect VLDL-TG clearance in E3L.CETP mice
Since bexarotene similarly affected both TG levels and cholesterol distribution in E3L.
CETP mice as in humans, further elucidation of the effects of bexarotene on plasma 
lipid metabolism was performed using E3L.CETP mice. First, we analyzed the cause 
of the bexarotene-induced hypertriglyceridemia. To investigate whether bexarotene 
decreased TG clearance, the effect of bexarotene on the clearance of [3H]TO and [14C]
CO double-labeled TG-rich VLDL-like emulsion particles was investigated. Bexarotene 
treatment did not affect the plasma half-life of [3H]TO as compared to control treatment 
(t½ = 6.0±0.8 min vs. 6.8±1.4 min) (Figure 5A), nor the uptake of [3H]TO-derived fatty 
acid by the various organs (Figure 5B). [14C]CO disappeared at a slower rate from plasma 
than [3H]TO, but bexarotene treatment did not affect its plasma half-life (t½ = 11.5±1.8 
min vs. 12.4±2.6 min) (Figure 5C). Likewise, the uptake of [14C]CO was not different for 
any organ but for the liver (Figure 5D), which is explained by a slightly increased liver 
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only in E3L.CETP mice. E3L (A, C) and E3L.CETP (B, D) mice were fed a diet with or without 
0.03% bexarotene. After 3 weeks blood was drawn and plasma was pooled per group. Pooled 
plasma samples were fractionated using FPLC and the individual fractions were assayed for TG 


























































































































































































































Figure  5.  Bexarotene  does  not  affect  the  clearance  of  VLDL-like  TG-rich  particles  and 
increases VLDL-TG production without affecting VLDL-apoB production in E3L.CETP mice. 
E3L.CETP mice were fed a diet with or without 0.03% bexarotene for 3 weeks. For VLDL-like 
particle clearance studies, mice received an intravenous bolus of [3H]TO and [14C]CO double-
labeled VLDL-like emulsion particles (1 mg TG per mouse). At 2, 5, 10, 20 and 30 minutes after 
injection, blood samples were taken and 3H (A) and 14C (C) activities in plasma were counted 
and calculated as a percentage of the injected dose (ID). At 30 minutes after injection, mice 
were euthanized, organs were isolated and uptake of 3H (B) and 14C (D) activity by the organs 
was measured. For VLDL production studies, mice received intravenous injections of Tran35S 
to label protein and Triton WR1339 to block lipolysis. At 0, 15, 30, 60 and 90 minutes after 
injections, blood samples were taken and plasma was assayed for TG (E). TG production rates 
were determined by linear regression analysis. At 120 min, mice were exsanguinated and VLDL 
was isolated and assayed for 35S-apoB (F). Values are means ± SD (n=7-8, **P<0.01; ***P<0.001 











































































































































































































































































































































































































































weight observed in bexarotene-treated mice.
Bexarotene increases VLDL-TG production in E3L.CETP mice
As no difference was observed in TG clearance between E3L.CETP mice with or without 
bexarotene treatment, it is likely that the bexarotene-induced increase in TG levels can be 
explained by an increased rate of VLDL-TG production. Indeed, the VLDL-TG production 
rate was strongly increased in mice treated with bexarotene compared to control mice 
(+68%, P<0.01) (Figure 5E), whereas 35S-apoB production was not changed (Figure 
5F). These data indicate that bexarotene increases TG levels by enhancing VLDL-TG 
production without affecting VLDL particle production.
Table 1. Hepatic expression levels of genes involved in VLDL production.







                       1.90 (0.83) *
                       3.71 (1.31) **
0.84 (0.26)
Hepatic gene expression levels of control and bexarotene-treated E3L.CETP mice. Gene 
expression levels are normalized relative to the control group. Fas, fatty acid synthase; Scd1, 
stearyl-coenzyme A desaturase 1; Apob, apolipoprotein B. Values are means (SD). *P<0.05; 
**P<0.01 compared to control group.
 Analysis of the hepatic expression of genes involved in VLDL production 
showed that bexarotene increased the expression of the lipogenic genes fatty acid 
synthase (Fas) (1.9-fold; P<0.05) and stearyl-coenzyme A desaturase 1 (Scd1) (3.7-fold; 
P<0.01), while the expression of Apob was not changed (Table 1).
Bexarotene increases CETP activity and mass in E3L.CETP mice
By comparing the effects of bexarotene on the plasma cholesterol distribution in E3L 
and E3L.CETP mice (Figures 3 and 4), it became clear that the bexarotene-induced 
decrease in HDL-C is dependent on CETP expression. To determine if this effect is 
dependent on CETP expression per se or if bexarotene affects CETP activity, mass and/
or expression, plasma of E3L.CETP mice with or without bexarotene treatment was 
assayed for CETP activity (Figure 6A) and mass (Figure 6B). Furthermore, mRNA was 
isolated from livers of mice with or without bexarotene treatment, and expression of 
CETP mRNA was determined. Mice treated with bexarotene both had a higher plasma 
CETP activity (+41%, P<0.01) and CETP mass (+41%, P<0.01), whereas bexarotene did 
not change hepatic CETP expression (Figure 6C).
Discussion
Patients treated with bexarotene, a chemotherapeutic agent used for the treatment of 
cutaneous T-cell lymphoma, frequently develop dyslipidemia. In this study we show 
that bexarotene increases VLDL-TG and VLDL-C, while decreasing HDL-C in humans. 
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Studies in E3L and E3L.CETP mice provide evidence that increased VLDL-TG production 
is the cause of the bexarotene-induced hypertriglyceridemia. Furthermore, our data 
demonstrate that the shift in cholesterol distribution upon bexarotene treatment is a 
consequence of increased endogenous CETP activity.
 Our present data show that bexarotene induces hypertriglyceridemia in 
patients with metastases of DTC. This is in accordance with the hypertriglyceridemic 
effect of bexarotene observed earlier in other human studies in patients with cutaneous 
T-cell lymphoma 8,26,27. In addition we show by experimental studies that bexarotene also 
induces hypertriglyceridemia in mice, irrespective of CETP expression, by increasing 
VLDL-TG production rather than by reducing VLDL clearance. The observation that 
bexarotene did not decrease the clearance of VLDL-TG in vivo suggests that earlier 
findings that bexarotene increased the expression of the LPL-inhibitors apoCIII 10 and 
Angptl3 9 may not be relevant for the observed hypertriglyceridemic effect of bexarotene 
in vivo.
It is interesting to speculate about the mechanism underlying the increasing 
effect of bexarotene on the VLDL-TG production. This increase in VLDL-production could 
be the result of increased expression of lipogenic LXR target genes through bexarotene-
induced stimulation of LXR-RXR heterodimerisation. Indeed, in line with a previous 

























































































Figure  6.  Bexarotene  increases 
endogenous  CETP  activity  and  CETP 
mass, but not CETP mRNA expression  in 
E3L.CETP mice. E3L.CETP mice were fed a 
diet with or without 0.03% bexarotene for 3 
weeks. Then, blood was drawn and plasma 
CETP activity (A) and CETP mass (B) were 
determined. After blood sampling, the mice 
were sacrificed and livers were isolated for 
mRNA analysis. CETP mRNA expression 
levels were determined (C). Values are 





genes Fas and Scd1, which are both involved in the de novo production of TG in the 
liver. In contrast, the expression of Apob, a gene involved in lipid metabolism but not 
under control of LXR, was not changed. The hypothesis of bexarotene-induced LXR-RXR 
heterodimerisation is also supported by a recent report showing that the bexarotene-
induced increase in TG levels is not observed in LXRa/b knock out mice 28. In fact, LXR 
agonism in mice by a dual LXRa/b agonist on VLDL production showed that this LXR 
agonist increases the VLDL-TG production rate, without affecting apoB production 29, 
which is similar to our current observations with the RXR agonist bexarotene. Taken 
together, these data support the hypothesis that bexarotene increases the LXR-RXR 
mediated transcription of LXR target genes leading to increased VLDL-TG production, 
without affecting VLDL particle production.
We show that bexarotene not only increases plasma TG, but also increases 
plasma total cholesterol in humans. This is in agreement with previous observations by 
others 26,27, albeit that those studies did not discriminate between cholesterol associated 
with the various lipoproteins. We now reveal that the increased cholesterol levels are a 
combined result of increased VLDL-C and decreased HDL-C. Mouse studies investigating 
the effect of bexarotene or other RXR agonists on HDL-C have shown conflicting data 9,11. 
However, it should be noted that, in contrast to humans, mice naturally lack expression 
of CETP, which is a crucial determinant for distribution of plasma cholesterol over 
the various lipoprotein fractions. In fact, we have shown previously that the HDL-C 
modulating effects of atorvastatin 13, fenofibrate 14, niacin 15 and torcetrapib 16 are CETP-
dependent. Similarly, we show here that the HDL-C lowering effect of bexarotene is also 
mediated through CETP, as the HDL-C lowering effect is seen in E3L.CETP mice, but not 
in E3L mice.
The question arises whether the bexarotene-induced shift of cholesterol over 
lipoproteins in plasma results from expression of CETP per se, or whether an additional 
effect of bexarotene on CETP expression is involved. Previous studies have indicated 
that liver cholesterol content is positively correlated with hepatic CETP mRNA 
expression and plasma CETP concentration 13-15,30,31. The lipogenic effect of bexarotene 
suggested a bexarotene-induced increase in liver cholesterol content and thereby of 
CETP expression via LXR activation. However, liver lipid analysis did not reveal an effect 
of bexarotene on the hepatic cholesterol content (1.09±0.14 µg cholesterol/mg liver 
without bexarotene treatment vs. 0.99±0.11 µg cholesterol/mg liver with bexarotene 
treatment in E3L.CETP mice), indicating LXR mediated gene transcription is probably 
not increased via increased hepatic cholesterol, but just through increased LXR/RXR 
heterodimerisation. In line with this hypothesis, the bexarotene-induced expression 
of the LXR-target genes Fas and Scd1 is less pronounced than the induction observed 
after stimulation with a typical activator of LXR, T0901317 32. Apparently, the effect 
of bexarotene on the LXR-pathway is limited and too weak to increase hepatic CETP 
expression. The observation that bexarotene increases CETP mass in plasma of mice is 
thus not caused by increased mRNA expression but may result from either increased 
CETP synthesis via posttranscriptional pathways or decreased CETP clearance from 
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plasma. CETP gene expression is similarly regulated in E3L.CETP mice and humans, as 
E3L.CETP mice express human CETP under control of its own promoter and regulatory 
flanking regions. Despite this, bexarotene increases CETP mass in mice and not in 
humans by an as yet unknown mechanism.
 In humans and mice bexarotene increases endogenous, i.e. lipoprotein 
dependent, CETP activity in plasma. TG are a driving force of CETP activity 33. Also, our 
data showing that bexarotene increases TG levels in E3L mice (in absence of CETP), 
indicate that increased TG is rather a cause than a consequence of increased CETP 
activity. These data suggest that the bexarotene-induced increase in VLDL-TG induces 
the increase in CETP activity that we observed. This increased CETP activity would then 
cause a decrease in HDL-C and a concomitant increase in VLDL-C. Thus, the shift in 
cholesterol distribution upon bexarotene treatment is likely the effect of an increased 
VLDL-TG production and a resulting increase of the endogenous CETP activity.
The findings of this study support the current clinical practice to initiate 
lipid lowering therapy in patients using bexarotene who develop relevant 
hypertriglyceridemia. Statins are the preferable therapy, as no interaction between 
bexarotene and statins has been demonstrated. Fibrates are not recommended, because 
concomitant use of gemfibrozil has been shown to raise plasma bexarotene levels. It 
is however not clear yet if the bexarotene-induced lipid abnormalities in humans 
represent an adverse cardiovascular risk profile: interestingly, bexarotene prevented the 
development of atherosclerotic lesions in APOE2 knock-in mice, despite the induction 
of hypertriglyceridemia 9. However, it should be realized that these APOE2 knock-in 
mice lack CETP expression.
 In conclusion, we show that bexarotene causes hypertriglyceridemia by 
increasing the VLDL-TG production rate. Furthermore, bexarotene increases VLDL-C 
and decreases HDL-C through increasing the CETP-dependent transfer of cholesterol 
from HDL to VLDL, as a consequence of an increased VLDL-TG pool.
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Cardiovascular disease (CVD) is one of the major causes of death in the Western society 
and is mainly caused by atherosclerosis. Hypercholesterolemia is an important risk 
factor for the development of atherosclerosis, and several treatment strategies aim 
at reducing plasma cholesterol levels (e.g. statins) to reduce cardiovascular disease 
prevalence. Unfortunately, statins prevent only about one third of all cardiovascular 
events. Therefore, other strategies to treat patients at risk for cardiovascular disease 
are needed. Since statins are very efficient in lowering low density lipoprotein (LDL)-
cholesterol (C), therapeutic strategies targeting risk factors other than LDL-C have the 
strongest potential to have an additional beneficial effect on top of statin treatment 
in reducing CVD. Two factors are increasingly recognized as risk factors for CVD 
development: inflammation and low levels of high density lipoprotein (HDL)-C. An 
important protein in HDL metabolism is the cholesteryl ester transfer protein (CETP), 
which transfers cholesteryl esters (CE) from HDL to (very) low density lipoprotein ((V)
LDL) in exchange for triglycerides (TG). By facilitating this transfer, CETP thus lowers 
HDL-C levels and increases (V)LDL-C levels and is therefore regarded a risk factor for 
the development of atherosclerosis.
 The studies described in this thesis evaluate the role of inflammation and of 
CETP, besides that of LDL-C, in atherosclerosis. In this chapter, the main conclusions and 
the implications of our findings are discussed.
Inflammation
Inflammation has been shown to play an important role in various stages of 
atherosclerosis development, starting with the activation of endothelial cells (ECs). 
This is followed by recruitment of leukocytes (T-cells, neutrophils, macrophages) 
into the vasculature, forming an early atherosclerotic lesion. Amplification of the 
inflammatory response by macrophages leads to progression into a more complex 
lesion, which may eventually rupture. The inflammatory stimuli that contribute to 
atherosclerosis development and progression can either have a local or a non-vascular 
origin. Non-vascular sources of inflammation that have been shown to be risk factors 
for atherosclerosis development include chronic infection, inflammatory diseases such 
as rheumatoid arthritis or systemic lupus erythematosus, and nutrient surplus.1-3 This 
part of the general discussion will focus on metabolic inflammation (i.e. originating from 
nutrient surplus) and on vascular inflammation as processes that affect atherosclerosis 
development and that may be modulated to reduce CVD.
Metabolic inflammation
Metabolic inflammation is different from ‘classic’ acute phase inflammation in several 
aspects. Acute phase inflammation is a strong response of the host to fight infection. 
This type of inflammation has a short duration and is principally beneficial. In contrast, 
metabolic inflammation is a form of chronic, low-grade inflammation, which has 
detrimental effects as it is associated with the development of metabolic syndrome and 
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CVD.4 The mechanisms underlying the development of metabolic inflammation have 
not been fully elucidated as yet. Since it is difficult to gain mechanistic insight in (patho)
physiological processes underlying a disease from human studies, animal models have 
been used for this purpose. In this thesis, we used the APOE*3-Leiden (E3L) mouse 
model to gain insight in processes involved in the development of inflammation and 
in atherosclerotic disease. E3L mice develop atherosclerotic lesions that are similar in 
pathology to human atherosclerotic lesions, and these mice respond to lipid-lowering 
drugs in a similar way as humans do. Furthermore, high cholesterol diet feeding induces 
a hepatic inflammatory response in E3L mice,5  similar to what has been reported in 
humans.6
A recent study showed that E3L mice fed a high cholesterol diet, accompanied 
with induction of hepatic inflammation, develop more atherosclerosis than E3L mice 
fed a low cholesterol diet, accompanied by a non-inflammatory status of the liver.5 
These data suggest that a detrimental chronic liver-derived inflammatory status can be 
induced by metabolic dysregulation, thus accelerating atherosclerosis. In our Western 
society, abundance of food leads to an increased prevalence of chronic inflammation 
resulting from metabolic dysregulation. Nutrients such as fatty acids and glucose, 
to which individuals are nowadays exposed in high quantities, can induce ER stress, 
leading to the induction of an inflammatory response in metabolically active tissues 
such as liver and adipose tissue.4,7,8 Since it was not known how cholesterol induces 
inflammation, we studied this by feeding E3L mice a diet with a low dose of cholesterol 
(not causing inflammation) or a high dose of cholesterol (causing low-grade hepatic 
inflammation). By studying cholesterol homeostasis we showed that a high amount 
of dietary cholesterol disturbs cholesterol homeostasis, leading to increased hepatic 
free cholesterol (FC) levels. Increased FC then induces ER stress and a concomitant 
inflammatory response. (Chapter 2) The ER thus seems to be important in sensing 
metabolic surplus of different nutrients and in the translation of this metabolic surplus 
into an inflammatory response.
 The simplest strategy to tackle metabolic inflammation is of course reducing 
metabolic overload by keeping a healthy diet. Since in practice this measure proves 
to be very difficult for a lot of people, therapeutic strategies may be developed to 
reduce metabolic inflammation. One approach could be the development of drugs that 
increase the capacity of the liver to process nutrients such as cholesterol. We showed 
that two drugs that modulate lipid metabolism, rosuvastatin and fenofibrate, normalize 
the HC-diet induced increase in hepatic FC levels and concomitantly reduce hepatic 
inflammation (Chapter 2). Normalization of hepatic FC levels may thus contribute to 
the anti-inflammatory nature of these drugs. Another drug that could be useful to reduce 
metabolic inflammation is salicylate. We showed that salicylate can partly suppress high 
cholesterol diet-induced inflammation in E3L mice. (Chapter 3) Interestingly, our data 
also show that adding salicylate to a high cholesterol diet strongly and acutely reduces 
plasma cholesterol levels. (Chapter 3) Although the mechanism by which salicylate 
reduces plasma cholesterol levels is not known yet, these data underscore the notion 
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that lipid metabolism and inflammation are strongly intertwined processes, although 
much remains to be learned about their relationship. A different approach to target 
metabolic inflammation may be via reduction of ER stress. Since ER stress seems to be 
a common denominator underlying the induction of metabolic inflammation by various 
nutrients,(5-7 and Chapter 2) drugs that reduce ER stress or inhibit downstream 
mediators of ER stress may prove to be attractive tools to reduce metabolic inflammation 
and thereby CVD. 
Vascular inflammation
In the vasculature, macrophages seem an interesting target, since these cells are 
abundantly present in lesions, and upon accumulation of lipids they reside in the 
lesion where they amplify the inflammatory response. Recent evidence suggests that 
macrophages in the atherosclerotic lesion consist of two subtypes: M1 or ‘classically’ 
activated macrophages represent inflammatory macrophages, while M2 or ‘alternatively’ 
activated macrophages represent anti-inflammatory macrophages. The two types of 
macrophages can be distinguished based on the expression of specific markers, such 
as TNFα, MCP-1 and IL-6 (classic) or mannose receptor, CD163 and IL-10 (alternative).9 
At present, it is thought that classic macrophages have a detrimental role and that 
alternative macrophages have a beneficial role in atherosclerotic disease progression.
 A number of ways in which the amount or the type of macrophages in 
atherosclerotic lesions could be influenced include: 1) reducing the influx of 
new macrophages, 2) changing the ratio of classic to alternative macrophages in 
atherosclerotic lesions, 3) increasing the turn-over rate of macrophages in the lesion, 4) 
stimulating the efflux of cholesterol out of macrophages and 5) stimulating emigration 
of macrophages out of lesions.
 The influx of new macrophages may be reduced by suppressing the expression 
of adhesion molecules on ECs. Several studies have shown that atherosclerosis 
development is reduced in mice that lack the expression of one specific adhesion 
molecule.10 Strategies to inhibit the function of a specific adhesion molecule, for example 
by administering a monoclonal antibody against this adhesion molecule, are now under 
development. So far, no effects of such therapies on atherosclerosis development have 
been reported. However, drugs targeting one specific adhesion molecule may not be 
very successful, as other adhesion molecules then can still bind leukocytes, which will 
enter the vessel wall. Therefore, reducing the general inflammatory status of ECs by 
targeting a central mediator of adhesion molecule expression, NF-κB, may be a more 
promising strategy. By studying the mechanisms underlying the atheroprotective effect 
of the LXR-agonist T-0901317 on atherosclerosis development in E3L mice, we showed 
that T-0901317 reduced the amount of active NF-κB in ECs, which was accompanied 
by reduced ICAM-1 and E-selectin expression, a reduction in the number of monocytes 
adhering to the endothelium and a reduced macrophage content of lesions. (Chapter 4) 
Reducing adhesion molecule expression thus is an important strategy, as the presence 
of macrophages in the vessel wall per se characterizes the early atherosclerotic lesion 
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and as macrophages play a central role in the progression into a lesion that is eventually 
prone to rupture and to cause thrombosis.
Changing the ratio of classic to alternative macrophages in atherosclerotic 
lesions would ideally be done by changing the phenotype of a resident macrophage 
from classic to alternative. However, it was recently shown that upon activation of 
PPARγ in macrophages, the macrophage phenotype could not be changed anymore. 
Alternatively, circulating monocytes can be targeted to shift their phenotype from classic 
to alternative, e.g. by PPARγ activation.11 As yet, the effect of shifting the monocyte 
population from classic to alternative monocytes on atherosclerosis is not known. It is 
possible that a relative increase in alternative monocytes in the circulation may lead to 
an enhanced recruitment of alternative monocytes to the site of lesion development or 
of lesions in regression. Once having entered the vessel wall and having differentiated 
into macrophages, the alternative macrophages may beneficially affect processes 
involved in lesion remodelling. More research is needed to investigate the effects of 
shifting the balance between monocyte subsets on atherosclerotic lesion development 
and regression.
Increasing macrophage turnover could lead to a decrease in the macrophage 
content of lesions. Important processes determining the cell turnover rate are cell 
survival and apoptosis. In atherosclerosis development, apoptosis can both be 
beneficial and detrimental, depending on the stage of lesion development.12 In early 
atherosclerotic lesions, apoptosis can reduce accumulation of macrophages and thereby 
reduce progression into more advanced lesions.13-15 On the other hand, in advanced 
atherosclerotic lesions, apoptotic macrophages that are not efficiently cleared by 
efferocytosis may undergo ‘secondary’ necrosis, thereby increasing the inflammatory 
phenotype of lesions and thus the risk for plaque rupture and thrombosis.12,16 The 
role of apoptosis under regressive conditions has not been studied yet. However, one 
could reason that apoptosis contributes to plaque regression under certain conditions. 
Upon plasma cholesterol lowering, lipid deposition in the vessel wall will decrease. As 
a result, there is less need for macrophages to clean up lipid deposits in the vessel wall. 
Macrophages that undergo apoptosis may then be efficiently efferocytosed by newly 
infiltrating macrophages that would otherwise clean up lipid deposits. In this way, 
apoptosis does not leave any cell residues and thus does not increase the inflammatory 
phenotype of the lesion, but contributes to the reduction in macrophage content that is 
the first step for lesion regression. Interestingly, our study evaluating the role of the NF-
κB inhibitor salicylate on lesion regression in E3L mice suggests that increased apoptosis 
may be one of the mechanisms underlying the rapid disappearance of macrophages 
from pre-existing lesions. (Chapter 3) Although more research is needed, induction 
of macrophage apoptosis may provide a strategy that promotes lesion regression, at 
least when efferocytosis of apoptotic cells is efficient and no inflammatory residues of 
apoptotic cells remain.
Accumulation of free cholesterol (FC) in macrophages has been shown to 
activate NF-κB, leading to increased cytokine production.17 Furthermore, macrophages 
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that lack the cholesterol exporters ATP binding cassette transporter (ABC)A1 and ABCG1 
also accumulate FC and show concomitantly increased expression of inflammatory 
genes.18 As a consequence, macrophage inflammation might be reduced by stimulating 
cholesterol efflux. Potential strategies to increase cholesterol efflux are activation of 
LXR, PPARα or PPARγ. Activation of either of these nuclear receptors was shown to 
increase the expression of ABCA1 and/or ABCG1, which could increase cholesterol 
efflux.19,20 (Chapter 4) It is important to note that increasing the expression of 
cholesterol transporters in macrophages likely is only effective if the plasma of a subject 
has sufficient capacity to mediate cholesterol efflux through extracellular cholesterol 
acceptors (i.e. apoAI, apoE, HDL).
Another treatment strategy that involves macrophages is stimulating 
emigration of macrophages out of pre-existing lesions. Plasma cholesterol lowering has 
been shown to be an important trigger for emigration of macrophages out of lesions 
to lymph nodes via a C-C chemokine receptor (CCR)7-dependent mechanism.21-23 We 
showed that treating E3L mice with the LXR agonist T-0901317 strongly reduced the 
macrophage content of pre-existing lesions. This was likely the result of increased CCR7 
expression, leading to increased emigration of macrophages out of pre-existing lesions. 
Interestingly, the reduction in macrophages induced by T-0901317 occurred even in 
the presence of high plasma cholesterol levels, (Chapter 4) showing that plasma 
cholesterol lowering is not a prerequisite for macrophage emigration. As the field of 
macrophage emigration is just starting to be explored, other factors that can stimulate 
macrophage emigration may be discovered in the future. It would be interesting to find 
out if additional chemokine receptors besides CCR7 can also stimulate macrophage 
emigration.
We showed that a number of processes that affect macrophage inflammation 
can be positively influenced by T-0901317. Unfortunately, T-0901317 and other LXR-
agonists that have been tested in in vivo models cause a fatty liver, hypertriglyceridemia 
and hypercholesterolemia by increasing de novo TG synthesis in the liver, which 
hampers further development of these compounds. Treatment with LXR-agonists 
thus only has potential provided that compounds are developed that do not have this 
detrimental side effect. Hopes are now set on the development of LXR-agonists, which 
have specificity for LXRβ over LXRα, or which are selective towards macrophages, 
without targeting the liver. Because of the multiple beneficial effects we identified, such 
LXR-agonists are expected to have a strong potential to both reduce the development of 
new atherosclerotic lesions and to induce regression of pre-existing lesions.
HDL-C
HDL-C has been found to be inversely correlated with CVD prevalence in epidemiologic 
studies, and is therefore thought to exert an anti-atherogenic role. Therefore, HDL-




One of the first HDL-raising approaches tested in a clinical setting was CETP inhibition. 
Two compounds, dalcetrapib (JTT-705) and torcetrapib, were tested in humans, 
where they strongly increased HDL-C levels.24,25 However, large scale clinical trials 
evaluating the effect of torcetrapib on CVD progression did not show a beneficial effect 
on atherosclerosis progression as determined by Intravascular Ultrasound (IVUS) and 
Intima Media Thickness (IMT) measurements 26-28, and even led to an increase in overall 
mortality rate and death due to CVD in subjects treated with torcetrapib.29
 There are a number of explanations for the unexpected results obtained with 
torcetrapib, that relate to 1) the fact that torcetrapib was tested only in combination 
with atorvastatin, 2) the functionality of the HDL particles resulting from torcetrapib 
treatment, 3) the fact that CETP affects both (V)LDL and HDL particle levels, 4) possible 
effects of CETP on plaque stability and 5) compound-specific side-effects of torcetrapib.
 First, in the large clinical trials in which the effect of torcetrapib on 
atherosclerosis progression or cardiovascular endpoints was evaluated, all subjects 
were treated with atorvastatin and either without or with torcetrapib.26-29 Atorvastatin 
treatment resulted in low baseline LDL levels. In addition, atorvastatin treatment has 
been shown to reduce CETP mass and activity in plasma.30-32 Since CETP represents a 
major route for the clearance of HDL-CE from the circulation in humans, it is possible 
that a reduced level of cholesterol acceptor ((V)LDL) in combination with strongly 
reduced CETP activity led to disturbed transport of cholesterol to the liver. This reverse 
cholesterol transport (RCT) defect could mask possible anti-atherogenic effects of 
torcetrapib treatment per se. Interestingly, by investigating the effect of torcetrapib, 
alone or in combination with atorvastatin, on atherosclerosis development in E3L 
mice expressing human CETP (E3L.CETP mice), we found that torcetrapib treatment 
alone reduces atherosclerosis, but that it does not have an additional effect on top of 
atorvastatin treatment. (Chapter 5)
 Second, the effect of CETP (inhibition) on apoB-containing lipoprotein levels 
might be more important with respect to atherosclerosis development than the effect 
on HDL-C. Torcetrapib treatment led to an increase in HDL-C levels of up to +60%, and 
to a reduction in LDL-C levels of up to -20%. Therefore, torcetrapib is mainly regarded 
as an HDL-raising drug. However, the relative contribution of CETP-induced changes 
in (V)LDL-C and HDL-C levels to atherosclerosis development is unclear. In this thesis, 
we showed that the increase in VLDL-C levels rather than the decrease in HDL-C levels 
upon CETP expression in E3L mice can largely explain the atherogenic effect of CETP. 
(Chapter 6) These data are in line with post-hoc analyses of the RADIANCE 1 and 2 
trials, showing that cIMT progression was related to changes in LDL-C, but not HDL-C, 
levels in the torcetrapib-treated group.33 Since the changes in LDL-C were relatively 
modest in the torcetrapib trials, this may have contributed to the lack of efficacy of 
torcetrapib on atherosclerosis progression.
 Third, we found indications that CETP may affect plaque stability. By 
studying the effect of torcetrapib, either alone or in combination with atorvastatin, on 
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atherosclerosis development in E3L.CETP mice, we found that torcetrapib increased 
the macrophage content and decreased the collagen content of lesions both when given 
alone, or in combination with atorvastatin, resulting in the formation of lesions with 
a more unstable phenotype. (Chapter 5) While this study could not discern whether 
this was a compound specific effect of torcetrapib or a more general effect of CETP 
inhibition, we showed in a follow-up study that the presence of CETP per se leads 
to an increased collagen content of atherosclerotic lesions in E3L mice. (Chapter 6) 
Together, these data suggest that CETP positively affects the stability of atherosclerotic 
lesions by an as yet unknown mechanism, and that CETP inhibition may thus reduce 
lesion stability. Although plaque rupture usually does not occur in mice, in humans the 
phenotype of a high lipid content and a low collagen content is considered a risk factor 
for plaque rupture. Extrapolation of our data to humans thus suggests that increased 
plaque rupture may (partly) have caused the increase in cardiovascular events and 
death in the ILLUMINATE trial.
 Fourth, torcetrapib may have had compound-specific, adverse side effects 
that led to an increase in cardiovascular events and cardiovascular death in the 
torcetrapib-treated group. Torcetrapib was found to increase blood pressure with 
about 5 mm Hg in clinical trials,26-29 which effect is compound-specific, as the CETP 
inhibitors anacetrapib and dalcetrapib do not increase blood pressure. This increase 
in blood pressure by torcetrapib was found to be related to cIMT progression in the 
RADIANCE 1 and 2 trials.33 Although the increase in blood pressure is very small, and 
not likely to completely explain the increased death rate in the ILLUMINATE trial, it can 
at least have contributed to the detrimental effects observed. Other effects that were 
observed in subjects treated with torcetrapib were decreased serum potassium, and 
increased serum sodium, bicarbonate and aldosterone levels. A recent study showed 
that the increase in aldosterone was also a compound-specific effect of torcetrapib, 
as anacetrapib did not share this effect.34 Although aldosterone can influence blood 
pressure, this study showed that the acute effect of torcetrapib on blood pressure is 
independent of aldosterone. Interestingly, aldosterone has been shown to increase 
atherosclerosis, inflammation and oxidative stress in animal models.35-37 The observed 
increase in aldosterone may thus very well have causally contributed to the detrimental 
outcome of the torcetrapib trials and predominated potentially beneficial effects of 
torcetrapib-induced increases in HDL-C.
Having given several explanations for the failure of the torcetrapib trials, 
it is important to note that there are also indications that torcetrapib-treatment has 
beneficial effects. Subgroup analysis of the ILLUSTRATE trial revealed that there was 
a dose-dependent, inverse relation between change in HDL-C and change in percent 
atheroma volume (PAV) in combination-treated subjects, but not in subjects treated 
with atorvastatin alone. In this combination-treated group, subjects with the highest 
increases in HDL-C even showed regression of PAV, indicating that the increase in HDL-C 
level upon torcetrapib treatment is protective against CHD progression.38
Overall, it is not yet clear if CETP inhibition provides a safe strategy to increase 
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HDL-C levels and thereby reduce CVD. Ongoing clinical trials with anacetrapib and 
dalcetrapib will hopefully shed more light on this question. In the mean time, other 
strategies to increase HDL-C are also under development. These will be discussed below.
Other strategies to increase HDL-C levels
CETP inhibitors strongly reduce CETP activity, which may have contributed to the 
negative outcome of the clinical trials, e.g. by reducing the RCT pathway as outlined 
above. However, it is also possible to reduce hepatic CETP expression, which leads to a 
milder reduction of plasma CETP activity. It has been shown that the lipid-lowering drugs 
atorvastatin, fenofibrate and niacin all mildly increase HDL-C levels by reducing hepatic 
CETP expression, probably by lowering the hepatic lipid content.31,39,40 Furthermore, 
we showed that the RXR-agonist bexarotene modulates CETP activity, independent of 
changes in hepatic lipid levels. (Chapter 7) This is most likely an indirect effect of LXR/
RXR-mediated transcriptional regulation, suggesting that nuclear receptors could also 
be targeted to mildly reduce CETP activity.
Niacin currently is the most effective drug used in the clinic to raise HDL-C 
(with increases up to +35%), and niacin also reduces LDL-C and TG (up to -25% and 
-50%, respectively).41 A frequently reported side effect of niacin treatment is flushing, 
which often leads to discontinuation of the treatment. Combination treatment with the 
prostaglandin D2 receptor 1 antagonist laropiprant reduces the flushing, which may 
thus increase the use of niacin. Ongoing clinical trials evaluating the effect of niacin, 
when added to a statin, on cardiovascular endpoints (AIM-HIGH and HPS2-THRIVE) will 
hopefully show that this combination therapy is successful in further reducing CVD.
Strategies to improve HDL functionality
Although HDL-C levels are inversely correlated to CVD, a direct protective effect of 
increasing HDL-C on CVD has not (yet) been shown. An explanation for this may lie in 
the functionality of HDL particles. HDL is thought to be protective by mediating reverse 
cholesterol transport from macrophages to the liver, and by having anti-inflammatory, 
anti-oxidative and anti-thrombotic properties. Therapeutic approaches that increase 
HDL-C by interfering in HDL maturation or HDL clearance may negatively affect HDL-
functionality. As a consequence, such therapies may not always have an atheroprotective 
effect. Therefore, therapies aiming at improving HDL functionality rather than at 
increasing HDL-C levels may prove to be more efficient in reducing CVD.
 ApoAI, the most abundant apolipoprotein on HDL, is thought to exert at least 
part of the potentially beneficial properties of HDL. A therapeutic approach that may 
improve HDL functionality is thus to increase apoAI levels. One approach to do this 
is via upregulation of ABCA1, the transporter that mediates the lipidation of apoAI in 
plasma, thereby preventing the immediate clearance of apoAI by the kidneys. ABCA1 
gene expression can be increased using LXR agonists. Increasing apoAI levels is thus 
another beneficial property of LXR agonists that can be added to the ones mentioned 
in the section on inflammation. However, LXR agonists may also increase hepatic 
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CETP expression and thereby CETP activity, which could neutralize its effects on HDL 
levels. This side effect may be reduced by combined treatment with a lipid-lowering 
drug that reduces hepatic CETP expression, such as atorvastatin. A new experimental 
approach to increase apoAI levels targets ABCA1 degradation: a recent report shows 
that spiroquinone and diphenoquinone, oxidation products of probucol, reduced 
ABCA1 degradation, which was accompanied by increased HDL-C levels and reduced 
atherosclerosis development in rabbits.42 This strategy needs further evaluation to 
prove its efficacy in humans. Another method that seems promising to increase apoAI 
levels is upregulation of apoAI expression. The compound RVX-208 is a small molecule 
drug that was tested in early phase clinical trials, where it increased plasma apoAI and 
preβ-HDL levels.43 So far, no side effects have been reported. Clinical trials now need to 
show if this compound also reduces CVD.
A different strategy to improve HDL functionality could be infusion of apoAI in 
complex with phosphatidylcholine (also called reconstituted HDL or rHDL). Infusion of 
rHDL has been shown to reduce inflammation,44 and rHDL can induce cholesterol efflux 
from macrophages.45 Furthermore, experiments have been performed with a variant 
of rHDL, containing apoAI(Milano), which is apoAI containing a rare point mutation 
that was found in subjects in a town in northern Italy, who have a reduced incidence 
of CVD despite low HDL levels. In one study, 5 weekly infusions of apoAI(Milano)-
phosphatidylcholine disks caused a reduction of atheroma volume in patients 
with CVD.46 However, long-term or follow-up studies have not been performed yet. 
Unfortunately, this strategy is very expensive, and it is tough for patients to undergo 
weekly infusions. The same holds for selective HDL delipidation, in which case large, 
CE-rich HDL of a patient is isolated, delipidated ex vivo, and infused back into the patient 
as small, CE-poor HDL. After the delipidation procedure, the capacity of plasma to 
induce cholesterol efflux in vitro was found to be strongly increased, and a twelve week 
treatment in monkeys tended to reduce atherosclerosis.47 A method that is presumably 
cheaper and less incriminating for patients is the oral administration of apoAI-mimetic 
peptides. These are peptides that have no sequence homology to apoAI, but that mimic 
apoAI functionally and structurally. The most studied apoAI-mimetic peptide is D-4F. 
Infusion of D-4F in apoE-/- mice was shown to increase the capacity of HDL to mediate 
cholesterol efflux and to exert anti-inflammatory effects.48 Administration of D-4F was 
found to be safe in clinical trials. Unfortunately, the oral bioavailability of this peptide is 
very low, which may hamper its further development. A new challenge thus lies in the 
development of apoAI-mimetic peptides with a better bioavailability.
Concluding remarks  
The most important treatment strategy available to reduce CVD is lowering of LDL-C. 
Statins are very effective in doing this, but residual risk has led to the search for additional 
risk factors that can be targeted to reduce CVD. Despite the inverse correlation between 
HDL-C and CVD, increasing HDL-C is not atheroprotective per se, as exemplified by the 
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torcetrapib trials. There are indications that HDL-raising has anti-atherogenic effects, 
although we should keep in mind that improving HDL functionality likely is more 
important than increasing HDL levels per se in the search for drugs that are effective in 
reducing CVD.
The role of inflammation in atherosclerosis development is now well-
established and therapies that suppress inflammation are under development. 
Macrophages especially represent an important target that may be influenced in several 
ways to reduce atherosclerosis development and even induce regression of pre-existing 
lesions.
 Since atherosclerosis is a multifactorial disease, targeting multiple factors is 
likely the best approach to further reduce CVD. Hopefully, future studies will provide us 
with successful therapies that suppress inflammation and/or improve HDL functionality, 
and that can be safely used in combination with statins.
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Cardiovascular disease (CVD) is a major cause of morbidity and mortality in the 
western world and is mainly caused by atherosclerosis. One of the major risk factors for 
atherosclerosis development, high levels of low density lipoprotein (LDL)-cholesterol 
(C), can be efficiently treated with cholesterol-lowering drugs such as statins. However, 
treatment with statins prevents only about 30% of all cardiovascular events, thus a 
significant residual risk remains. Therefore, therapeutic strategies targeting other 
risk factors than high LDL-C levels may be useful to further reduce CVD. Two other 
risk factors for CVD have been identified: inflammation and low levels of high density 
lipoprotein (HDL)-C. In the first part of this thesis, we focused on cholesterol as an 
inducer of inflammation, and on the role of inflammation in atherosclerosis. In the 
second part of this thesis we studied the role of CETP, an important protein in HDL 
metabolism, in lipid metabolism and atherosclerosis. For these studies we used the 
APOE*3-Leiden (E3L) and the E3L.CETP transgenic mouse models. These mice respond 
to a high cholesterol diet with induction of hyperlipidemia and hepatic inflammation 
and respond to lipid-modifying drugs in a similar way as humans do. Furthermore, these 
mice develop atherosclerotic lesions that are similar in pathology to atherosclerotic 
lesions in humans.
The first part of this thesis focused on inflammation. Studies in humans and in mice 
have shown that cholesterol can induce a hepatic inflammatory response. Since the 
molecular mechanism underlying the induction of inflammation by cholesterol is not 
known, we aimed to elucidate this mechanism in Chapter 2. To this end, we fed E3L 
mice a diet without cholesterol (control) or with low cholesterol (LC) or high cholesterol 
(HC) concentrations, which caused the liver to switch from an adaptive state (control 
and LC diet) to an inflammatory state (HC diet). Cholesterol feeding dose-dependently 
increased plasma cholesterol levels and hepatic cholesteryl ester (CE) content and 
dose-dependently decreased cholesterol synthesis in the liver. In contrast, the hepatic 
free cholesterol (FC) concentration and plasma levels of the hepatic inflammation 
marker serum amyloid A (SAA) increased only with HC diet feeding and were found 
to be significantly correlated. Microarray analysis of livers suggested that HC, but not 
LC, evokes endoplasmic reticulum (ER) stress. Furthermore, the activity of ER stress-
inducible transcription factors and positive regulators of SAA expression, NF-κB and 
STAT3, were found to be enhanced upon HC, but not LC feeding. We concluded that HC 
diet feeding induces hepatic inflammation and SAA gene expression in the liver through 
an increase of hepatic NF-κB and STAT3 activity, putatively as a result of an FC-induced 
ER stress response.
The stimulatory role of inflammation in atherosclerosis development is now 
widely established. It is not known if inflammation also plays a role in atherosclerosis 
regression. In Chapter 3 we wondered if suppressing inflammation using the NF-κB 
inhibitor salicylate leads to atherosclerosis regression on top of cholesterol-lowering. 
To this end, ApoE*3-Leiden (E3L) mice were fed a high cholesterol diet to induce 
the formation of mild atherosclerotic lesions. Subsequently, one group of mice was 
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sacrificed to determine lesion area and lesion severity at the start of different regression 
treatments (reference group). A second group of mice was then fed a high cholesterol 
diet supplemented with salicylate (HC+SAL) to suppress NF-κB activity. As salicylate 
not only quenched inflammation, but also reduced plasma cholesterol levels (- ~49%), 
a third group of mice was fed a low cholesterol (LC) diet to establish similar plasma 
cholesterol levels as obtained by salicylate treatment. Compared to the reference group, 
HC+SAL suppressed hepatic NF-κB activity, tended to suppress hepatic STAT3 activity 
and reduced plasma levels of the hepatic inflammation marker SAA. Compared to 
HC+SAL, LC diet feeding suppressed hepatic NF-κB activity to a lesser extent, similarly 
suppressed STAT3 activity, and more strongly reduced plasma SAA levels; HC+SAL and 
LC feeding similarly suppressed aortic NF-κB activity. At 16 weeks after starting the 
regression treatments, neither HC+SAL or LC treatment showed an effect on lesion area 
(compared to the reference group), but HC+SAL had reduced the macrophage area of 
lesions and increased the plaque stability index (ratio of collagen to macrophage area) 
more strongly than LC diet feeding. These data led us to conclude that the combined 
effect of suppressing NF-κB activity and reducing plasma cholesterol with SAL improves 
lesion severity and promotes lesion regression more efficiently than cholesterol 
lowering alone.
LXR agonists are a class of compounds that regulate various cellular processes, 
including inflammation. LXR agonists can both prevent atherosclerosis development 
and induce regression of pre-existing lesions. However, the mechanisms underlying 
their atheroprotective effects have not been fully explored. In Chapter 4 we therefore 
investigated the mechanisms underlying the anti-atherogenic potency of the LXR agonist 
T0901317 under both lesion-progressive and lesion-regressive conditions, in a time-
dependent manner. Using E3L mice, we showed that T0901317 strongly suppresses 
lesion evolution and promotes lesion regression. We found that under progressive (high 
cholesterol diet) as well as regressive (cholesterol-free diet) conditions T0901317 (i) 
significantly increased plasma triglyceride and total cholesterol levels; (ii) did not affect 
the systemic inflammation marker SAA; (iii) suppressed endothelial monocyte adhesion; 
and (iv) induced the expression of the cholesterol efflux-related genes apoE, ABCA1 
and ABCG1. Furthermore, under progressive conditions, T0901317 suppressed the 
vascular inflammatory status, lowered lesional macrophage accumulation, and blocked 
the transition from lesional stage II to III. Under regressive conditions, T0901317 
induced lesional macrophage disappearance and increased the expression of the C-C 
chemokine receptor CCR7, a factor functionally required for regression. Taken together, 
we showed that the LXR-agonist T0901317 retards atherosclerotic lesion development 
and promotes lesion regression by exerting several atheroprotective effects on the 
vasculature. Furthermore, our findings support that vascular LXR is a potential anti-
atherosclerotic target.
The second part of this thesis addressed the role of CETP in lipid metabolism and 
atherosclerosis. As CETP decreases HDL-C levels, CETP inhibition is being regarded a 
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promising strategy to increase HDL-C levels and thereby reduce CVD. The first CETP 
inhibitor tested in large clinical trials was torcetrapib. Although torcetrapib increased 
HDL-C levels with about 60% in humans on a background of atorvastatin, torcetrapib did 
not reduce atherosclerosis progression, and even increased cardiovascular death rate. 
Importantly, the effect of torcetrapib on atherosclerosis progression and cardiovascular 
endpoints in humans was only studied in combination with atorvastatin. Therefore, we 
evaluated the anti-atherogenic potential of torcetrapib with and without atorvastatin in 
E3L.CETP mice in Chapter 5. Furthermore, we aimed to gain insight in the adverse effects 
underlying the increase in cardiovascular death rate in humans. To this end, E3L.CETP 
mice were fed a cholesterol-rich without drugs or with torcetrapib, atorvastatin or both. 
Torcetrapib decreased plasma cholesterol, albeit to a lesser extent than atorvastatin or 
the combination of torcetrapib and atorvastatin. Torcetrapib similarly increased HDL-C 
in the absence and in the presence of atorvastatin. Torcetrapib and atorvastatin alone 
reduced atherosclerotic lesion size to a similar extent, and combination therapy did not 
further reduce atherosclerosis. Remarkably, as compared to atorvastatin, torcetrapib 
induced enhanced monocyte recruitment and expression of monocyte chemoattractant 
protein-1 and resulted in lesions of a more inflammatory phenotype, as reflected by 
an increased macrophage content and a reduced collagen content. In conclusion, we 
showed that CETP inhibition by torcetrapib per se reduces atherosclerotic lesion size but 
does not enhance the anti-atherogenic potential of atorvastatin. However, as compared 
to atorvastatin, torcetrapib introduces lesions of a less stable phenotype.
CETP adversely affects the plasma lipoprotein profile by increasing VLDL-C 
and decreasing HDL-C. However, the relative contribution of either of these changes 
to atherosclerosis development is not known. Therefore, we investigated in Chapter 
6 to what extent the increase in VLDL-C can explain the atherogenic action of human 
CETP expression in E3L mice. For this purpose, E3L and E3L.CETP mice were fed a low 
cholesterol (LC) diet, resulting in an increased VLDL-C level as well as an increased 
atherosclerotic lesion area in the aortic root in E3L.CETP mice compared to E3L-LC mice. 
E3L mice fed a high cholesterol (HC) diet to match for the increased VLDL-C levels in 
E3L.CETP mice, displayed a similar atherosclerotic lesion area as observed in E3L.CETP 
mice. Despite similar atherosclerosis development, E3L.CETP mice had lower HDL-C 
as compared to E3L-HC mice. Remarkably, atherosclerotic lesions in CETP-expressing 
mice were enriched in collagen, suggesting a role of CETP or the diet in modifying the 
collagen content of lesions. These data led us to conclude that, in this experimental 
setting, the pro-atherogenic effect of CETP is largely explained by increased VLDL-C.
The drug bexarotene, an RXR agonist, is being used as a strategy to treat patients 
with different types of cancer. A common dose-limiting side effect of treatment with 
bexarotene is dyslipidemia. In Chapter 7, we evaluated the effects of bexarotene on 
plasma lipid metabolism in patients with metastatic differentiated thyroid carcinoma 
(DTC). To this end, ten patients with metastatic DTC were treated with bexarotene. 
Bexarotene increased plasma TG, primarily in VLDL, and raised plasma total cholesterol 
(TC). However, while bexarotene increased VLDL-C and LDL-C, it decreased HDL-C and 
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tended to decrease apoAI concomitant with an increase in endogenous CETP activity. 
To evaluate the cause of the bexarotene-induced hypertriglyceridemia and the role of 
CETP in the bexarotene-induced shift in cholesterol distribution, E3L and E3L.CETP 
mice were treated with bexarotene. Bexarotene increased VLDL-TG in both E3L and 
E3L.CETP mice, by increasing VLDL-TG production. Bexarotene did not affect the TC 
levels or distribution in E3L mice, but increased VLDL-C and decreased HDL-C as well 
as apoAI in E3L.CETP mice, concomitant with increased endogenous CETP activity. This 
increased CETP activity by bexarotene treatment is likely due to the increase in VLDL-
TG, a CETP substrate that drives CETP activity. We concluded that bexarotene causes 
combined dyslipidemia as reflected by increased TG, VLDL-C and LDL-C and decreased 
HDL-C, which is the result of an increased VLDL-TG production that causes an increase 
of the endogenous CETP activity.
Taken together, the studies described in this thesis show that inflammation and CETP 
are both important factors in lipid metabolism and atherosclerosis. In the first part of 
this thesis we showed that high dietary cholesterol can induce hepatic inflammation 
via disturbed cholesterol homeostasis and ER stress, revealing new targets for the 
treatment of metabolic inflammation. Next, we demonstrated that intervention in 
both systemic and vascular inflammation can reduce atherosclerosis progression and/
or induce regression, highlighting the importance of developing drugs targeting the 
inflammatory component of atherosclerotic disease. In the second part of this thesis 
we showed that CETP inhibition per se may be anti-atherogenic, but that combination 
therapy of the CETP inhibitor torcetrapib with atorvastatin may have obscured its 
atheroprotective effect. Furthermore, we showed that the VLDL-increasing effect of 
CETP largely explains its atherogenic effect, at least in APOE*3-Leiden.CETP mice, and 
that CETP inhibition may negatively affect lesion stability. Our data suggest that CETP 
inhibition may not be the most optimal strategy to increase HDL-C levels and thereby 
reduce atherosclerosis. We anticipate that strategies improving HDL functionality, 






Hart- en vaatziekten zijn een zeer belangrijke doodsoorzaak in de westerse 
wereld. Een belangrijke oorzaak van hart- en vaatziekten is aderverkalking, ofwel 
atherosclerose. Atherosclerose is een proces dat gekenmerkt wordt door ophoping 
van vetten (waaronder cholesterol) en cellen van het immuunsysteem in de vaatwand. 
De belangrijkste cel van het immuunsysteem betrokken bij atherosclerose is de 
macrofaag, die naar de vaatwand toe komt om cholesterol dat zich daar ophoopt als 
een soort stofzuiger op te ruimen, maar die er daarna voor kan zorgen dat het proces 
van atherosclerose verergert. Ophoping van cholesterol en macrofagen in de vaatwand 
leidt namelijk tot de vorming van een zogenaamde atherosclerotische lesie. Dit is een 
verdikking van de vaatwand (met onder andere cholesterol en macrofagen erin) die het 
bloedvat vernauwt. Een dergelijke lesie kan ervoor zorgen dat er minder bloed door het 
vat stroomt, waardoor er een tekort aan zuurstof en aan voedingsstoffen kan ontstaan 
in weefsel dat door dit bloedvat wordt voorzien van deze stoffen. Ook kan het gebeuren 
dat een lesie openscheurt, waarbij een soort wond ontstaat. Vetten, macrofagen en 
materialen uit de vaatwand die zich in de lesie hebben opgehoopt komen dan in direct 
contact met het bloed. Dit zorgt ervoor dat het bloed stolt en een bloedprop, ofwel 
trombus, vormt. Dit wordt trombose genoemd. Een bloedprop kan een bloedvat zo 
ernstig verstoppen dat dit bijvoorbeeld tot een hart- of een herseninfarct leidt.
 Er zijn verschillende factoren die het risico op het ontstaan van atherosclerose 
verhogen. Dit zijn bijvoorbeeld een te hoge bloeddruk en een te hoog niveau van 
het cholesterol in bepaalde deeltjes die cholesterol via het bloed door het lichaam 
transporteren: het lage dichtheids lipoproteïne (LDL) en het zeer lage dichtheids 
lipoproteïne (VLDL). VLDL-cholesterol en LDL-cholesterol kunnen ervoor zorgen 
dat cholesterol zich ophoopt in de vaatwand en staan hierdoor ook wel bekend als 
‘slecht’ cholesterol. Er zijn wel medicijnen waarmee het VLDL-cholesterol en LDL-
cholesterol efficiënt verlaagd kunnen worden. De klasse medicijnen die hiervoor het 
meest voorgeschreven wordt, is de statine. Helaas leidt behandeling met statines 
slechts tot een vermindering van ongeveer 30% in het aantal incidenten van hart- en 
vaatziekten. Het lijkt er dus op dat er ook nog andere belangrijke factoren zijn die een 
rol spelen in deze ziekten. In de voorbije jaren zijn ook andere risicofactoren voor hart- 
en vaatziekten geïdentificeerd. Dit zijn onder andere ontsteking en een laag niveau van 
cholesterol in het hoge dichtheids lipoproteïne (HDL) in het bloed.
 Ontsteking kennen we over het algemeen als een proces dat het lichaam 
beschermt tegen infecties van bijvoorbeeld bacteriën of virussen. Hoewel zo’n 
ontsteking vervelend kan zijn door de pijn die ermee gepaard gaat, heeft deze vorm van 
ontsteking een beschermende werking, omdat deze in staat is de ziekteverwekkers op 
te ruimen. Verder is een dergelijke ontstekingsreactie hevig van intensiteit en van korte 
duur. Er is echter ook een andere vorm van ontsteking, die juist matig van intensiteit en 
langdurig is. Deze chronische vorm van ontsteking vormt een risico voor het ontstaan 
van hart- en vaatziekten.
 Hoge HDL-cholesterol niveaus in het bloed zijn geassocieerd met een laag 
risico op hart- en vaatziekten, en daarom staat HDL-cholesterol ook wel bekend als 
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‘goed’ cholesterol. Mensen hebben in hun bloed een eiwit (proteïne) dat er voor zorgt 
dat cholesterol uit het HDL terechtkomt in het LDL. Dit eiwit, dat cholesteryl ester 
transfer proteïne (CETP) heet, zorgt er dus voor dat het HDL-cholesterol niveau wordt 
verlaagd, terwijl het LDL-cholesterol niveau omhoog gaat. Dit zijn twee effecten die 
allebei het risico op hart- en vaatziekten kunnen verhogen.
 De studies die beschreven zijn in dit proefschrift zijn uitgevoerd om meer te 
weten te komen over de rol van ontsteking en van HDL-cholesterol in het ontstaan 
van hart- en vaatziekten, en de rol van deze factoren bij de mogelijke behandeling 
van hart- en vaatziekten. In mensen is het niet goed mogelijk om deze factoren te 
bestuderen, omdat een proces zoals het ontwikkelen van atherosclerose het beste 
onderzocht kan worden door organen zoals het hart in verschillende stadia van het 
ziekteproces op moleculair niveau te bestuderen. Weefsels van mensen zijn doorgaans 
alleen beschikbaar na een chirurgische ingreep, en vaak zelfs pas als iemand overleden 
is. Bovendien is het dan meestal alleen mogelijk om het eindstadium van de ziekte te 
onderzoeken en niet de processen die hieraan vooraf zijn gegaan. Daarom hebben we 
voor dit onderzoek gebruik gemaakt van speciale muismodellen, namelijk de APOE*3-
Leiden (E3L) muizen met en zonder het eiwit CETP. In deze E3L muizen en E3L.CETP 
muizen verloopt het ontstaan van hart- en vaatziekten via vergelijkbare stappen als 
in mensen. Ook reageren deze muizen op een vergelijkbare manier als mensen op 
medicijnen tegen hart- en vaatziekten.
De studies in het eerste deel van dit proefschrift waren gericht op ontsteking. Studies 
in mensen en in muizen hebben laten zien dat de inname van grote hoeveelheden 
cholesterol kan leiden tot een chronische ontstekingsreactie van de lever, een 
belangrijk orgaan voor het verwerken van cholesterol en andere vetten. Omdat het 
niet op moleculair niveau bekend was hoe te veel cholesterol in het voedsel zorgt voor 
ontsteking van de lever, hebben wij dit mechanisme onderzocht in Hoofdstuk 2. Wij 
hebben E3L muizen een dieet gegeven dat geen cholesterol (controle groep), een lage 
hoeveelheid cholesterol (LC groep) of een hoge hoeveelheid cholesterol (HC groep) 
bevatte. Dit zorgde ervoor dat de lever omschakelde van een status waarin deze zich nog 
goed kan aanpassen (onder de controle en LC omstandigheden) naar een status waarin 
zij zich niet meer kan aanpassen en ontstoken raakt (onder HC omstandigheden). Door 
de productie, verwerking en afvoer van cholesterol te bestuderen lieten wij zien dat 
cholesterol in de voeding op een dosisafhankelijke manier het cholesterol niveau in 
het bloed, de hoeveelheid veresterd cholesterol (opgeslagen cholesterol) in de lever en 
de aanmaak van cholesterol in de lever beïnvloedt. Dit in tegenstelling tot het niveau 
van vrij cholesterol (de direct beschikbare voorraad) in de lever en van de indicator 
voor leverontsteking die in het bloed gemeten kan worden: serum amyloid A (SAA). 
De niveaus van deze twee parameters gingen alleen omhoog in muizen die HC voeding 
kregen en niet in de muizen die LC voeding kregen vergeleken met de controle groep, 
en er was een onderling verband tussen de stijging van elk van deze parameters. Uit 
geavanceerde analyse (zogenaamde microarray analyse) van de ‘activiteit’ van genen 
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in de lever bleek dat in de HC groep, en niet in de LC groep, sprake was van stress in 
het endoplasmatisch reticulum (ER), een onderdeel van een cel waar veranderingen in 
cholesterolniveaus waargenomen worden. Factoren die geactiveerd worden door stress 
in het ER, en die kunnen leiden tot leverontsteking (NF-κB en STAT3), waren inderdaad 
geactiveerd in de HC groep, en niet in de LC groep. Hieruit trokken wij de conclusie dat 
een grote hoeveelheid cholesterol in de voeding leidt tot leverontsteking doordat het 
niveau van vrij cholesterol in de lever verhoogd wordt, wat leidt tot stress in het ER en 
een verhoging van factoren die leverontsteking veroorzaken.
 Het is tegenwoordig duidelijk dat ontsteking belangrijk is voor het ontstaan van 
hart- en vaatziekten, maar het is nog niet bekend of remming van ontsteking ook een rol 
speelt in de genezing hiervan. Het doel van het onderzoek in Hoofdstuk 3 was daarom 
om te bepalen of onderdrukking van ontsteking met de NF-κB remmer salicylaat 
bijdraagt aan de genezing van atherosclerose bovenop verlaging van cholesterol. Om 
dit te onderzoeken gaven wij E3L muizen een hoog cholesterol dieet, waardoor deze 
muizen milde atherosclerotische lesies ontwikkelden. Vervolgens werd de ontwikkeling 
van atherosclerose geanalyseerd in één groep muizen die diende als referentiegroep. 
Een tweede groep muizen kreeg vervolgens een hoog cholesterol dieet waar salicylaat 
aan was toegevoegd (HC+salicylaat), om de activiteit van de ontstekingsmediator NF-
κB te remmen. Het HC+salicylaat dieet verlaagde het cholesterol in het bloed met -49%. 
Daarom kreeg een derde groep muizen een dieet met een lage hoeveelheid cholesterol 
(LC), wat resulteerde in een vergelijkbare hoeveelheid cholesterol in het bloed als 
bij de muizen die met HC+salicylaat behandeld werden. De activiteit van NF-κB was 
onderdrukt in de levers van muizen die het HC+salicylaat dieet kregen in vergelijking 
tot de referentiegroep. Ook waren de niveaus van de indicator voor leverontsteking 
SAA in het bloed waren verlaagd. In vergelijking tot de HC+salicylaat behandelde groep 
onderdrukte het LC dieet de activiteit van NF-κB in de lever minder sterk en was het 
niveau van SAA in het bloed verder verlaagd. Verder onderdrukten het HC+salicylaat dieet 
en het LC dieet de activiteit van NF-κB in de aorta in dezelfde mate. Beide diëten hadden 
geen effect op de grootte van de ontwikkelde atherosclerotische lesies. Daarentegen 
verminderde het HC+salicylaat dieet de hoeveelheid macrofagen en verbeterde dit 
dieet de verhouding tussen collageen (stabiliserend materiaal) en macrofagen, wat een 
indicatie is voor de stabiliteit van de lesies en dus voor het risico op het scheuren van 
een lesie en op trombose. Deze effecten waren sterker bij het HC+salicylaat dieet dan 
bij het LC dieet. Op grond van deze gegevens concludeerden wij dat de combinatie van 
onderdrukking van de activiteit van NF-κB en verlaging van het cholesterol in het bloed 
met salicylaat een betere behandeling van bestaande atherosclerotische lesies is dan 
het verlagen van het cholesterol in het bloed alleen. Het is belangrijk om te onderzoeken 
of behandeling met salicylaat ook een goede behandeling is voor mensen met hart- en 
vaatziekten.
Activatoren (agonisten) van de lever X receptor (LXR) behoren tot een klasse van 
stoffen die verschillende belangrijke processen in lichaamscellen reguleren, waaronder 
ontsteking. Het is al bekend dat LXR agonisten in diermodellen zowel het ontstaan 
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van hart- en vaatziekten kunnen voorkomen als genezing van hart- en vaatziekten 
kunnen bewerkstelligen. De mechanismen die aan de beschermende werking van LXR 
agonisten ten grondslag liggen zijn echter niet uitgebreid bestudeerd. Daarom hebben 
wij in Hoofdstuk 4 bestudeerd via welke mechanismen één bepaalde LXR agonist, 
T0901317, beschermt tegen het ontstaan van hart- en vaatziekten, en hoe deze stof kan 
leiden tot genezing van hart- en vaatziekten. Uit ons onderzoek, dat werd uitgevoerd in 
E3L muizen, bleek dat een aantal effecten zowel optreedt tijdens het voorkomen van de 
ontwikkeling als bij het genezen van atherosclerotische lesies. Ten eerste veroorzaakte 
T0901317 een aanzienlijke verhoging van de hoeveelheid vetten (cholesterol en 
triglyceriden) in het bloed. Dit is een effect dat in principe ongunstig is voor de 
ontwikkeling en genezing van atherosclerose. Ten tweede zorgde T0901317 niet voor 
een verlaging van de indicator voor leverontsteking SAA in het bloed. De beschermende 
werking van T0901317 kon hierdoor dus niet worden verklaard. Er werden ook een 
aantal gunstige effecten van T0901317 ontdekt. Het eerste gunstige effect was dat 
T0901317 ervoor zorgde dat er minder macrofagen aangetrokken werden naar de plek 
waar een atherosclerotische lesie is. Het tweede gunstige effect was dat T0901317 de 
activiteit van genen (apoE, ABCA1 en ABCG1) die ervoor zorgen dat cholesterol weer 
uit macrofagen in een atherosclerotische lesie kan verdwijnen verhoogde, zodat het 
cholesterol daar minder ophoopt. Het derde gunstige effect was dat T0901317 het 
ontstaan van atherosclerose kan verminderen door de ontstekingsgraad in de vaatwand 
te verlagen. T0901317 doet dit laatste door ervoor te zorgen dat er minder macrofagen 
ophopen in de vaatwand en door ervoor te zorgen dat er geen vermenigvuldiging van 
spiercellen vanuit de vaatwand in de lesie plaatsvindt. Ook droeg T0901317 bij aan 
genezing van atherosclerose door ervoor te zorgen dat macrofagen die al in de lesie 
aanwezig waren hieruit verdwenen. Ondanks het feit dat T0901317 dus een ongunstig 
effect heeft op de niveaus van vetten in het bloed, zorgen de gunstige effecten op 
ontsteking er uiteindelijk voor dat de E3L muizen die met T0901317 behandeld werden, 
minder atherosclerose ontwikkelden. Samengevat hebben wij laten zien dat T0901317 
op een aantal manieren een direct beschermend effect op de vaatwand heeft, waardoor 
zowel het ontstaan van atherosclerose geremd, als de genezing van atherosclerose 
gestimuleerd wordt. Omdat verschillende onderzoeken in diermodellen hebben laten 
zien dat T0901317 ook ongunstige bijwerkingen heeft op de lever, onder andere door 
de hoeveelheden van vetten in de lever heel sterk te verhogen, wordt dit medicijn niet 
gebruikt om in mensen hart- en vaatziekten te verminderen. Onze bevindingen wijzen 
erop dat LXR in de vaatwand een belangrijk eiwit kan zijn om aan te pakken met nieuw 
te ontwikkelen medicijnen, die de hoeveelheden van vetten in de lever en in het bloed 
niet mogen verhogen.
In het tweede deel van dit proefschrift is onderzoek beschreven dat was gericht op de rol 
van HDL-cholesterol, en met name van het eiwit CETP in de verwerking van cholesterol 
en triglyceriden (vetten) uit HDL, in het ontstaan van atherosclerose. Aangezien CETP 
het HDL-cholesterol verlaagt, wordt remming van CETP gezien als een veelbelovende 
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therapie om HDL-cholesterol te verhogen en daardoor hart- en vaatziekten te verlagen. 
Daarom worden er medicijnen ontwikkeld om specifiek dit ene eiwit, CETP, te 
remmen. Torcetrapib is ontwikkeld als potentieel medicijn dat het eiwit CETP remt 
en torcetrapib was de eerste CETP remmer die getest werd in grote groepen patiënten. 
Alle patiënten in dit onderzoek werden behandeld met de LDL-cholesterolverlager 
atorvastatine, en de helft van de mensen kreeg daarbij nog torcetrapib. Zoals gehoopt 
zorgde torcetrapib voor een sterke stijging van het HDL-cholesterol. Maar onverwacht 
bleek dat torcetrapib de ontwikkeling van hart- en vaatziekten niet verminderde, en dat 
in de groep mensen die met de combinatie van torcetrapib en atorvastatine behandeld 
werd zelfs meer mensen stierven aan hart- en vaatziekten dan in de groep die alleen 
behandeld werd met atorvastatine. Dit betekende het einde van de ontwikkeling 
van torcetrapib als nieuw medicijn om HDL-cholesterol te verhogen. Een belangrijke 
opmerking hierbij is dat het effect van torcetrapib op hart- en vaatziekten alleen 
is bestudeerd in combinatie met atorvastatine. Omdat het effect van torcetrapib in 
combinatie met atorvastatine anders kan zijn dan het effect van torcetrapib alleen, 
hebben wij in Hoofdstuk 5 onderzocht wat het effect van torcetrapib alleen en in 
combinatie met atorvastatine is op de ontwikkeling van atherosclerose. Verder hebben 
we geprobeerd inzicht te krijgen in de manier waarop torcetrapib heeft geleid tot een 
toename in sterfte aan hart- en vaatziekten. Om dit te onderzoeken hebben we E3L.
CETP muizen een dieet met daarin veel cholesterol te eten gegeven. We verdeelden de 
muizen in vier groepen. Er was één groep die geen medicijn kreeg, één groep kreeg 
alleen torcetrapib, één groep kreeg alleen atorvastatine en één groep kreeg deze twee 
in combinatie. Torcetrapib verlaagde het plasma cholesterol, hoewel dit effect iets 
minder sterk was dan dat van atorvastatine of van de combinatietherapie. Torcetrapib 
verhoogde het HDL-cholesterol als monotherapie en als combinatietherapie in gelijke 
mate. Behandeling met torcetrapib of atorvastatine alleen verminderde de grootte van 
atherosclerotische lesies even sterk. De combinatietherapie was niet effectiever dan 
elk van de afzonderlijke behandelingen in het verminderen van lesie grootte. Het viel 
op dat behandeling met torcetrapib, vergeleken met atorvastatine behandeling, leidde 
tot het aantrekken van meer macrofagen naar de plaats van de lesies. Omdat de lesies 
van muizen die met torcetrapib behandeld waren meer macrofagen bevatten en minder 
stabiliserend materiaal, werden deze lesies als meer ontstoken en mogelijk minder 
stabiel gekarakteriseerd. Onze conclusie was dat remming van CETP met torcetrapib op 
zich leidt tot minder ontwikkeling van atherosclerose, maar dat torcetrapib in combinatie 
met atorvastatine geen extra effect heeft op het voorkomen van atherosclerose. Verder 
leidt behandeling met torcetrapib in vergelijking tot behandeling met atorvastatine tot 
lesies die een groter risico hebben om te scheuren en zo trombose en zelfs de dood te 
veroorzaken.
 Recent hebben we aangetoond dat CETP expressie in E3L muizen tot meer 
atherosclerose leidde, wat gepaard ging met verlaging van HDL-cholesterol en verhoging 
van VLDL-cholesterol. Deze beide tegenovergestelde veranderingen kunnen het risico 
op hart- en vaatziekten verhogen. Het is echter niet bekend wat het relatieve effect 
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van elk van deze veranderingen op het ontstaan van atherosclerose is. In Hoofdstuk 
6 hebben wij onderzocht in hoeverre het verschil in VLDL-cholesterol tussen E3L 
muizen met en zonder CETP kan verklaren dat CETP leidt tot meer atherosclerose. 
Om dit te bestuderen hebben we E3L en E3L.CETP muizen een dieet met een lage 
hoeveelheid cholesterol (LC dieet) te eten gegeven. De E3L.CETP muizen hadden op dit 
dieet een hoger VLDL-cholesterol dan de E3L muizen en ook meer atherosclerose. Om 
te bestuderen in hoeverre dit verhoogde VLDL-cholesterol kon verklaren dat de E3L.
CETP muizen meer atherosclerose hadden, onderzochten we ook een derde groep met 
E3L muizen die een dieet met een hoge hoeveelheid cholesterol (HC) te eten kregen. 
De hoeveelheid cholesterol in het HC dieet was zo gekozen dat de E3L muizen op dit 
HC dieet evenveel VLDL-cholesterol hadden als de E3L.CETP muizen. Verder zagen we 
dat deze muizen atherosclerotische lesies hadden die vergelijkbaar in grootte waren 
met de lesies van de E3L.CETP muizen. Deze gegevens wijzen erop dat het verhoogde 
VLDL-cholesterol grotendeels verklaart waarom de aanwezigheid van CETP meer 
atherosclerose veroorzaakt. Hoewel de E3L muizen en E3L.CETP muizen met evenveel 
VLDL-cholesterol ook in vergelijkbare mate atherosclerose ontwikkeld hadden, 
hadden de E3L.CETP muizen lagere HDL-cholesterol niveaus. Het lijkt er dus op dat 
het verschil in HDL-cholesterol niveaus in dit geval geen effect had op de ontwikkeling 
van atherosclerose. Iets anders dat opviel was dat de atherosclerotische lesies in de 
muizen met CETP meer collageen bevatten. Dit suggereert dat CETP de hoeveelheid 
collageen in atherosclerotische lesies, en daarmee het risico op scheuren van een lesie 
en trombose, kan beïnvloeden. Wij concludeerden op grond van deze gegevens dat, 
onder de omstandigheden die wij hebben onderzocht, CETP voornamelijk tot meer 
atherosclerose leidt doordat CETP het VLDL-cholesterol niveau in bloed verhoogt.
In Hoofdstuk 7 hebben we eerst een medicijn bestudeerd dat gebruikt 
wordt bij patiënten met verschillende types kanker. Dit medicijn, bexaroteen, is 
een activator van het eiwit retinoide X receptor (RXR) en heeft als bijwerking dat de 
niveaus van verschillende vetten (cholesterol en triglyceriden) in het bloed omhoog 
gaan. Wij onderzochten meer specifiek welke veranderingen er optraden in de 
niveaus van vetten in het bloed van mensen die met bexaroteen behandeld werden. 
Daarnaast onderzochten we in E3L en E3L.CETP muizen de oorza(a)k(en) van deze 
veranderingen. Voor dit onderzoek behandelden we tien patiënten met uitzaaiingen 
van schildklierkanker met bexaroteen. Bexaroteen veroorzaakte een stijging van het 
niveau van verschillende vetten (triglyceriden en cholesterol) in het VLDL en LDL, maar 
juist een daling van het HDL-cholesterol. Om de onderliggende oorzaak te achterhalen 
behandelden we E3L en E3L.CETP muizen met bexaroteen. Ook in deze muizen leidde 
behandeling met bexaroteen tot een stijging van de triglyceridenniveaus in VLDL. Wij 
toonden aan dat dit werd veroorzaakt door een verhoogde productie van triglyceriden 
in de lever. Opvallend was dat het effect van bexaroteen op cholesterol in de E3L en 
E3L.CETP muizen verschillend was. Bexaroteen had geen effect op het cholesterol in 
E3L muizen, terwijl bexaroteen in E3L.CETP muizen het VLDL-cholesterol verhoogde 
en het HDL-cholesterol verlaagde, wat vergelijkbaar is met wat we in mensen zagen. 
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Hierbij zagen wij ook dat de activiteit van het eiwit CETP, dat cholesterol van HDL naar 
VLDL en LDL kan transporteren, hoger was na behandeling met bexaroteen. Aangezien 
triglyceriden de activiteit van CETP kunnen beïnvloeden (meer triglyceriden zorgen 
voor een hogere CETP activiteit), is de verhoogde CETP activiteit die wij waarnamen 
hoogstwaarschijnlijk het gevolg van de toename van de triglyceridenniveaus in het 
bloed. Wij concludeerden uit deze gegevens dat bexaroteen een ongunstige verandering 
in de hoeveelheid vet in het bloed (dyslipidemie) veroorzaakt (zowel een verhoging 
van triglyceriden, VLDL-cholesterol en LDL-cholesterol als een verlaging van HDL-
cholesterol), die veroorzaakt wordt door een verhoogde productie van triglyceriden in 
de lever, wat weer leidt tot een hogere CETP activiteit.
 Samengevat laten de onderzoeken die in dit proefschrift beschreven zijn, zien 
dat ontsteking en CETP twee belangrijke factoren zijn bij het verwerken van cholesterol 
en voor de ontwikkeling van hart- en vaatziekten. In het eerste deel van dit proefschrift 
lieten we zien dat een grote hoeveelheid cholesterol in het voedsel leverontsteking kan 
veroorzaken door ophoping van vrij cholesterol, wat leidt tot stress in een bepaald 
onderdeel van de cel, het ER. De ophoping van vrij cholesterol en het ontstaan van 
ER stress zijn processen waar mogelijk nieuwe medicijnen tegen ontwikkeld kunnen 
worden. Vervolgens lieten we zien dat het de moeite waard is om zowel ontsteking 
in de vaatwand als ontsteking op andere plaatsen in het lichaam (zoals de lever) te 
remmen, omdat dit de ontwikkeling van hart- en vaatziekten kan remmen, en zelfs tot 
genezing van hart- en vaatziekten kan leiden in E3L muizen. Dit is veelbelovend voor de 
ontwikkeling van ontstekingsremmende medicijnen die uiteindelijk in mensen zullen 
moeten worden getest om hart- en vaatziekten te verminderen. In het tweede deel van 
dit proefschrift lieten we zien dat het remmen van CETP op zich hart- en vaatziekten 
kan verminderen, maar dat de combinatietherapie van de CETP-remmer torcetrapib 
samen met de LDL-cholesterolverlager atorvastatine dit gunstige effect mogelijk 
tegengewerkt heeft. Ook lieten we zien dat het feit dat CETP het VLDL-cholesterol 
verhoogt grotendeels verklaart waarom CETP tot meer atherosclerose leidt in E3L.CETP 
muizen. Bovendien bleek dat remming van CETP mogelijk het risico op het scheuren 
van een atherosclerotisch lesie, en dus op trombose, verhoogt. De uitkomsten van ons 
onderzoek suggereren dat het remmen van CETP mogelijk niet de beste manier is om 
HDL-cholesterol niveaus te verhogen, en daardoor hart- en vaatziekten te verminderen. 
Het is waarschijnlijk beter om therapieën te ontwikkelen die er voor zorgen dat HDL 
zijn beschermende functie beter kan uitvoeren, dan therapieën die er uitsluitend op 
gericht zijn om HDL-cholesterol niveaus te verhogen. Wij denken dat therapieën die 
rekening houden met de beschermende functie van HDL uiteindelijk dus een grotere 
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